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ABSTRACT
Most in vitro systems employ the standard cell culture maintenance conditions of 95 %
air with 5 % CO2 to balance medium pH, which translates to culture oxygen tensions of
approximately 20 % - above the typical ≤ 6 % found in most tissues. The current investigation,
therefore, aims to characterize the effect of maintenance and toxicant exposure with a particular
focus on the α,β-unsaturated aldehyde, acrolein, in the presence of physiologically relevant
oxygen tension using a differentiated H9c2 cardiomyoblast subclone. H9c2 cells were
maintained separately in 20.1 and 5 % oxygen, after which cells were differentiated for five days,
and then exposed to acrolein in media containing varying concentrations of tricarboxylic acid
and glycolytic substrates. Cells were then assessed for viability and metabolism via the MTT
conversion assay. H9c2 cells were assessed for mechanistic elucidation to characterize
contributors to cellular death, including mitochondrial membrane potential (ΔΨm) reductions (JC1), intracellular calcium influx (Fluo-4), and PARP activation. Exposure to acrolein in differing
oxygen tensions revealed that standard culture cells are particularly sensitive to acrolein, but
cells cultured in 5 % oxygen, depending on the medium pyruvate concentration, can be rescued
significantly. Further, reductions in ΔΨm were reversed by co-exposure of 5-10 mM EGTA for
both culture conditions, while intracellular calcium transients were noted only for standard
cultures. The results demonstrate significant metabolic reprogramming which desensitizes
differentiated H9c2 to acrolein-induced cytotoxicity. Further, PARP and extracellular calcium
contribute to the fate of these cells exposed to acrolein, though clotrimazole-associated TRPM2
channels may not be significantly involved. Conclusively, significant alteration of toxicogenic
vi

response was noted in this cell line when cultured under physiologically relevant conditions, and
may have a substantial impact on the reliability and predictive power and interpretive application
of in vitro-based toxicity models cultured under standard culture conditions, depending on the
parent tissue.
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CHAPTER ONE:
INTRODUCTION

1.1 Cyclophosphamide and Acrolein
Cyclophosphamide is a DNA alkylating nitrogen mustard prodrug approved for the
treatment of hematopoietic neoplasms, e.g., leukemias, lymphomas, multiple myeloma as well as
ovarian adenocarcinoma and breast carcinoma. As cyclophosphamide can cross the blood-brain
barrier, malignancies within the central nervous system, such as retinoblastoma and
neuroblastoma, have also been treated using cyclophosphamide1. Cyclophosphamide is also
utilized as a pre-treatment immunosuppressant agent in preparation for bone marrow transplant
procedures due to the drug’s significant bone marrow toxicity2. Treatment is, however, doselimiting, as the major associated side-effect was traditionally acrolein-induced hemorrhagic
cystitis3; a side effect largely attenuated with co-administration of the antioxidant mesna without
negating the anti-neoplastic action of cyclophosphamide4,5. While the dose-limiting side effect of
hemorrhagic cystitis has been largely reduced, a second, potentially fatal side-effect of
cyclophosphamide, drug-induced cardiomyopathy, has been shown to afflict between 5 % and 22
% patients treated6-8; a higher incidence of cardiomyopathy is suggested in patients with a
previous treatment history with anthracycline treatment9. Unlike anthracycline antineoplastic
agents, e.g., doxorubicin, idarubicin, etc., the risk of cyclophosphamide-induced cardiomyopathy
has not been associated with cumulative dose10 nor has this effect been characterized as latent,
i.e., several months to years post treatment, but rather may manifest as early as three weeks after
1

initializing treatment11-13. Goldberg and colleagues showed a possible dose threshold of 1.55 g
cyclophosphamide/m² body surface/day, above which cardiotoxicity is associated with increased
incidence6; however, case reports in the literature have demonstrated significant toxicity in
patients below this value14, particularly those with renal co-morbidities15.
As of yet, no standard care for attenuating cyclophosphamide-induced cardiotoxicity
exists14. While the mechanism of cardiomyopathy remains incompletely elucidated, a toxic,
unsaturated α,β-aldehyde metabolite, acrolein, is among the most probable of implicated the
species. Despite acrolein’s high reactivity, the biological half-life of acrolein is expected to be
substantially longer than other ROS species16, especially when adducted to glutathione or
endogenous biomolecules17 (Reviewed in-depth in Kehrer and Biswal18). The blood
concentration of acrolein after cyclophosphamide treatment, nonetheless, is not negligible.
Measured unbound peak blood acrolein in five patients after a 1-hour infusion of 60 mg/kg i.v.
for three consecutive days consistently registered between 6.2 µM and 10.2 µM, with no
apparent difference in unbound blood concentration over the course of therapy19. The extent of
protein-acrolein binding remains a significant determinant of free acrolein bioavailability, and
routine fluorometric measures only detect the unbound fraction. For example, the peak unbound
fraction of acrolein reported above was determined by Ren and colleagues19, but fails to measure
protein-bound acrolein, as the method for acrolein detection was performed by m-aminophenol
derivatization of acrolein to a fluorescent 7-hydroxyquinoline (Max λ Emission/ Excitation: 350
nm/515 nm) in accordance with the method described by Alarcon in 196820. Without rapid crosssections of acrolein concentration determination, the peak concentration in blood may indeed be
higher.
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In the presence of microsomal metabolism, such as that found in the liver, and to a
smaller extent the lung, rapid acrolein is rapidly degraded17. For example, an investigation by
Baumann and colleagues21 characterized the time- and protein-dependency of free acrolein in
liver microsomal preparations, noting inverse proportionality of unbound acrolein with respect to
microsomal protein preparation concentrations ranging from 0.25 and 2 mg/mL; acrolein
concentration determination was performed in mouse liver microsomal isolates after a 20 minute
incubation at 37°C and a pH of 7.4 when controlling for protein by simple dilution. The unbound
acrolein fraction decreased substantially at initial acrolein concentrations below 62.44 µM
compared to the unbound fraction (75.3 %) of the highest initial acrolein concentration of 89.20
µM. In the presence of 2.0 mg/mL protein, the unbound fraction was starkly reduced to 17.6 %
of the initial 89.20 µM acrolein group. Baumann and colleagues21 further exacted the timedependency of acrolein within the same microsomal isolate system over a range of 120 minutes
at 37°C, pH 7.4, and in the presence of 1 mg/mL protein. At initial acrolein concentrations of 1.0
µg/mL, 2.0 µg/mL and 5.0 µg/mL, the derived half-lives were estimated to be 3 minutes, 5
minutes, and 17 minutes, respectively; the half-life estimates were directly proportional to initial
acrolein addition concentration, denoting metabolic capacity saturation (Zero-order kinetics) was
not reached. Aside from microsomal systems, however, the physical property of the matrix
contributes to acrolein degradation. The half-life of acrolein in acidic urine (pH 5.5) is
approximately 20 minutes, and was reduced three-fold (approximately 6.7 minutes) with
alkalization to a pH of 7.316. These results, while not apparently comparable to blood or serum
half-lives, characterize the influence of pH on acrolein degradation–a parameter crucial in
performing deproteinization and derivatization of acrolein-containing media in preparation for
the fluorometric measure of free acrolein concentrations20. In vitro, the contribution of acrolein
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scavenging by metabolically inert proteinaceous components of fetal bovine serum has been
shown to reduce peak unbound acrolein concentrations up to 65 % in M199 culture medium
containing 10 % v/v serum22. In the same investigation, a negligible proportion of acrolein was
bound in serum-free culture media, denoting serum-free media as a plausible solution for
controlling bioavailability in in vitro systems. While circulating acrolein may result in systemic
exposure, especially to cardiac tissue, an endogenous source within cardiomyocytes remains
plausible. Clearance of cyclophosphamide via cardiac metabolism has not been well
characterized, but is expected to be minimal due to the low CYP isoform presence (Reviewed in
Chaudhary, Batchu, Seubert 23) of primary contributors, such as CYP3A isoforms; nonetheless,
the cytochrome isoform 2J2 has been denoted as the main implicated cytochrome isoform
responsible for cyclophosphamide metabolism in cardiac tissue24, and may produce localized
elevations in acrolein within cardiomyocytes during and after cyclophosphamide treatment.
As previously mentioned, no standard of care is proposed for cyclophosphamide-induced
cardiotoxicity. The use of antioxidants and radical scavengers has been shown effective in
vitro25, but little evidence of pharmacological intervention exists with regards to in vivo
models26. Since genetic ablation of glutathione S-transferase sensitizes rodents to acrolein and
cyclophosphamide metabolite cardiotoxicity27, the importance of electrophilic detoxification in
reducing adverse cardiac events seems expectedly paramount, despite little evidentiary efficacy
when applying antioxidant intervention. Complexation of acrolein with glutathione forms GSpropionaldehyde with the potential for further aldehyde dehydrogenase- or xanthine oxidaseinduced ROS generation28, denoting glutathione adduction does not necessarily confer complete
detoxification. With respect to DNA adduction, DNA replication by inhibited by 40 % in the
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murine mammary carcinoma FM3A cell line after exposure to 15 µM acrolein29. Replication is a
parameter closely associated with another in vitro phenomenon, which shall be discussed next.

1.2 Hyperoxic Culturing
The most important atmospheric constituent in cellular respiration, oxygen, is maintained
at 140-150 mmHg, which is approximately 20.1 % mol/mol under standard culturing conditions,
and corresponds to concentrations 5- to 10-fold higher than those found within most
physiological niches30. Measurements of cardiac tissue reference oxygen tension in the canine31
and rat32 as falling within the range of 20 to 30 mmHg (2.6-3.9 %), and varies depending on the
proximity to perfusion beds32. While the effects of high oxygen tension on in vitro systems
remains primarily focused on stem cell and embryo systems, only scant research exists on the
consequences of high oxygen tension on mechanistic characterization of cytotoxicity.
Surprisingly, this is especially true of oxidative stress for which oxygen bioavailability is crucial
for peroxynitrite formation-based stress33. Murine blastocysts cultured under 20 % oxygen
demonstrate 5-fold increased levels of oxidative stress markers, such as γ-H2AX-positive
staining, compared to blastocysts cultured in lower oxygen-containing atmospheres as well as in
vivo parental tissue34. Additionally, rates of aneuploidy and general DNA instability are
markedly reduced in stem cells cultures under physiologically relevant oxygen tension (5 %; 38
mmHg) when compared to typical culture conditions35,36, likely the result of proliferating
reactive oxygen species formed during hyperoxic culturing conditions37,38. ROS proliferation and
genomic instability have been associated with enhanced senescence, the latter of which is closely
associated with γ-H2AX-positivity in cell culture systems39,40.
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Oxygen tension in vitro has been shown as a critical factor in cellular respiration and
adenine nucleotide formation. At oxygen partial pressures 30-100 mmHg, the lactate-to-pyruvate
ratio in culture medium supporting MEFs exhibits a biphasic relationship, characterized by an
initial negligible ratio increase at onset, followed by a rapid increase in lactate production at day
three when oxygen partial pressure was fixed at 12 mmHg41. Neurons cultured under an
atmosphere containing oxygen partial pressures below 35 mmHg typically exhibit lactic
acidosis42, similar to observations in stem cell cultures43; however, in vitro neurons adapt with
time to such metabolic acidosis and demonstrate an approximately 25 % enhanced peak
proliferative capacity compared to standard culture conditions42, so long as respiration demand
does not exceed the rate of dissolved oxygen permeation44. The induction of lactic acid
production in cell culture is suggestive of a paradigmatic energy production shift towards
glycolysis43, and is found to be triggered by activation of hypoxia-inducible factor 1α (HIF1α)45,46. Extracellular acidification was also observed in cardiac myoblast precursor cells,
demonstrating a relatively applicable respiratory response to oxygen tension among heart
progenitor cells47. Consequently, HIF-1α activation causes a fall in the rate of oxygen
consumption and, thus, restricts the rate of oxidative phosphorylation kinetically to oxygen
availability48. Basal and maximal oxygen respiration levels may depend on oxygen tension,
though oxidative stress, e.g., hydrogen peroxide, may substantially modulate reserve oxygen
consumption capacity47. Unfortunately, investigations directly linking high oxygen tension ROS
production to such modulation are lacking. The work of Hoffman and colleagues offered some
indirect evidence by demonstrating that endogenous hydrogen peroxide formation, which
depends on superoxide, is reduced dramatically under low oxygen conditions38, though
metabolic capacity was not measured. Coincidently, superoxide leakage itself depends on the
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rate of oxygen reduction via the ETC45. It, therefore, stands to reason that decreasing oxygen
tension in cell culture to physiologically relevant oxygen tensions should ultimately reduce
reactive oxygen species formation as a by-product of oxidative phosphorylation without
deleteriously affecting cellular viability.

1.3 Poly(ADP-ribose) Polymerase
While

poly(ADP-ribose)

polymerase-mediated

parthanatos

has

been

recently

characterized as an important mechanism of cellular death49, the exact role of PARP
overactivation in mediating cellular death remains partitioned between two general mechanisms:
energy crisis or nuclear apoptosis-inducing factor (AIF) translocation. Oftentimes, neither
mechanism occurs apparently with mutual exclusivity (Reviewed in Cregan and colleagues50).
NAD+ depletion is credited as an crucial outcome of PARP overactivation leading to eventual
DNA fragmentation51, for which competitive inhibition of PARP by small molecules, e.g., 3aminobenzamide, PJ-34, and DIQ, has been shown to be efficacious in promoting a rescue
phenotype52. Remarkably, results of in vitro studies of PARP overactivation-associated
cytotoxicity amelioration with common citric acid cycle substrates, such as pyruvate, glutamine,
and glutamate, among others, has been shown as effective as PARP inhibitors (PARPi)
themselves53-57, suggesting a unified mechanism of metabolic stress and energy crisis as
attenuated by tricarboxylic acid (TCA) substrates. On the one hand, Alano and colleagues58,59
credit cytosolic and nuclear NAD+ depletion as both necessary and sufficient to induce cellular
death; however, the role of reactive oxygen scavenging by antioxidants oftentimes cannot be
separated from metabolic status rescue, as is the case for pyruvate - one of the most effective
TCA cycle substrate in reducing PARP-induced NAD+ depletion and cellular crisis. Pyruvate has

7

known antioxidant properties, which was corroborated by demonstrating a similar antioxidant
capacity of a structural pyruvate analogue with no known TCA cycle metabolic pathway60. On
the other hand, parthanatos has been shown to be dependent on AIF translocation, and operates
independent of caspase-3 activity57,61,62. Interestingly, AIF-neutralizing antibodies do not
abrogate cellular death under instances of PARP overactivation (Parthanatos), but partially
attenuates reductions in cellular viability by approximately 40 %63. Therefore, AIF translocation
and/or NAD+/ATP depletion are not mutually exclusive mechanisms of cellular death, and may
ultimately complement one another, resulting in cellular death. What is known, however, is that
intracellular ROS formation and free cytosolic ADP-ribose (ADPr) polymers (Herein denoted
simply as: PAR) induce a sharp increase in intracellular calcium levels; promote mitochondrial
dysfunction, possibly through opening of the mPTP; and uncouple mitochondrial proton motive
force driving oxidative ATP formation64. Combined with decreased glycolytic processing under
hyperoxic conditions, some cell types may be artificially sensitized to PARP-mediated cellular
crisis under atypical non-physiological conditions. As a result, discrepancies in the efficacy of in
vitro pharmacological treatment versus in vivo for certain PARP-mediated pathologies may be
explained by this phenomenon, and can detrimentally confound the mechanistic interpretation of
in vitro-based cytotoxicity investigations.

1.4 H9c2 Cardiomyoblast Cell Line, Oxygen Tension, and TRPM2 Channels
The H9c2 rat cardiomyoblast cell line is a commercially available cell line which retains
the potential for myogenic differentiation65-67. The value of the H9c2 model has been
demonstrated by the ability to simulate in vivo hormone-specific responses. For example,
antidiuretic hormone stimulation in both differentiated and non-differentiated H9c2
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cardiomyoblasts recapitulates the hypertrophic response observed in isolated adult rat
cardiomyocytes68,69, thus demonstrating a tissue-specific receptor-mediated response66. While the
undifferentiated H9c2 cell model is utilized as both a toxicological and a physiological cardiac
model, interest in committing cultured H9c2 cells to a myogenic lineage, whereby further
differentiation to skeletal muscle or cardiomyocytes can be promoted67,70, and subsequent
attainment of a cardiac-like phenotype more requisite representation for myocardial or skeletal
muscle tissue has enhanced the discussion of potential models with high fidelity tissue responses.
This becomes important when considering mechanistic elucidation, especially within a system
where respiration may be important in elucidating tissue-specific toxicogenic responses.
Serum reduction to 1 %, with or without supplemented all trans-retinoic acid (RA), alters
the expression profile of phase-specific mitogenic promoters71 ultimately leading to cell-cycle
arrest72. The determinant for commission to a cardiomyocyte-like phenotype, as opposed to
skeletal muscle myotubes, requires culturing for a period of 5-7 days with supplemented RA at
concentrations between 1.0 and 1,000 nM, after which significant alterations of mRNA
expression are found66,73. As a result, differentiation was shown to significantly alter
mitochondrial biogenesis and morphology. In addition to biogenesis and general morphological
changes, e.g., mitochondrial size and mass, functional inter-mitochondrial networks are formed,
i.e., highly enhances mitochondrial interconnected networks74, with an increased propensity for
both high- and low-potential mitochondrial membrane polarization, though the former is more
favorably selected after differentiation75. While differentiation with RA without serum reduction
neither directly alters succinate utilization within oxidative phosphorylation nor alters
mitochondrial membrane polarization (ΔΨm), RA itself does seem to enhance oxidative
phosphorylation via two central routes: increasing ATP synthase activity by intensifying F0/F1
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ATPase assembly and coupling, and enhancing citrate synthase activity, resulting in accelerated
pyruvate utilization for TCA adenine nucleotide production75. Differentiation, however, is not an
H9c2-specific phenomenon. For example, differentiation of mouse C2C12 skeletal muscle
myoblasts has been shown to significantly alter the sensitivity of the cells to oxidative stress, in
particularly to PARP activity and oxygen consumption76. The influence of differentiation on
toxicosis provides an attractive area of research, especially when considering metabolic stress
after targeted oxidative stress. Despite the attraction, the wide utilization of differentiated models
and physiologically relevant culture systems remains scant.
Most in vitro toxicological research utilizes standard culture conditions, i.e., humidified
95 % air mixed with 5 % CO2 under 37 °C. Only limited evidence of non-standard oxygen
tension (Other than standard 19-20.1 % O2) culturing of H9c2 cardioblasts is available, and less
so for toxicological response modeling. Largely, the model has been utilized for the elucidation
of ischemic pre-conditioning; otherwise, primary cell cultures from non-cardiac tissue have
dominated the ischemic pre-conditioning literature, especially neuronal tissue. Furthermore, the
assertion of physionormal oxygen tension remains contested. H9c2 cells cultured under an O2
partial pressure of 13 % was described as “mild chronic hypoxia” and served as a protective
factor against acute ischemia/reperfusion primarily mitigated through ERK/PI3K activation77. It
was shown that HIF-1α was not induced, to which the authors credited chronic “hypoxia” as a
protective factor against total hypoxia. While the induction of HIF-1α acutely does not
necessarily confer HIF-1α involvement, exposure to a 13 % partial pressure of oxygen does not
meet the criteria for hypoxia, especially when the baseline for comparison for typical culturing
conditions is 20 %. Therefore, the appropriateness of denoting mild chronic hypoxia (13 %) as
protective against acute ischemia comes into question, especially since the activity of key
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glycolytic participants remained uncharacterized. Some information on acute toxicogenic cell
death was obtained in hypoxia pre-conditioned neuronal cells that were exposed to an ischemia
for 15 minutes, followed by reperfusion for 24 hours prior to treatment hypoxia or MNNG
treatment78. Ischemic pre-conditioned PARP KO cells or exposed to a PARP inhibitor
demonstrated significantly reduced neuronal death by 70 % or more. The implication of this
investigation, therefore, denotes that the efficacy or potential for eventual neuronal death in
response to DNA damage and/or metabolic crisis likely impinges upon an underlying oxygendependent factor. While HIF-1α mRNA constructs were not measured, the long-term effect of
ischemic pre-conditioning on cellular rescue may serve as a preliminary representative model of
HIF-1α-induced transcriptional adaptation to lower oxygen tension79, similar to the recapitulation
of endogenous cardiac HIF-1α induction under analogous conditions80. Therefore, cytoprotection
of pre-conditioning may implicate an underlying metabolic shift by increasing pyruvate
metabolism and glucose influx into cardiomyocytes (Reviewed by Martin-Puig and
colleagues81), and subsequently incur resistance to reductions in oxygen bioavailability. Recent
evidence of the role of Parkin and PINK1 in selective mitophagy after ischemic preconditioning
support this notion, as pre-ischemic conditioning has been associated with increases in total
ΔΨm82,83 and seemingly operates in close association to increased oxidative maximal oxygen
consumption rate and oxygen consumption reserve capacity offered by pyruvate influx84. Since
excess reactive oxygen species formation is known to contribute to mitochondrial dysfunction85,
ischemic pre-conditioning studies indirectly implicate that hyperoxic culturing may sensitize
cells to transient energy substrate depletion. In turn, pyruvate equivalents offered to the TCA
cycle and subsequent ETC production yield is restricted to fixed capacity, ultimately resulting in
an increased propensity for energy crisis and cellular metabolic collapse. The role of normoxic
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culturing on cell fate, however, does not operate in isolation of differentiation state with the
H9c2 cell line.
Evidence has shown that H9c2 differentiation to a cardiomyocyte-like phenotype
significantly alters anthracycline and adrenergic agonist-induced cytotoxic response73,86,
suggesting retinoic acid supplementation with serum reduction induces not only differentiation,
but also alters cellular machinery responsible for sensitization to toxicogenic injury86. While the
exact specific mechanistic underpinnings leading to sensitization after differentiation remain
unknown, alterations in mitochondrial metabolism, energy production, and calcium-influx
response may be partially responsible. Basal ROS load of H9c2 cells under low-serum conditions
increases87 and may confer altered ROS sensitivity, though ROS loading may remain within
physiological tolerance when coupled with up-regulation of SOD expression observed in
differentiated H9c2 cells73; whether SOD up-regulation keeps pace with the basal increase in
ROS is unknown and requires further investigation. However, it is definitively known that
cardiac ROS generation is functionally linked with intracellular calcium concentrations88 and
mitochondrial integrity (Reviewed in Zorov and colleagues89). Within mitochondria, several
TCA cycle enzymes are stimulated by calcium, thereby likely promoting increased ATP
production, the effect of which may act as partially a compensatory mechanism independent of
free-fatty acid metabolism90,91 to fulfill energy demands during excitation-contraction coupling.
Even still, evidence suggests that calcium serves as the factor responsible for coupling aerobic
metabolism and myocardial work across the sarcoplasmic-mitochondrial interface92. When
inhibiting the sarcoplasmic SERCA transporter in a mixed suspension of isolated SR and
mitochondria, mitochondrial respiration is reduced by 88 %92, likely suggesting the extra-SR
calcium enrichment is mediated by SERCA, especially with novel evidence that microdomain at
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the interface of the SR and mitochondria may facilitate calcium concentrations required for
initiating intra-mitochondrial calcium influx and subsequent stimulation of F0F1-ATPase
activity93. At high cytosolic calcium levels, e.g., greater than 700 nM, respiratory uncoupling
occurs and proves cytotoxic when coupled to high concentrations of reduced adenine
equivalents94,95. Overtly, extreme concentrations of intra-mitochondrial calcium seemingly
promote mitochondrial membrane permeabilization transition pore (mPTP) formation, an event
which has been implicated as a premier cytotoxic trigger leading to respiratory collapse96. The
evidence for this association, paradoxically, is not directly discernable, as a simple correlation
between calcium influx and mPTP formation does not fully explain mitochondrial sensitivity to
calcium overload.
Reaching the mitochondrial calcium-loading maximum has not been shown sufficient to
trigger mitochondrial failure96, particularly when considering calcium-induced calcium release
and the sodium-calcium exchanger. Mitochondrial calcium loading, as a supposed function of the
low-affinity, high capacity mitochondrial calcium uniporter (MCU)97, has been shown to provide
acute facilitation of respiration support, e.g., OCR intensification, in response to stress-mediated
myocardial contraction without altering basal respiratory function or maximal calcium influx
98,99

, owing to a generalized mechanism of calcium-workload coupling via respiratory

compensation. Since the MCU is voltage- and cytosolic calcium concentration-dependent, the
MCU functions also acts as a mediator of cytosolic calcium buffering97 and may also modulate
mitochondrial ROS generation100. Pathologically, the MCU has been considered a possible
indicative source of mitochondrial dysfunction, as some evidence suggests that mitochondrial
calcium overload specifically through the MCU can lead to ΔΨm reduction and eventual
dysfunction101,102. Coupling with ΔΨm dissipation, MCU calcium conductance has been shown to
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undergo conductance reversal, mitochondrial matrix calcium efflux, and reduction in respiratory
support, thus offering an explanation to the association between metabolic failure and MCU
cycling, particularly under acute stress103. Paradoxically, lackluster rescue via MCU genetic
ablation and specific pharmacological inhibition via ruthenium red 360 provides a paradigm,
whereby MCU calcium loading does not ultimately decide cellular fate104,105. These results were
in opposition to those utilizing ruthenium red; the difference may ultimately lay with the nonspecific inhibitory nature of ruthenium red, especially at the concentrations required for MCU
inhibition106. It is to be noted here that the MCU does not operate as the only calcium
conductance channel. Under pathological conditions, ΔΨm collapse occurs simultaneously with
altered function of the cyclosporine A-sensitive, sodium-dependent calcium exchanger (NCX),
which further intensifies the rate of mitochondrial matrix calcium influx in a cytosolic sodiumdependent manner98,107. Therefore, an increase in calcium influx rate is likely more important
than maximal loading in leading to mPTP formation and eventual respiratory collapse105,108.
Since undifferentiated H9c2 cells have been shown to express endogenously a similar
cyclosporine A-sensitive NCX109,110, the role of cytosolic calcium overload is of considerable
interest.
Although cardiomyocytes have voltage-dependent calcium channels to facilitate
electrogenic

contraction,

the

non-specific

cation-permeable,

voltage-independent

2-

aminoethoxydiphenyl borinate (2-APB)-sensitive111-113 melastatin type-2 transient receptor
potential (TRPM2) channel has received interest in its role in facilitating ROS-mediated cation
influx from extracellular extracellular matrices114-116. Several inhibitors of the TRPM2 channel
have

been

described,

including

2-APB117-121,

anthranilic

acid

derivatives

N-(p-

amylcinnamoyl)anthranilic acid (ACA)117,120-123 and flufenamic acid (FFA)112,120,121,123,124, and
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anti-fungal agents miconazole112, econazole125, and clotrimazole (CTZ)119-121,125-127. The activity
of TRPM2 has been shown to be independent of ryanodine receptor activation128, IP3 receptor
activation129, SERCA cycling129, and intracellular kinase receptor signaling

130

. It is to be noted

that each small molecule inhibitor aforementioned is not TRPM2-specific, and, in the case of 2APB, may also lead to activation of vanilloid-type TRP channels131 and allow calcium influx. 2APB also inhibits TRPC channels132, further complicating isolation of oxidative stress-related
conductance. Further still, 2-APB inhibits calcium conductance via intracellular acidification118,
most implicated by inhibition of the IP3 receptor133-135, while the anthranilic acid derivatives
have been largely recognized as promoting reduction or inhibition of calcium conductance
through extracellular acidification136. Interestingly, intracellular addition of 2-APB was less
effective in abrogating enhanced calcium conductance in RB-1 cells137, and, thus, may
demonstrate cell-dependency. Hwang and colleagues138 concluded, even in the absence of ACA,
FFA, and 2-APB, that acidification does indeed alter intracellular calcium; the main stores
affected by intracellular acidification seem to involve ER and sarcoplasmic reticulum and can
occur independent of TRP channel activation and extracellular calcium influx139. Nonetheless,
the presence of TRPM2 and TRPM8, particularly the former, is required for certain triggers of
calcium conductance130. Therefore, CTZ, although as non-specific as anthranilic acid derivatives
and 2-APB, does not induce compartmental or extracellular acidification, and is likely the most
pertinent inhibitor to delineate TRPM2 channel conductance.
The exact contribution of TRPM2 activation on membrane excitability remains unknown,
but ADP-ribose can activate the channel in as little as 1 µM of free ADP-ribose140; other adenine
nucleotides do not interact significantly with the channel140,141. During gating, a proportion of the
total TRPM2 conductance is carried by calcium, while approximately 50 % of the total charge is
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carried by sodium142,143. Thereafter, not only does the TRPM2 induce a slight plasma membrane
depolarization, but the increased calcium influx acts as a promoter of intracellular signaling,
especially since TRPM2 channels allow relevant cationic conductance at physiologically relevant
membrane potentials144, i.e., conductance does not likely only occur under pathological
conditions which likely result in obligate cell death. With calcium conductance, TRPM2
activation can promote cytosolic calcium transients, potentially leading to increasing
mitochondrial calcium stores and respiratory support, particularly when TRPM2 activation has
been associated with enhanced glucose metabolism in vivo145. The importance of extracellular
calcium stores in facilitating metabolic response to cellular toxicity via TRPM2 conductance
deserves further attention, as calcium conductance may be integral for cardiomyocyte metabolic
compensation under acute metabolic insufficiency or after oxidative stress146,147. Nonetheless, the
degree to which calcium loading becomes pathological is not clearly demarcated. Since
extracellular calcium entrance is not confined to TRPM2 channels alone, the dependence of other
calcium-permeable channels in membrane excitability, or direct co-dependence of TRPM2
channel activation, is similarly not yet delineated. Though, it must be noted that, when free PAR
is fixed within the physiological range for TRPM2 activation, human TRPM2 channels
expressed in Xenopus oocytes require a certain threshold concentration of intracellular calcium to
induce gating and subsequent closure148. The reliance of the TRPM2 channel activation on
parallel calcium store conductance mechanisms, e.g., L- and T-type calcium channels, has been
demonstrated within only some tissue-specific models149. Nonetheless, the influence of TRPM2
channels in initiating or modulating cellular death programs remains ill-defined, but deserves
further attention since PARP overactivation has been shown functionally linked to channel
calcium conductance.
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TRPM2 channels contain a c-terminus NUDT9 pyrophosphatase domain, which
hydrolyzes ADP-ribose to AMP, and may also be implicated for TRPM2 activation150,151.
Indeed, micromolar concentrations of intracellular ADP-ribose (10-100 µM) activate the channel
with a Km of approximately 13 ± 1 µM143,144,151-153. ADP-ribose gating values as low as 1.1 µM
were observed in patch-clamp readings154, but this threshold may be dependent upon the cell
type and ionic composition of the patch-clamp bath. Various adenine nucleotides have also been
shown to gate TRPM2 channels, such as cyclic ADP-ribose

155

, NAD+156,157, NAAD and

NAADP153,155; however, none of these adenine nucleotides are effective in gating TRPM2
channels when contaminating ADP-ribose was removed

153,158

. Similarly, various glycosylated

nucleotides also do not activate the channel151, owing to the likely specificity of PAR in
mediating TRPM2 channel opening with subsequent calcium influx. Nonetheless, TRPM2
gating, specifically due to high intracellular ADP-ribose concentrations, may act as an
endogenous adaptive signal against oxidative stress and subsequent PARP activation, as the
evolution of free PAR requires PARG159. Evidence suggests that redox alterations, i.e., hydrogen
peroxide accumulation, though shown to activate TRPM2 channels, are not sufficient to induce
specific TRPM2 gating142,160, at least in non-cardiomyocyte cell types149,161. Alternately, high
concentrations of hydrogen peroxide (≥ 500 µM) demonstrate non-specific conductance peaks,
denoting a TRPM2-independent manner of cation conductance162 likely via cell membrane
permeation. Where redox stressors becomes particularly important is under a model, whereby
ADP-ribose may actually synergize with redox and calcium sensors, i.e., through calmodulin, to
activate TRPM2 channels and allow rapid, but sustained, cationic influx130,143,156,163-166. Others
contest that oxidative stress is absolutely necessary for TRPM2 gating, and can occur
irrespective of free PAR123,167. It must be noted that, indeed, oxidative stress purportedly can act

17

independently of PARP activation; however, these two phenomena are not mutually exclusive.
Yang and colleagues168 looked at PARP activation and TRPM2 activation by H2O2 treatment in
primary rat ventricular cardiomyocytes. Within 20 minutes of treatment with 20-100 µM H2O2,
marked intracellular PAR accumulation was noted which was expectedly reduced by PARPi.
Characteristic of the non-specific cationic TRPM2 channel, intracellular concentrations of both
sodium and calcium increased – an effect also ablated by exposure with a PARPi. Ultimately,
cardiomyocytes eventually lost viability to a myriad of cellular death pathways, primarily
apoptosis and necrosis. When having applied the PARPi in combination with the direct TRPM2
inhibitor CTZ, morphological and biochemical signs of cytotoxic endpoints were prevented.
While the exact role of oxidative stress mediators in TRPM2 gating remains to be elucidated, the
unequivocal role of ADP-ribose has been established.

1.5 Poly(ADP-ribose) Polymerase and Cytotoxicity
Pharmacological inhibition of PARP is known to reduce calcium transients during
cytotoxic ischemia/reperfusion injury through reduction of free ADP-ribose169. Coincidently,
TRPM2-mediated extracellular calcium transients during I/R injury are known to be sensitive to
PARP inhibition128,169,170, indicating free PAR as a functional link between calcium influx and
I/R injury. Following, I/R injury returns a similar mechanistic pathway compared to oxidative
injury, especially when considering the markers of calcium influx, PARP activation, and ROS
generation. Therefore, PARP activity, under oxidative stress and electrophilic DNA damage, is a
likely fundamental link between cellular injury and transient calcium influx via TRPM2 channels
and would inevitably require intact PARG171; the role of ARH3 in TRPM2 activation has not
been investigated161, but may also contribute. As mentioned previously, the rate of calcium
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influx may present an important factor in determining whether PAR-dependent TRPM2 gating
would sufficiently induce a rapid calcium influx to the degree required to translate to a cytotoxic
endpoint. Though little evidence has yet to imply a definitive answer, the rapid PAR transients
typically observed may offer some circumstantial evidence of plausibility. The half-life of ADPribose polymers is short (< 30 seconds), and increases with increased branching172. Larger, more
complex ADP-ribose polymers are considered more toxic than short-branching, low molecular
weight polymers173. Since genetic ablation of PARG in neurons results in significant DNA
instability and phenotypic lethality in mouse embryonic fibroblasts and stem cells174, utilizing
PARG knockout cell or animal models for characterizing PAR in toxicological assessment
remains untenable. However, short-term gene knockdown studies have proved fruitful answers.
PARG siRNA knockdowns were similarly effective in decreasing calcium influx as TRPM2
siRNA knockdowns169, likely due to reduced long cytosolic PAR polymer accumulation175,176.
These results implicate PARP, PARG, and TRPM2 constituting a single mechanistic unit,
whereby significant PARP activity can result in modulating calcium-dependent intracellular
signaling programs depending on the intensity of PAR formation. Conversely, Geistrikh,
Visochek, Klein, Miller, Mittelman, Shainberg, Cohen-Armon
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demonstrated significant

calcium-dependent increases in PARP activity after cardiomyocyte angiotensin II administration.
Unfortunately, though the role of calcium and underlying PKC/MEK/ERK activation in
increasing PARP activity was the focus of this investigation, the notion of calcium-induced
mitochondrial ROS promotion was left unresolved. Nonetheless, limited evidence of PARP
activation perpetuation through cytosol-derived MCU channel mitochondrial calcium flux has
been reported100. Hitherto, confirmation of a mechanistic unit among PARP activation, PARG
hydrolysis, and TRPM2 activation remains quite tentative, and requires further investigation,
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especially under faithful physiological conditions, but adequately lends insight into the
mechanistic data culminated currently.
While free ADP-ribose is known to trigger TRPM2, PARP activity itself has been shown
to consistently influence cellular energetics and mitochondrial integrity. Physiologically, high
levels of endogenous PAR are associated with diminished ΔΨm178, for which PARP inhibition
has been shown ineffective in completely abrogating, but effective in merely delaying, such ΔΨm
dissipation179. Linking PARP activity mechanistically with mitochondrial permeabilization may
be dependent upon the calcium-dependent cyclophilin D. Ppif -/- mouse MEFs and
cardiomyocytes retain expression of vdac1, and ant isoforms 1 and 2, but are refractory to ΔΨm
dissipation caused by ischemia/reperfusion180, thus implicating a calcium-dependent modality for
determining mitochondrial fate. Previous in vitro models have confirmed these findings found in
vivo181. In bridging in vivo and in vitro mechanisms, the cyclophilin-dependent AIF may be the
prominent determinant in dictating cellular fate.
AIF was identified as part of the apoptotic machinery, leading to large-scale nucleic acid
fragmentation and cell death182, and associated with nuclear translocation in primary rat
hippocampal neurons after ischemia/reperfusion-induced oxidative stress183,184. Since AIF
knockouts result in an embryolethal phenotype, the genetic AIF knockdown Harlequin mouse,
which produces approximately 80 % WT AIF expression levels185, has assisted in resolving the
link between neuronal oxidative stress and AIF translocation in triggering cellular death63,173.
The AIF protein contains a putative PAR-binding domain186, and, when complexed with PAR, is
understood to be the effector whose mobilization ultimately results in DNA fragmentation and
parthanatos. This is not surprising, since direct addition of complex PAR causes synthetic
lethality187. Furthermore, the association between AIF translocation and ΔΨm dissipation is
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unequivocal; however, the temporal relationship of PARP-mobilized AIF translocation and
mPTP formation or vice versa is still debated182,188,189. Likewise, the dependence of ΔΨm
dissipation upon mPTP formation remains in question, and undermines the dependence of AIF
mobilization in promoting mPTP formation. This becomes apparent when both cyclosporine-A
sensitive cyclophilin isoforms (A and D) are implicated in AIF execution and mPTP
formation190. In a mouse model of cerebral ischemia, cyclophilin A was co-localized with AIF
nuclear translocation after ischemia/reperfusion, an observation previously uncharacterized in
neuronal tissue191. In the same investigation, a CypA (-/-) knockdown model caused a significant
reduction in the volume of reperfusion tissue necrosis by 33.8 % compared to WT controls,
offering at least some neuroprotection. Unfortunately, the effect of CypA KO on mitochondrial
integrity was not directly explored, though the dependency of calcium in determining
mitochondrial integrity was characterized. These results tentatively confer evidence of universal
calcium sensitization of mPTP formation, which may be cyclophilin-dependent, after reperfusion
injury in heart tissue192.
When considering in vitro investigations of parthanatos, the functional isolation of the
outer membrane-associated AIF, intramembranous mitochondrial AIF, and mPTP formation
cannot be segregated sufficiently to explain the contributory role of metabolic crisis
simultaneously with other mechanisms. Given some evidence of AIF localization to the
mitochondrial membrane outer leaf193, the necessity of mitochondrial function in determining
cellular fate with respect to parthanatos seems mechanistically unresolved. Were this true, and
the outer leaf isoform of AIF contributed to cell execution, mitochondrial dysfunction may
ultimately be irrelevant in determining cell fate. This interpretation would stand in juxtaposition
to those focusing primarily on metabolic failure, despite in vitro investigations having shown the
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efficacy of pyruvate in attenuating MNNG or H2O2 toxicosis similar to that of PARPi54. While
these results may indicate a plausible metabolic rescue by supplementation of pyruvate to the
TCA cycle56, the antioxidant potential of pyruvate may confound the mechanistic interpretation
of pyruvate rescue. Indeed, even pyruvate at levels typically found in standard DMEM (1 mM), a
level approximately 10-fold found in rodent whole blood194-196, has been shown to significantly
alter toxicogenic response under oxidative stress197. Therefore, whether pyruvate actually results
in a rescue phenotype or merely reduces ROS, particularly that of H2O2, load remains
unelucidated.
Respiratory support under cytotoxic stress by certain glycolytic and TCA substrates has
been, nonetheless, shown under similar circumstances, i.e., standard culturing conditions, albeit
neuronal rescue by glucose has proven inconsistent54,198. These results are not surprising, since
neurons are highly dependent upon glucose metabolism for producing reducing equivalents
required for energy production, but whose glycolytic capacity is likely reduced under standard
culturing conditions. For example, rotenone sensitivity is reduced under hyperoxic standard
culturing conditions compared to reduced (5.0 %) oxygen conditions in the neuroblastoma SHSY5Y cell line199 – evidence that reducing equivalent through complex I of the ETC becomes
blunted under an oxygen-rich environment. The ED50 for complex I inhibition by rotenone was
reduced to 1.98 ± 0.04 µM at 5 % oxygen, compared to 49.8 ± 0.03 µM at 20 % oxygen,
denoting significant oxygen-dependent protection under 20 % oxygen culturing. Further still,
under hypoxia (0.1-0.5 % oxygen), cells require glycolysis in order to support ATP production
via complex I reduction, and represents a functional proteomic shift from partial reliance of
complex II reduction for promoting F0F1-ATPase support200. ATP production under hypoxia
depends upon functional pyruvate dehydrogenase, implicating a respiratory model whereby
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metabolic contribution by fermentation is rather negligible45. Since the other TCA substrates
used in metabolic rescue after PARP activation, except pyruvate, operate downstream of
pyruvate dehydrogenase and citrate synthase, the weight of shunting glycolytic pyruvate on
metabolic rescue thus remains unknown, but is of critical consideration for the interpretation of
in vitro findings with respect to toxicodynamic effects which imping upon metabolic disruption.
When considering the significantly increased citrate synthase production in differentiated H9c2
cardiomyoblast, the role of glycolysis-derived pyruvate production coupled to increased citrate
synthase activity in reducing or abrogating metabolic crisis requires attention both in vitro and in
vivo.
In summation, two fundamentally competing mechanisms are obviously tantamount in
the current literature: One characterized by AIF translocation, which likely relies upon ΔΨm
reduction, and a second which describes metabolic failure which may act independently of AIF
translocation, though co-dependence later in the mechanistic pathway, e.g., ETC respiratory
failure after AIF-dependent potential dissipation, cannot substitute for the underlying acute
mechanisms which effectively commit the cell to death. This investigation focuses on the latter
of the two in an effort to indirectly implicate the role of oxygen in determining cellular fate by
altering respiratory capacity derived from functional TCA and glycolytic pathways

1.6 Problem Statement
In considering the potential sensitization of cardiomyoblast H9c2 cells to metabolic crisis
when cultured under hyperoxic conditions (20 % oxygen), confounders of mechanistic
elucidation undermine the interpretation of studies, and cast doubt upon the in vitro model to
recapitulate the circumstances under which cell-specific toxicodynamics may actually differ.
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Since parthanatos involves the nuclear translocation of AIF: a translocation which occurs
generally concomitantly with ATP-dependent mitochondrial membrane dissipation108,201,202,
respiratory rescue either through PARP inhibition or TCA substrate supplementation provides a
strong case for implicating NAD+ and ATP depletion as sufficient for determining cellular fate
under the pretenses where respiratory capacity cannot be sustained directly from alteration of
respiratory machinery. The influence of metabolic rescue for in vitro cardiomyoblasts under
representative physiological conditions has not been completely investigated with an appropriate
model. In this investigation, differentiated H9c2 cells were cultured under normoxic conditions
(5 % O2) prior to exposure to an electrophilic compound known to induce cardiomyopathy,
acrolein. The purpose was to characterize the role of poly(ADP-ribose) polymerase in
determining cellular fate under the conditions of normoxia in order to characterize the
toxicological and mechanistic effect of normoxia on determining cellular fate under term of
metabolic stress. Since a majority of in vitro toxicological studies involve the utilization of
physiologically non-relevant oxygen conditions, the discordant efficacy of in vitro to in vivo
translational research requires further investigation.

1.7 Hypotheses
The current investigation aims at examining the influence of oxygen tension in
modulating acrolein-induced cytotoxicity in the differentiated H9c2 cardiomyoblast model, along
with a mechanistic characterization of cytotoxicity. As such, three hypotheses are proposed.
Hypothesis One. Since several TCA and glycolytic substrate have been
shown to attenuate toxicosis in several cell models. Therefore, supplementation of such TCA and
glycolytic substrates will have a differential capacity for attenuating cell death among
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differentiated H9c2 under physiologically relevant oxygen tension (5 %) compared to standard
culturing after acrolein exposure:
a)

L-pyruvate will attenuate acrolein-induced reductions in cell viability;

b)

L-glutamine will attenuate acrolein-induced reductions in cell viability;

c)

α-ketoglutarate will attenuate acrolein-induced reductions in cell viability;

d)

D-glucose will attenuate acrolein-induced reductions in cell viability; and

e)

L-glutamate will not attenuate acrolein-induced reductions in cell viability, and will
demonstrate similar sensitivity compared to standard condition cultured cells.
Hypothesis Two. Depletion of adenine nucleotides has been shown effective in mitigating

cytotoxic stress with various toxicants. Therefore, inhibition of PARP by co-exposure with
olaparib will significantly attenuate acrolein-induce cytotoxicity compared to exposure-only cells
cultured under physiologically relevant oxygen conditions.
Hypothesis Three. Overactivation of PARP under oxidative stress is associated with
induction of calcium transients; the latter of which is associated with pathological reduction of
mitochondrial membrane potential. Therefore, inhibition of PARP by olaparib among
differentiated H9c2 cells cultured under physiologically relevant oxygen conditions will:
a.

result in attenuation of clotrimazole-sensitive extracellular calcium conductance
in H9c2 cardiomyoblasts, and

b.

retain mitochondrial membrane potential polarization to acrolein-unexposed cell
levels
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CHAPTER TWO:
METHODS

2.1 H9c2 (2-1) Cardiomyoblast Culturing and Treatment
A subclone (2-1) of the commercially available H9c2 cardiomyoblast cell line derived
from the rat (Rattus novegicus) was purchased from the American Type Culture Collection
(ATCC; Manassa, VA) and utilized as the cardiac model for this investigation. H9c2 cells were
cultured and maintained under standard culturing conditions (37 °C humidified 5 % CO2/
balance air atmosphere) with Dulbecco’s Modified Eagle’s Medium (Abbr. DMEM; SigmaAldrich; St. Louis, MO) + 10 % FBS (ATCC) in 100 mm glass Petri dishes with a rotating use of
100 IU/mL penicillin/100 µg/mL streptomycin (ATCC). Medium was changed every 2-3 days,
until cells were passaged with pH-balanced 0.25 % trypsin/2.21 mM EDTA Hank’s buffered
saline solution (Corning; Manassa, VA) when reaching 75- 80 % confluency after a brief wash
with calcium- and magnesium-deficient Dulbecco’s phosphate buffered saline (D-PBS; SigmaAldrich), and seeded at a ratio of 1:3 or 1:4. All manipulations were performed within a standard
Class II biological safety cabinet.
H9c2 cells maintained under reduced oxygen, e.g., 5 % denoted as physiologically
relevant oxygen tension, were supplied an air mixture of 5 % O2/5 % CO2/ Balance N2 in order
to attain normal oxygen tension roughly equivalent to that of in situ cardiomyocytes31. Culture
and maintenance medium was analogous to 20.1 % oxygen cultures (DMEM + 10 % FBS in 100
mm glass Petri dishes with a rotating use of 100 IU/mL penicillin/100 µg/mL streptomycin),
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though the DMEM was pre-equilibrated within culture flasks with affixed 0.22 µm filtercontaining venting caps to ensure microbial exclusion. Cell passaging was performed similarly to
standard culture H9c2 cells, except with the use of 5 % oxygen pre-equilibrated medium. For all
procedures with a duration longer than 10 minutes, e.g., microplate seeding, maintenance, and
treatment in 96-well plates, such procedures were executed within a custom-built transparent
acrylic chamber (Appendix 3), wherein the intra-chamber oxygen concentration was reduced to,
and maintained at, 5 % via nitrogen gas displacement. Nitrogen gas was supplied via 125-pound
nitrogen tank (Purity 99.99 %; Airgas; Radnor, PA) with purge flow regulation at 5-10 L/min
using a Coplay-Norstar heavy-duty inert gas flow-meter (Model N302014; Coplay, PA); nitrogen
gas was further purified via a 0.22 µm in-line filter prior to entry. Intra-chamber oxygen was
monitored in real-time via the Traceable® Digital Oxygen Meter during and after purging to
ensure optimal 5.0 ± 0.5 % oxygen partial pressure within the main chamber along the duration
of procedure execution.
In preparation for experimentation, passaged H9c2 cells were resuspended in DMEM +
10 % FBS, counted via trypan blue (Corning) exclusion using a hemocytometer, and then plated
in 96-well tissue culture-treated plates (5,000 or 10,000 cells/well), in Corning Costar 12-well
tissue culture-treated plates (80,000 cells per well), or on 22 x 22 mm coverslips (7,500
cells/cover slip), and allowed 24-48 hours to adhere. For live cell imaging, H9c2 cells were
seeded on coverslips. At least two days prior to seeding, 30 mL or more of a 2M NaOH in
reverse osmosis water solution was prepared. Fresh coverslips were initially cleaned with mild
detergent, rinsed copiously with dH2O, and submerged in the 2 M NaOH for 2 hours on a rocker
platform to remove contaminants from the glass. After the two-hour wash period, coverslips
were soaked in the same 2 M NaOH solution overnight. The following day, the coverslips were
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rinsed copiously with dH2O and stored in 70 % reagent alcohol until the day of use. Immediately
prior to use, coverslips were sterilized by autoclaving for 30 minutes at 121 °C in a glass 100
mm Petri dish. One sterile coverslip was placed per single well of a 6-well plate and coated with
200 µL of 100 µg/mL sterile poly-l-lysine (MW > 150,000 Da; Sigma-Aldrich) in dH2O for 10
minutes at room temperature, followed by copious rinsing with sterile dH2O, and air drying.
After drying, 200 µL of cell suspension (37,500 cells/mL) were placed onto the center of each
coverslip. Cells were allowed to adhere and attach for two days under the desired culture
condition; thereupon, seeded cells were treated analogously to microplate-seeded cells.

2.1.1 H9c2 Cardiomyoblast Differentiation
The H9c2 cardiomyoblast model is a widely utilized in vitro cardiotoxicity and
mechanistic elucidation model, as the cells can recapitulate the electrophysiological and
biochemical nuances of cardiac muscle203. Despite the ability to differentiate, however, most
studies utilize the stock undifferentiated H9c2 cardiomyoblast model for toxicity testing204. In
order to promote differentiation, the culture medium was replaced with fresh DMEM + 1 % FBS
with 10 nM retinoic acid (Stock 50 mM retinoic acid (Sigma-Aldrich) in sterile DMSO (ATCC)
under 100 % nitrogen) on the second day post-seeding; medium was changed as described in
Figure 1 for the five days prior to experimentation65,66,86. The prevalence of differentiation
among H9c2 cardiomyoblasts is expected to be approximately 25-27 %73, and was checked
visually via light microscopy in order to confirm morphological changes and general cell health.
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Figure 1. H9c2 Differentiation Scheme. Cultured cells were subdivided at 75-80 % confluency and plated at
specific densities, depending on plate geometry or if on coverslips (See specific Methods). Thereafter, cells were
differentiated according to the scheme above while maintained within their respective oxygen tension, e.g., 20.1 or 5
%, either under open atmosphere or under an oxygen-controlled environment.

2.1.2 TCA and Glycolytic Substrate Media
From a stock powder DMEM (Sigma-Aldrich) without D-glucose, L-glutamine, sodium
L-pyruvate, sodium bicarbonate, and phenol red, a 1.11 X medium, denoted pre-basal medium,
was made containing (In mM): 1.0 glucose, 0.12 pyruvate, 0.6 glutamine, and 0.25 glutamate
(All Purchased from Sigma-Aldrich), when diluted to 1X strength using sterile ddH2O. The prebasal medium was sterilized via vacuum filtration through a 47 mm polyethersulfone (0.2 µm
pore; ≥ 150 µm to < 200 µm thickness; Millipore; Billerica, MA) membrane; the solubilized
medium was then be supplemented with 1 % (v/v) fetal bovine serum up to the working prebasal medium with a concentration of ≈ 1.05 X. Individual substrate media were formulated from
the working pre-basal medium by aliquoting aseptically 95 mL into sterile 100 mL media culture
bottles, followed by addition of required substrate volume/weight in order to attain the desired
TCA/glycolytic substrate concentration denoted in Table 1; the remaining portion of the 5 mL
volume was composed of sterile ddH2O and added to the original 95 mL working pre-basal
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medium via a 10 mL syringe filtered through a syringe-driven 0.22 µm PES filter (33 mm
diameter; Millipore), bringing the final substrate-specific medium to 1X strength at 100 mL. The
exact concentrations of TCA and glycolytic substrates in each respective substrate medium are
shown explicitly in Table 1. The medium closest in concentration to rat blood for TCA substrates
and glucose was supplemented with 5.0 mM glucose in addition to standard concentrations of
TCA substrates found in blood. For the purpose of standardizing labeling, the 5.0 mM glucose
group were henceforth designated as “rat physiological” and abbreviated as “RP”. Basal RP
medium substrate components were determined as approximately 0.12 mM for pyruvate194-196,
0.6 mM for L-glutamine, 0.25 mM for L-glutamate, and 5.0 mM for glucose54.

2.1.3 Acrolein Treatment
Acrolein (90 % w/v acrolein with 0.3 % w/v hydroquinone in sterile ddH2O) and pure
hydroquinone were purchased from Sigma-Aldrich. Acrolein was diluted in either low-serum
differentiation DMEM or TCA/glycolytic substrate medium immediately prior to use. Controls
received a similar dilution of freshly prepared hydroquinone (0.3 % w/v stock solution in sterile
ddH2O water) in order to adjust for hydroquinone stabilizer (0.25-0.35 % w/v). Unless otherwise
stated, cells were exposed to concentrations of acrolein ranging from 0.5 to 250 µM for thirty
minutes, after which the complete medium volume was aspirated and replaced with acroleindeficient medium (Washout) or protocol specific buffers/reagents.
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Table 1: DMEM Composition and TCA Substrate and Glucose Supplementation

Low-Serum
DMEM

Glutamate 1.0 mM

Glutamine 5.0 mM

Pyruvate 2.5 mM

Pyruvate 1.0 mM

Glucose 10 mM

α-Keto-glutarate
5.0 mM

Minerals/amino
acids/vitamins
FBS
Penicillinstreptomycin
d-Glucose
Pyruvate
L-Glutamine
L-Glutamate
α-Ketoglutarate

Glucose-Deficient

Rat Physiological

Medium Designation

5.0 mM
0.12 mM
0.6 mM
0.25 mM
5.0 mM

25 mM
1.0 mM
2.0 mM
-

See Appendix 2: Dulbecco’s Modified Eagle’s Medium
1.0 % v/v Fetal Bovine Serum
100 I.U./mL Penicillin, 100 (µg/mL) Streptomycin
5.0 mM
0.12 mM
0.6 mM
0.25 mM
-*

1.0 mM
0.12 mM
0.6 mM
0.25 mM
-*

10 mM
0.12 mM
0.6 mM
0.25 mM
-*

5.0 mM
1.0 mM
0.6 mM
0.25 mM
-*

5.0 mM
2.5 mM
0.6 mM
0.25 mM
-*

5.0 mM
0.12 mM
5.0 mM
0.25 mM
-*

5.0 mM
0.12 mM
0.6 mM
1.0 mM
-*

*α-Ketoglutarate is not a typical constituent of DMEM, nor found in significant quantities (< 0.1 mM in human serum)205. At
the selected concentration of 5.0 mM, α-ketoglutarate was subsequently found to interact with MTT reactivity, as described
below. Therefore, media composites do not contain basal concentrations of α-ketoglutarate.

2.2 Endpoint Analysis and Quantitation

2.2.1 Unbound Acrolein Determination
All reagents utilized for derivatization and protein precipitation were purchased from Fisher
(Pittsburg, PA). Unbound acrolein concentration determination was performed in accordance
with Baumann and colleagues 21. Low serum DMEM (DMEM + 1 % FBS) supplemented with
acrolein or hydroquinone was combined with one volume equivalent of derivatization solution
containing 6 mg/mL m-aminophenol and 6 mg/mL hydroxylamine HCl in 1 MCl, and boiled for
30 minutes at 95 °C protected from light. Thereafter, samples were vortexed briefly and allowed
to come to room temperature for 10 minutes. Upon cooling, 200 µL of derivatized sample were
abstracted and sequentially combined with 0.4 volume ice-cold 2 % w/v ZnSO4 (Fisher) in
ddH2O, 0.4 volume room temperature saturated barium hydroxide in ddH2O, and 0.2 volume icecold hydrochloric acid; insoluble protein and barium sulfate complexes were cleared by
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centrifugation (16,000 x g; 5 minutes; room temperature) followed by supernatant recovery.
Finally, sample supernatants were assayed for fluorescence (Emission λ 328/40; Excitation λ
528/20) in microplate format using the Synergy HT fluorescent microplate reader (BioTek;
Winooski, VT) integrated with the KC4 data acquisition software (BioTek). Known
concentrations of acrolein were diluted in medium to serve as calibration standards in calculating
sample acrolein concentrations.

2.2.2 MTT Metabolism and Cell Viability
The reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to
an insoluble blue formazan salt was first described by Mosmann206, and will serve as a measure
of metabolism and viability. While the exact composition and partition of metabolic system(s)
responsible for MTT reduction remains elusive

207

, the proportional reduction of MTT to

formazan as a function of viable cells confers the method’s value to assessing both viability and
general cell metabolic capacity. The MTT reagent is prepared by solubilizing pure MTT powder
(Sigma-Aldrich) in 1X D-PBS to a concentration of 5 mg/mL; non-solubilized MTT powder was
removed by sedimentation. Solubilized MTT reagent may be stored for up to one year in aliquots
frozen at -20°C, when protected from light.
H9c2 cells were passaged, and diluted in order to seed 96-well microplate(s) at 5,000
cells/well for samples; a simultaneous standard curve of varying H9c2 cell densities (0 cells to
7,500 cells per well) was established in order to assess for viability in preparation for
differentiation up to the point of treatment. Thereupon, the medium was completely aspirated
and replaced with 100 µL of acrolein-containing or vehicle (Hydroquinone-containing) medium
for 30 minutes, followed with or without a washout period in respective acrolein- and

32

hydroquinone-deficient medium. In trials without a washout period, MTT reduction was initiated
directly after treatment. In trials with a washout period, each well was aspirated of acroleincontaining medium, washed with 150 µL D-PBS, and replaced with respective medium for 2
hours. Viability assessment was performed by incubating cells in 100 µL of a 1:9 MTT
reagent:respective acrolein-deficient medium for 2.5-3 hours at 37 °C. Formazan crystal
development was checked via brightfield microscopy to ensure assay compliance. If sufficiently
developed, wells were completely aspirated of medium and dried via inversion, followed by
solubilization of formazan crystals in 100 µL DMSO (Fisher). Thereafter, homogenization was
ensured via gentle mixing for ten minutes and quantified at 570 nm using a microplate
spectrophotometer.

2.2.3 Poly(ADP-ribose) Polymerase Activity
H9c2 cells were maintained and subdivided as described above. After passaging, H9c2
cells were seeded at 80,000 cells per well in 12-well tissue culture-treated plates and allowed 48
hours for attachment prior to differentiation. On the day of treatment, 25 µM dilutions of acrolein
or hydroquinone controls in RP medium were made to accommodate a 800 µL per well treatment
volume. After 5 or 15 minutes of exposure (See Results), wells was aspirated of medium, washed
with 1,000 µL of ice-cold 1X D-PBS, and lysed in 100 µL of PARP lysis buffer containing; 50
mM Tris-HCl (pH 8.0; Fisher), 1.0 % Triton X-100 (Sigma-Aldrich), 400 mM NaCl, 2 mM
MgCl2 (Fisher), 100 ng/µL BSA (Pierce; Rockford, IL), 1 mM D-l-1,4-dithiothreitol (Fisher).
Lysed cells were incubated for 25 minutes on ice. Thereafter, the total volume lysate was moved
into sterile 0.6 mL microcentrifuge tubes, from which a 5 µL sample was removed and combined
with 45 µL 0.9 % (w/v) saline in order to quantify total protein via the Bradford method208.
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96-well high-binding microplates (Perkin Elmer; Waltham, MA) used for PARP activity
detection were prepared in-house. Microplates were coated with 25 µg of fraction V histones
(MP Biologicals; Santa Ana, CA) in a bicarbonate/carbonate buffer (pH = 10.5) per well, and
allowed to attach overnight at 4 °C. The following day, wells were washed twice with 1X
Dulbecco’s modified phosphate buffer saline (Without calcium or magnesium) supplemented
with 0.05 % v/v Tween-20 (D-PBSTw; Fisher), followed by two washes with 1X D-PBS without
Tween-20. Wells were then blocked overnight at 4 °C with a 3 % w/v solution of bovine serum
albumin composed of 3 parts pre-made 10 % BSA blocking solution (Pierce) and seven parts 1X
D-PBS without calcium or magnesium.
On the day of PARP activity detection, the blocking solution was dispensed from wells
via inversion, followed by gentle tapping on Kim-Wipe, and washed twice each with D-PBSTw
and D-PBS consecutively. An eight-point calibration curve composed of purified high-specific
activity PARP enzyme (Trevigen, Gaithersburg, MD) from 10 mU to 5 U per well in a buffer
containing 50 mM Tris, 10 mM MgCl2, 100 µg/mL bovine serum albumin, 0.1 % Triton-X100,
pH adjusted with HCl to 8.00, allowed quantification of samples. 25 µL of whole-cell lysate or
PARP activity standard were plated per well in triplicates, to which an equal volume of the
reaction buffer containing 50 mM Tris, 10 mM MgCl2, 100 µg/mL, 0.1 % Triton-X100, 4 ng/µL
sheared herring sperm DNA (Promega; Madison, WI), 4 mM biotinylated NAD+ (Trevigen), pH
8.00, was added, followed by a two hour incubation at room temperature. Wells were then
washed thrice with each D-PBSTw and cleared with three washes D-PBS. Stock streptavidinconjugated horseradish peroxidase (Pierce) was diluted to 25 ng/mL in a D-PBSTw buffer
containing 100 µg/mL bovine serum albumin immediately prior to completion of washes. After
completion of washes, 100 µL of diluted streptavidin-conjugated horseradish peroxidase were
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added per well, and incubated for 1 hour at room temperature. Wells were again washed and
cleared in D-PBSTw and D-PBS trice, respectively, prior to addition of 50 µL of Turbo-3,3',5,5'tetramethylbenzidine ELISA solution (Pierce) per well and incubation for 25 minutes at room
temperature protected from light. The reaction was stopped with 75 µL of 0.2M HCl and read on
microplate reader (µQuant; BioTek) at 450 nm with data acquisition using the KC Junior
software platform (BioTek). Results are expressed as control-normalized PARP activity derived
from PARP activity per µg whole-cell lysate.

2.2.4 Mitochondrial Membrane Potential
JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetramethylbentimidazolylcarbocyanine iodide) dye
use as a fluorometric probe to monitor mitochondrial potential was described by Lan Bo Chen
and colleagues209. JC-1 is a delocalized lipophilic cation that distributes within the
mitochondrion and forms aggregates in a voltage potential-dependent manner. Because potential
measures can be performed on a ratiometric basis of the J-aggregate to the monomer, potential
measurement remains independent of the individual mitochondrion’s size, shape, or density.
Evidence suggests that neither rhodamine 123 nor DiOC6(3) are sensitive markers of
mitochondria membrane potential changes, especially under apoptosis or mitochondrial
uncoupling210. The monomeric dye form has an emission maximum of ≈526 nm. The dye, at
higher concentrations or potential, forms red fluorescent J-aggregates with an emission
maximum at 590 nm (Table 2).
JC-1 powder (Adipogene; San Diego, CA) was solubilized in anhydrous neat DMSO to a
concentration of 10 mM immediately prior to experimentation, and stored in aliquots at -20°C
until use. Immediately prior to labeling, a working solution of 20 µM JC-1 labeling solution was
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prepared in low-serum DMEM. The incubation medium was combined with an equal volume of
JC-1 labeling solution for 15 minutes at 37 °C; as a positive control of ΔΨm dissipation, a
solution containing 200 µM carbonyl cyanide m-chlorophenyl hydrazine (CCCP; SigmaAldrich) was combined in equal parts with the 20 µM JC-1 labeling solution (Final CCCP
concentration 100 µM). For qualitative measurements, cells were cultured and differentiated on
coverslips. After preparation of labeling reagents and CCCP, slides were incubated with the
labeling solution after copious washing with D-PBS as noted above. Thereafter, coverslips were
washed with cell culture medium lacking JC-1, and mounted in an aqueous medium for
fluorescent microscopy.

Table 2. JC-1 Label Parameters
Dye Form

Excitation
Maximum (nm)

Emission
Maximum (nm)

Filter Seta

Monomeric JC-1 Dye

514

529

FITC

J-aggregate form of JC-1

≈485-585

≈590

Cy5

a

Alternative filter set: Both monomer and aggregate can be viewed simultaneously with a standard LP
fluorescein filter set.

For quantitative analysis of ΔΨm, CCCP and JC-1 were prepared as above; however,
H9c2 cells were plated at 10,000 cells/well prior to differentiation. On the day of examination,
wells were aspirated completely of medium and promptly replaced with 200 µL of D-PBS
containing calcium and magnesium. 150 µL of D-PBS was then aspirated, and 50 µL of 2X JC-1
labeling solution added, followed by a 15-minute incubation at 37 °C. Each well was then
washed with 150 µL culture medium twice, ensuring wells retained 50 µL medium to avoid
drying out. The final wash was aspirated leaving 50 µL, to which and equal volume of 2X
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hydroquinone-only (Controls) or 2X acrolein (50 µM)-supplemented medium. With co-exposure
to small molecules, acrolein- or hydroquinone-supplemented treatment media were
supplemented with either 2X small molecule (200 µM olaparib; 10 µM CTZ, 10 mM EGTA) or
respective small molecule vehicle prior to incubation at 37 °C. At one, two, and four hours posttreatment, cells were analyzed for J-aggregates and monomers with the Synergy HT microplate
reader with filter sets composed of two narrow-band filters: J-aggregate fluorometric
measurements (Ex/Em 535/20 nm and 590/35 nm) and JC-1 monomers (Ex/Em 485/20 nm and
528/20 nm). Results are presented as the ratio of J-aggregate-to-monomer fluorescence
normalized against the respective time-matched controls.
Olaparib and CTZ were purchased from APExBio (Houston, TX) and EGTA was
purchased from Sigma-Aldrich. Stock solutions of olaparib and CTZ were made by solubilizing
in sterile DMSO, while EGTA was solubilized in sterile ddH2O with pH adjustment to 7.4 using
NaOH.

2.2.5 Calcium Conductance
Fluo-4AM incorporates the more intense fluorescein fluorophore, which operates at
visible wavelengths resulting in decreased cellular autofluorescence than UV excitation
fluorophores. All long-wavelength Ca2+ indicators use Ca2+ coupling chelation to inhibit
intramolecular fluoroquenching via electron transfer, resulting in emission intensity changes with
negligible excitation/emission shifts. Acetoxymethyl ester conjugation of the calcium
fluorophore indicator, while increasing permeabilization and specific intracellular localization,
decreases dye solubility. Pluronic F-127 allows for homogenous dispersion of large ester-
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containing molecule dyes which subsequently increases fluorescent amplitude and a more rapid
esterase hydrolysis211,212.
A stock 2.5 mM solution of Fluo-4AM (Molecular Probes; Waltham, MA) in sterile
DMSO (ATCC) was prepared and stored in aliquots at -20 °C. Immediately prior to use, Fluo4AM in DMSO was combined in an equal volume of 20 % Pluronic F-127 (Pierce), and
subsequently diluted to 5 µM in D-PBS containing calcium and magnesium. Cells were loaded
with Fluo-4AM for 30 minutes, and then be cleared of Fluo-4AM-containing D-PBS with
triplicate washes with 1X D-PBS, and allowed to de-esterify for 30 minutes at 37 °C prior to
treatment with acrolein in RP medium. For qualitative assessment, the cells were washed with
1X PBS, inverted upon two pieces of paraffin, sealed with melted VALAP, and imaged live. In
order to determine the origin of calcium influx, dosing media contained either CTZ (5 µM)113 or
EGTA (20 mM) to determine the role of extracellular calcium influx.
For quantitative measures, cells were exposed analogously to those described above,
except cells were plated in 96-well microplates at 10,000 cells/well prior to Fluo-4AM
assessment. Directly after Fluo-4AM de-esterification and subsequent treatment, cells were
assessed quantitatively every thirty seconds, for a total of thirty minutes using the Synergy HT
fluorescent microplate reader with excitation/emission filters 485/20 nm and 528/20 nm,
respectively. In quantitating each well, the lowest RFU value served as the respective blank,
followed by normalization against small-molecule exposed cells devoid of acrolein at each
respective time point; quantitated as a percent of maximal response for which the ionomycin
control served as the 100 % response; and normalized against vehicle-only containing
hydroquinone-exposed cells.
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2.3 Equipment

2.3.1 H9c2 Cardiomyoblast Culturing
H9c2 cells were maintained under standard culture conditions in the FormaTM Series II
3010 water-jacketed CO2 incubator (Thermo Fisher; Waltham, MA) with a pressure-regulated
(15 psig) CO2 supply. Ambient conditions of standard culture conditions included a humidified
37 °C, 5 % CO2/95 % atmosphere (Standard culturing conditions). For culturing under reduced
oxygen conditions (Physiologically relevant), cells were incubated in the FormaTM Series II 3030
water-jacketed oxygen-controlled CO2 incubator, linked to a pressure regulated (15 psig)
nitrogen (99.99 % pure; Airgas) tank and to a similarly regulated (15 psig) CO2 tank. The
ambient conditions for H9c2 maintenance was a humidified 5 %/5 % oxygen/CO2 balance
nitrogen 37°C atmosphere, and verified using the Traceable® Digital Oxygen Meter system
(Control Company; Friendswood, TX). The oxygen content under standard culture conditions
was verified at 20.1 ± 0.1 % using the Traceable® Digital Oxygen Meter system. Similarly, the
oxygen tension of the acrylic exposure chamber described in Table 3 and Appendix 3 was
measured and verified at 5 % during complex procedures in real-time in order to allow oxygen
concentration modulation via nitrogen purging when necessary to maintain the desired 5 %
oxygen atmosphere.
Prior to execution of procedures in the acrylic exposure chamber, the main chamber was
purged with nitrogen to offset atmospheric oxygen. However, since the ante-chamber provided
the only access to the main chamber when passing cells/materials between the main chamber and
the maintenance incubator, the oxygen concentration displacement in the main chamber with air
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trapped within the ante-chamber required quantification. Given the parameters estimated, a
rudimentary estimation of percent oxygen offset of the main chamber upon item passage, and

Table 3. Acrylic Exposure Chamber Parameters

Main Chamber**
Ante-chamber
Main Chamber
Less Antechamber**
Total Controlled
Volume†

Width

Depth

Height

89.54 cm

60.33 cm

44.45 cm

Approximate Percent Controlled
Volume
Volume*
240,100 cm3
3

-

20.32 cm

20.32 cm

15.24 cm

6,300 cm

2.6 %

-

-

-

235,800 cm3

97.4 %

-

-

-

242,100 cm3

100 %

*Control Volume pertains to the volume enclosed within the main chamber or ante-chamber.
**The Main Chamber measurements include those of the core height, width, depth measurements. Since the
ante-chamber protrudes into the main chamber (Approximately 4,300 cm3), no associated Percent Controlled
Volume was attributed to this measurement. Thus, the estimated volume of the main chamber considering the
ante-chamber displacement is exacted by subtracting the protruding ante-chamber from the core main chamber
volume, denoted by Main Chamber Less Ante-chamber.
† Sum of Main Chamber Less Ante-chamber and Ante-chamber.

subsequent ante-chamber atmosphere introduction into the main chamber, may be summarized
by the following equation:

%𝑂!!   𝑂𝑓𝑓𝑠𝑒𝑡 = ( %𝑂!! ∗ 𝑉! + %𝑂!! ∗ 𝑉! ) − %𝑂!!
Where:
%O2C

=

Initial Main Chamber O2 Percent

VC

=

Percent volume of Main Chamber

%O2A

=

Initial Ante-chamber O2 Percent

VA

=

Percent volume of Ante-chamber
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Assuming ante-chamber oxygen percent as 20.9-21.0 % typical of standard oxygen percent at sea
level, and the ideal main chamber oxygen percent during testing as 5.0 %, the theoretical oxygen
percent offset is equal to 0.4 %. Validity of the theoretical offset oxygen percent was assessed by
an experimental derivation of this parameter prior to experimentation. Additionally, the oxygen
infiltration rate (Oxygen retention decay) into the main chamber, expressed as percent oxygen
increased per hour, required experimental derivation, in order to assess whether long-duration
procedures (> 1 hour) could be performed without maintenance purging. Experiments measuring
ambient oxygen concentration were performed utilizing the using the Traceable® Digital
Oxygen Meter.

2.3.2 Spectroscopy
For

all

UV/Visible

spectrophotometric

quantification,

the

BioTek

µQuant

spectrophotometer with 96-well carrier was utilized. Similarly, the KCJunior data reduction
software was utilized in order to interface with the µQuant. For methods not requiring tissue
culture-treated plates (Bradford protein quantification and acrolein concentration determination),
high binding Grainger 96-well plates or, for the PARP activity assay, 96-well high binding
microplates were used. For fluorescent spectroscopy, the BioTek Synergy HT interfaced with the
KC4 data reduction software was utilized. The Synergy HT is affixed with eight individual
narrow bandwidth filters: four excitation and four emission filters. The excitation filters are as
follows: 360/40 nm, 485/20 nm, 530/25 nm, and 590/20 nm. The emission filters are as follows:
460/40 nm, 528/20 nm, 590/35 nm, and 645/40 nm. The appropriate combination of excitation
and emission filter sets was selected based on the specific wavelengths required for each
respective fluorescence application.
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2.3.3 Microscopy
A combination of brightfield and fluorescent microscopy was utilized in the completion
of this project. For brightfield microscopy, a Leitz Labovert FS (Leica; Wetzler, Deutschland)
inverted microscope was utilized, supporting a 6V, 20W Xenon lamp housing. The microscope is
affixed with the following objectives: Leitz Wetzlar 4X/0.12NA 160/- (519759); Leitz Wetzlar
10X/0.25NA EF L Phaco 1a 160/-; and Leitz Wetzlar 20X/0.30NA EF L Phaco 1a 160/-. The
Leitz Labovert FS inverted microscope was used for tasks within routine culture and cell
isolation counting.
For fluorescent microscopy, a Leitz LaborLux S (Leica) affixed with the 3-λ Ploemopak
fluorescent microscopy tube (Factor 1X) and the Leitz Wetzlar Type 307-148.002 mercury arc
lamp housing. A LEPLTD # 990002 50W Arc Lamp HBO AC power supply provides power to
the Osram 50W HBO mercury arc lamp (L2 voltage group; 34-39V/1.45A) for fluorophore
excitation. The LaborLux S is fitted with the following objectives: Leitz Wetzlar 10X/0.25NA
PLAN 160/-; Leitz Wetzlar 25X/0.50NA Phaco 2 EF 160/0.17; Leitz Wetzlar 40X/0.65NA
Phaco 2 EF 160/0.17; and Leitz Wetzlar 100X/1.25NA Phaco 3 EF 160/0.17. Supplied with the
3-λ Ploemopak, the following filter cube assemblies allow illumination of fluorophores (Table
4).

2.4 Statistical Analyses
All estimates were reported as the arithmetic mean. Except where noted, all uncertainty
measures correspond to the respective standard error of the mean. Statistical analyses were
performed using SPSS version 22 (IBM Corporation; Armonk, NY) and R version 3.3.1 (R
Foundation for Statistical Computing; Wien, Österreich) software platforms. Prior to statistical
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Table 4. Filter Sets for LaborLux S Microscope Affixed with 3-λ Ploemopak Binocular Incident
Light Fluorescence Illuminator

Filter Set Cube ID

λexcitation
(nm)

Dichroic
Mirror

Suppression
Filter
Filter Set† Dyes

A/DAPI

1582

340-380

400

425 LP

DAPI

Hoechst 33342

I3

513719

450-490

510

515 LP

FITC

Fluo-4, JC-1

N2

513609

515-560

580 LP

590 LP

Cy5

JC-1

†General equivalency to associated cube.

analyses, pertinent assumptions for parametric statistical comparisons were made regarding
normality about the mean, using the Shapiro-Wilk’s test213, and for homogeneity of distribution
variance, using the Levene’s equivalence of variance (Homoscedasticity) test
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. When both

statistical assumptions were valid, parametric tests were performed, e.g., one-way ANOVA
coupled with Student’s t-test comparisons. Otherwise, equivalent Mann-Whitney U tests under
the violation of parametric distribution assumptions, e.g., heteroscedasticity of variance and/or
non-normality, were performed. Significance was assumed to be based on the statistical
difference of arithmetic mean scores, and must meet a probability of observation difference level
less than 0.05, i.e., 5 %. Similarly, non-normality and heteroscedasticity were presumed when a
statistical difference less than 5 % (p < 0.05) was observed for individual Shapiro-Wilk’s or
Levene’s tests, respectively.
For acrolein-dependent IC50 value derivations across substrate-enriched media, the
statistical program R version 3.3.1 (R Foundation for Statistical Computing; Wien, Österreich)
with the statistical Package “drc”215 was utilized for distribution-specific estimate derivations.
Initially, a model selection algorithm was performed in order to characterize curve parameters of
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the acrolein concentration-response in H9c2 cells among curve parameters accepted within the
toxicological literature, e.g., Log-linear, Weibull, etc., based on residual error minimization and
Akaike information criterion (AIC) maximization for final IC50 derivation and associated
standard error estimates. In order to make comparisons viable, the distribution type, for which
residual error was most adequately explained for both oxygen tension cultures simultaneously,
was selected for estimate modeling; where necessary, single substrate groups were modeled
independently using the three-parameter Weibull distribution parameters when standard error
estimates were returned as “N/A”, denoting residua were infinitely large or zero. Thereafter,
statistical comparisons of substrate-specific IC50 values were performed in R via a Student’s ttest or Mann-Whitney U test.
The Ki value derivation for 3-aminobenzamide competitive inhibition of PARP was also
performed utilizing the “drc” Package in R version 3.3.1. Given the simple system and
competitive binding, the three-parameter log-logistic distribution was pre-selected for parameter
estimation. Results of Ki estimation are presented in Appendix 4.
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CHAPTER THREE:
RESULTS

3.1 Method Validation
Prior to data generation, validation of specific methods must be attained in order to
demonstrate analyte representation and applicability for the model system. Firstly, analyte
specificity with respect to acrolein determination must be ensured. The spectrophotometric
absorption signature of the derivatization product, 7-hydroxyquinoline, must be demonstrated, as
well as assurance of precise acrolein quantitation within a dynamic range. Further, the oxygen
concentration infiltration rate into the constructed acrylic exposure chamber must be performed
in order to determine whether retention and stability of reduced oxygen conditions will suffice
for routine maintenance procedures and for in vitro treatment regimens. Since the MTT assay is
not routinely performed in differentiated H9c2 cultures, the method must be validated for use
within this model under the experimental parameters. Finally, detection and quantitation of
intracellular calcium conductance, as well as qualitative assessment of ΔΨm, must be validated in
the differentiated H9c2 model prior to quantitative measurement and analysis with respect to
acrolein treatment and proposed intervention strategies.

3.1.1 Acrolein Determination and Decay in Aqueous Medium
In order to ensure repeatable exposure metrics with respect to acrolein concentrations, the
time-dependent decay rate in low serum medium establishment was imperative to minimize
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inter-trial heterogeneity, should decay outpace treatment preparation. Prior to temporal acrolein
decay determination, the fluorometric derivatization of acrolein to 7-hydroxyquinoline described
by Alarcon20 using 3-aminophenol in the presence of hydroxylamine must be validated in the
current system, and the limit of detection/quantification determined. The method by Alarcon was
modified in order to account for measurement in low-serum DMEM and for protein precipitation
via zinc sulfate/saturated barium hydroxide as per Baumann and colleagues21. Additionally,
protein concentration of low-serum medium was quantified to demonstrate the efficacy of
protein precipitation via the chosen method and to resolve heterogeneities in acrolein degradation
trends with respect to initial acrolein concentrations.
Protein quantitation of low-serum DMEM revealed an approximate concentration of
1,600 ng/µL (SD: 320 ng/µL) as reported by the BCA protein quantification method; protein
precipitation via the zinc sulfate-barium hydroxide method resulted in removal of 63 % as
reported by the BCA method; incubations with zinc sulfate exceeding 30 seconds on ice did not
produce higher efficacy in protein removal (Data not shown). Protein precipitation by this
method was presumed to remove 63 % of protein, despite ≥ 90 % removal efficiency among
standards containing 2,000 ng/µL purified bovine serum albumin containing used for calibration
curve composition.
Methodological validation for acrolein determination was established for the instrument
system available in our laboratory based on the recommendations outlined in the 1996
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for
Human Use (ICH) Validation of Analytical Procedures: Methodology216. In order to assure
specificity of derivatization, a spectral scan of the resultant derivatized acrolein in D-PBS (pH
7.4) was performed and matched to those described in Alarcon20. Spectral signatures taken
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demonstrate an absorption maximum between 344-352 nm, with a lesser secondary peak
centered about 303-305 nm (Figure 2); this absorption pattern is consistent with the results
published by Alacron20 with respect to acrolein derivatization at pH 7.0, denoting successful
derivatization of acrolein to 7-hydroxyquinoline in the current system. The magnitude of the
peak decreased with decreasing initial acrolein concentrations (A à G) as expected for
transmission spectroscopic measurements.

A

B
C
D

E-G

Figure 2. Spectral Scan of Derivatized Acrolein. D-PBS was spiked with seven concentrations of acrolein, in
addition to a vehicle-only blank, prior to derivatization with 3-aminophenol in the presence of hydroxylamine HCl.
Thereafter, 200 µL of derivatized solution were dispensed per well of a 96-well microplate and scanned from 300450 nm at 2 nm increments using the µQuant spectrophotometer. The resultant scans are blanked from the D-PBSonly vehicle, and presented above with the following designations: A) 100 µM; B) 50 µM; C) 25 µM; D) 12.5 µM;
E-G) in order: 6.25 µM, 3.125 µM, and 1.5623 µM (These three concentrations proved BDL in later testing, and
were combined in designation here for clarity). The blank, D-PBS only sample is designated as the 0.000 OD
horizontal axis. Each scan is composed of data from a single well.

Approximate linearity was shown up to the highest concentration of 250 µM along a
seven-point standard curve (Figure 3). Blanked RFU fluorescence was highly correlated with
acrolein concentration (R = 0.9998) with an equally high coefficient of determination (R2 =
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0.9997). To confirm hydroquinone contained within the stock solution did not apparently
interfere with the acrolein-associated fluorescent signal, a separate test was performed whereby
LS medium was spiked with a high concentration of hydroquinone above the analogous 250 µM
acrolein dilution. At such a high concentration, hydroquinone did not produce a detectable
fluorescent signal different than the low-serum DMEM blank (Data not shown), indicating

Blanked Fluorescence (RFU)

adjustment for hydroquinone content was not necessary.
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Figure 3. Representative Acrolein Quantification Calibration Curve. Low-serum DMEM was spiked with 250 µM
of acrolein, and diluted serially prior to derivatization by 3 mg/mL 3-aminophenol in the presence of 3 mg/mL
hydroxylamine HCl at 95 °C for 30 minutes. The standards were then deproteinated with 9.8 % w/v ice-cold zinc
sulfate octahydrate, followed by barium hydroxide saturation to promote precipitation. Precipitates were removed by
centrifugation at 16,000 x g for 5 minutes at room temperature. Samples from the supernatant were plated in 96-well
assay plates, and quantified using the Synergy HT microplate reader via fluorescent capture using an excitation and
emission filter set of 328/40 and 528/20, respectively. Each point consists of duplicate technical replicates with
associated SD denoted by error bars (Too small to see visually).

The limit of detection and quantification for acrolein determination was established based
on the standard deviation and slope of the response method aggregated across four independent
0-100 µM calibration curves for the purposes of LOD/LOQ derivations, as not all curves
produced linearity up to 250 µM as clearly as presented in Figure 3. The detection limit was
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determined as 3.3-fold the ratio of the standard deviation of the y-intercept and slope of the
response derived from the calibration curve regression function.

𝐿𝑂𝐷 =   

3.3 ∗ 𝜎!!!"#$%&$'#
𝑆𝑙𝑜𝑝𝑒

The limit of quantitation was derived analogously to the LOD, except the multiplier of the
standard deviation of the y-intercept and slope of the response was 10:

𝐿𝑂𝑄 =   

10 ∗ 𝜎!!!"#$%&$'#
𝑆𝑙𝑜𝑝𝑒

Aggregated from four calibration curves, the LOD and LOQ of fluorometric acrolein
determination via the derivatization method by Alarcon for our system were established as 2.2 ±
0.4 µM and 6.7 ± 1.2 µM (Mean ± SD), respectively. Validation of the LOD was performed
during temporal acrolein decay measurements with a battery of low-serum DMEM samples
supplemented with an initial acrolein concentration of 6.25 µM. Over the course of eight hours
(Three independent trials), reduction in acrolein concentration medium samples initially spiked
with 6.25 µM was not well-correlated with respect to time (Pearson Correlation Coefficient =
67.2 %) and concentration determinations were greater than the initial acrolein measurement at
time zero, i.e., > 100 % initial, denoting high uncertainty in resolute acrolein concentration
measurement below the derived LOQ. Therefore, the LOQ determination as 6.7 µM was
presumed the valid LOQ for the system available, and values at or below 6.7 µM were
henceforth denoted as below the limit of quantitation (≤ LOQ) for presentation purposes. For
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samples below this value, for which numeric incorporation to quantitative data would be
required, the replacement value was quantified as the LOQ divided by the square root of two.
Over the course of 24 hours, seven time-points spanning from 30 minutes to 24 hours,
including the baseline time zero, were selected for determining the rate of acrolein decay in lowserum medium. Initial testing included measures only up to 8 hours, as acrolein in aqueous
medium was expected to decay rapidly; later experimental protocols integrated an additional
time-point measure to include 24-hour sampling. Therefore, only few measures were taken at the
24-hour time point (n =3); the results are summarized in the table below (Table 5). With respect
to time, acrolein concentration did reduce incrementally up to 24 hours and demonstrated a slight
dependency of decay magnitude on the initial acrolein concentration, i.e., depletion was
inversely correlated with initial concentration, though this trend was not statistically significant
(F2,6 = 4.135; p = 0.074). Incidentally, the most rapid decay occurred within the first 30 minutes,
after which the rate of decay decelerated. While degradations to 81-85 % of initial concentrations
within 30 minutes were observed, the decay fraction did not differ with respect to the initial
concentration; measures to 4 hours after addition to low-serum medium between low-serum
media containing differing initial concentrations were not different (F2,6 = 0.090; p = 0.915),
denoting that resultant MTT reduction results after a 30-minute acute exposure should not be
substantially confounded by differential decay across the proposed concentrations in low-serum
DMEM below. At 24 hours, the remaining fraction of acrolein was 56.7 ± 3.8 %, 45.9 ± 1.8 %,
and 41.0 ± 5.4 % for the initial concentrations of 250 µM, 50 µM, and 25 µM, respectively. The
half-life in low-serum DMEM was greater than 8 hours, and greater than 24 hours at the high
initial acrolein concentration of 250 µM. No values fell on or below the limit of quantitation
during testing.
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Table 5. Time-dependent Acrolein Degradation In Low-serum Medium at 20 °C
Initial
Acrolein
250 µM
50 µM
25 µM

Acrolein
Remaining

0.5 Hour

1 Hour

2 Hours

215.6 ± 7.7 µM 197.7 ± 9.6 µM

4 Hours

8 Hours

24 Hours
147.4 ± 8.8 µM

250 µM

210.3 ± 12.5 µM

168.4 ± 10.9 µM

148.8 ± 13.3 µM

100.0 %

84.1 ± 5.0 %

86.2 ± 3.1 %

79.1 ± 3.8 %

67.4 ± 4.4 %

59.5 ± 5.3 %

56.7 ± 3.8 %

50 µM
100.0 %

42.4 ± 2.5 µM
84.8 ± 5.0 %

42.3 ± 2.1 µM
84.5 ± 4.3 %

41.2 ± 2.6 µM
82.5 ± 5.2 %

31.2 ± 1.2 µM
62.5 ± 2.4 %

29.9 ± 1.2 µM
59.7 ± 2.4 %

25.9 ± 3.0 µM
45.9 ± 1.8 %

25 µM

20.3 ± 1.4 µM

19.3 ± 1.1 µM

18.6 ± 1.9 µM

15.3 ± 4.6 µM

13 ± 1.3 µM

12.3 ± 2.2 µM

100.0 %

81.2 ± 5.7 %

77.3 ± 4.3 %

74.2 ± 7.8 %

61.1 ± 18.4 %

51.9 ± 5.2 %

41.0 ± 5.4 %

Each data point is composed of 3-5 replicates, depending on the time-point. Values are mean and percent remaining with
associated SEM.

3.1.2 Acrylic Exposure Chamber Validation
Exposure chamber purge with 99.99 % pure nitrogen resulted in a reduction of internal
oxygen concentration to 5.4 %, as the tank utilized was depleted in the process of purging. For
the purposes of initial validation, the baseline oxygen concentration was established at 5.4 % for
the retention decay with respect to time. Simultaneously, chamber temperature was recorded
using the Traceable® Digital Oxygen Meter which has a built-in temperature probe. Oxygen
measurements for the initial 3.5 hours demonstrated complete retention of established oxygen
(5.4 %) over this time (Figure 4), suggesting insignificant diffusion of oxygen into the main
chamber through the environment interface seals. At time point 3 hours 40 minutes, the
internally-facing ante-chamber door was opened, and then re-sealed to allow ambient air trapped
within the ante-chamber to infiltrate and equilibrate with that of the main chamber; oxygen
concentration measurements at time point 3 hours 50 minutes revealed an expected increase in
oxygen concentration, which stabilized at 5.7 % - an increase of 0.3 % from the 5.4 % pre-antechamber opening. Therefore, the experimentally-derived oxygen concentration offset was
determined to be 0.3 % when the main chamber was mixed with one volume of ambient air
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Figure 4. Acrylic Exposure Chamber Oxygen Retention Over Time. Initial validation of oxygen concentration
retention over time was performed by purging the main chamber with nitrogen to a final concentration of 5.4 %
mol/mol; real-time recordings of oxygen were taken via hand-held oximeter placed within the chamber and reported
over 99.5 hours post-purging (Red Diamonds with Point-to-point Line). Simultaneously, the oximeter also reported
ambient temperature and are presented here (Black Circles). Opening of the ante-chamber door leading into the main
chamber resulted in an expected increase in main chamber oxygen concentration, as denoted above, after which a
steady increase over time was observed.

(20.9-21.0 % oxygen-containing) contained within the ante-chamber, as opposed to the
theoretical value of 0.4 % calculated using the %O2C Offset equation presented above (See
Methods). Repeated measurements resumed over 99.5 hours at sporadic intervals to determine
the long-term low-oxygen concentration retention capacity and rate of decay. As seen in Figure
4, internal main chamber oxygen concentration increased approximately linearly over the
duration of measurement with a final measurement of 9.8 % approaching 100 hours. Regressing
the function of reported oxygen concentration against time beginning at the 3 hours and 50
minute time point (The time-point measurement after ante-chamber opening and internal oxygen
concentration stabilization), the rate of low-oxygen retention decay with respect to time was
estimated to be 0.045 % per hour (R2 = 0.9847). These results denote adequate retention of a
low-oxygen environment during the 1-4 hours required to complete medium changes, microplate
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seeding, acrolein treatment, and MTT viability testing. Continuous, real-time oxygen
measurements were taken during testing, as maintenance purging was required during
procedures, particularly when samples and materials were passed through the ante-chamber at
regular intervals during the testing period in order to ensure oxygen concentrations close to 5.0
% (Tolerance ± 0.5 %).

3.1.3 MTT Reduction Assay
In order to assess cellular viability using the MTT formazan reduction method developed
by Mosman206, the predictive power of the MTT assay in measuring the endpoint of interest must
be validated for experimental conditions. Each set of seeded cells intended for acrolein treatment
and metabolism/viability measurement was accompanied by an 8-point standard curve of known
cell seeding densities plated in triplicate. As presented (Figure 4), the plating procedure results in
a stable estimator of cells per well, even after the five-day differentiation period. While most
investigations normalize treatment samples against the control proportionally with optical
density, the presented quantification method allows derivation of sample cell counts over a
range, which, for our system, departs from linearity above 2,500 cells per well. As such,
measurements of minor cytotoxic insults resulting in low-magnitude alterations in MTT
reduction metabolic competency would be underestimated should a two-point linear
extrapolation be performed. These results denote the validity of utilizing the initial plating
seeding method as a valid methodological approach for assessing number of MTT reducingmetabolically competent cells per well for the differentiated H9c2 cardiomyoblast cell line, and
the use of a polynomial-derived regression function for quantification of cells over the range of
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Figure 5. Representative Standard Curve of MTT Reduction Assay. H9c2 cells cultured under standard conditions
were subdivided, counted via hemocytometer, and plated in a tissue culture-treated 96-well microplate at specified
cell densities. On day two, cells were differentiated for five days as mentioned Methods section, prior to exposure to
MTT tetrazolium salt for 3 hours at 37 °C under standard cell culture conditions. Thereafter, medium was aspirated
and well allowed to dry for 10 minutes. Thereafter, 100 µL DMSO were dispensed per well and mixed for 10
minutes prior to absorbance reading on µQuant spectrophotometer.

0-7,500 cells per well provides higher fidelity in ascertaining low-magnitude toxicity in our
system. With measurements of the 24-hour post-treatment washout period groups, an eight-point
standard calibration curve was derived with a maximum of 8,000 cells per well. The resultant
calibration curve was similar as presented above (Data not shown).

3.1.4 Intracellular Calcium Conductance
In validating the method Fluo-4 staining, differentiated H92c cells were exposed to 20
mM EGTA or 5 µM ionomycin – a well known intracellular calcium modulatory ionophore
(Figure 6). As expected, ionomycin induced a rapid increase in Fluo-4 fluorescence associated
with ionophore-mediated intracellular calcium influx; individual time points were blanked from
fluorescent signals of EGTA-exposed (Baseline) wells. Generally, differentiated H9c2 cultures
under standard oxygen conditions tended to result in higher peak fluorescence. Furthermore, 25
µM acrolein did not alter substantially the fluorescent signal magnitude or time-to-peak reported
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Figure 6. Baseline Adjusted Calcium/Fluo-4 Complex Fluorescence in the presence of Ionomycin. After a 30minute Fluo-4AM loading time, and equivalent de-esterification period, differentiated H9c2 cells cultured at either 5
% or 20.1 % oxygen were exposed to 5 µM ionomycin either in the presence (Treatment; Blue Diamonds) or
absence (Control; Black Diamonds) of 25 µM acrolein, and quantitated every thirty seconds for a period of thirty
minutes using the Synergy HT microplate reader pre-heated to 37 °C; the filter set utilized consisted of
excitation/emission spectra of 485/20 nm and 528/20 nm, respectively. Each point along the curve corresponds to
the mean baseline-adjusted RFU of triplicate technical replicates per trial over four independent trials with SEM
denoted by error bars.

by Fluo-4. Within the initial 90 seconds of fluorometric readings, a consistent, rapid reduction in
RFU was observed, followed by a nadir; this nadir was presumed the baseline for ionomycin
measurements. The results presented in Figure 6 do not include a 60-second delay in
fluorometric reading after exposure to ionomycin which includes the physical period between
exposure and initiation of microplate reading; the results here merely demonstrate the positive
control as a proxy of assay validation irrespective of time-to-efficacious calcium transient
induction. Results from calcium transient due to acrolein below include a 60-second delay in
order to align PARP-activity increases temporally with calcium transient data. As presented with
the ionomycin-exposed wells, the initial 90 seconds, corresponding to time-points 60-150
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seconds in acrolein-exposed samples, of initial calcium fluorometric readings were reported, but
disregarded for mechanistic purposes due to the erroneous readings consistently resultant of this
initial time period.

3.1.5 Mitochondrial Membrane Potential
In qualitatively validating JC-1 labeling for measurements of ΔΨm, H9c2 cells were
plated on poly-l-lysine-coated coverslips, and differentiated as described previously under
standard culture conditions. Thereafter, the H9c2 cells were washed with D-PBS and labeled for
10 minutes with 20 µM JC-1 at 37 °C prior to treatment with 100 µM CCCP or CCCP vehicle
(DMSO) in D-PBS in preparation for live fluorescent microscopy (Figure 7). Vehicle controls
demonstrate strong punctate fluorescence associated with J-aggregate signaling, whilst diffuse,
low-level JC-1 monomer fluorescence was observed. Cells exposed to CCCP showed an absence
of J-aggregate fluorescent signaling, and consistent monomer signals.
Extension of the JC-1 staining duration to 15 minutes enhanced the intensity of Jaggregate signal (Figure 8), while the monomer signal remained relatively constant (Not shown).
Therefore, subsequent quantitative analyses were executed with a 15-minute labeling period,
rather than the initial 10-minute labeling procedure. Of note, since image capture within the
system in the current investigation was not processed via software, a typical exposure balance,
which reduces the “background noise” associated with subsequent isolation of the signal of
interest, was not available; thus, the images contain a certain level of non-specific background.

3.2 Endpoint Analyses and Quantitation
Proxies of both cell metabolism (2-hour washout period) and cellular viability (24-hour

56

Figure 7. JC-1 Visualization via Fluorescent Microscopy. H9c2 cells under standard culture were seeded on
coverslips, and differentiated prior to JC-1 labeling and exposure to 100 µM CCCP. Immediately after CCCP
addition and slide mount, H9c2 cells were visualized via fluorescent microscopy. Images were taken using a handheld cellular device through objective eyepiece. (Top) Control (Left) and 100 µM CCCP-exposed (Right) H9c2
cells labeled with JC-1 were visualized with the N2 filter cube which specifically detects JC-1 aggregates, indicating
polarized mitochondria. Cells on the left exhibit punctate monomer signals, indicating detectable polarization, which
is absent in the CCCP-exposed cells (Right). (Bottom) Control (Left) and 100 µM CCCP-exposed (Right) H9c2
cells labeled with JC-1 were visualized with the I3 filter cube that detects both JC-1 aggregates (Red) and JC-1
monomers (Green). Cells exposed to CCCP (Right) demonstrate diffuse green labeling with negligible monomer
detection, whist control cells (Left) demonstrate diffuse JC-1 monomer labeling, but with strong monomer signals.

Figure 8. J-aggregate Visualization Among Controls After Extended Staining. A second coverslip of H9c2 cells
was labeled with JC-1 for 15 minutes. J-aggregate signaling was starkly enhanced with the addition of 5 minutes.
The poor solubility of JC-1 in D-PBS is exemplified by the numerous fluorescent particulate flakes observed in the
image (Black Arrows); these were also observed visually without the facilitation of a microscope. Solubalization in
low-serum DMEM in preparation for quantitative analyses greatly reduced the amount of particulate flakes
observed.
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washout period) were assessed via the MTT reduction assay on all substrate groups. With
discovery of interference of the MTT assay with 5.0 mM α-ketoglutarate, this particular group
was assessed for metabolism via trypan blue exclusion, and subsequently eliminated from further
testing; exposure with acrolein in standard low-serum DMEM replaced the α-ketoglutarate
substrate group for further analyses.
After viability and metabolism assessments, mechanistic elucidation using small
molecules – olaparib (PARPi), CTZ (Non-specific TRPM2 inhibitor), and EGTA (Calcium
chelator) – was performed in order to assess their respective effects on determining their
respective impact on acrolein-induced MTT metabolism and cell viability. Furthermore, the
same small molecules were utilized in order to determine their effect on calcium transients and
reduction in ΔΨm due to acrolein exposure. In order to do so, the latter two phenomena were
assessed quantitatively using intracellular calcium- (Fluo-4) and mitochondrial membrane
potential-specific (JC-1) fluoroprobes.

3.2.1 Acrolein Treatment-Response on Cellular MTT Metabolism and Viability
3.2.1.1 TCA substrate- and glucose-supplemented media. The MTT reduction assay
was performed on acrolein-exposed differentiated H9c2 cells maintained under 20.1 % and 5 %
oxygen conditions for two differing time points: 2 and 24 hours post-treatment. The two time
points respectively provide a proxy of short-term metabolic competency under a restricted acute
response as well as a proxy of cellular viability. In order to ascertain the influence of TCA- and
glycolytic substrates on acrolein-induced insult, acrolein was diluted in substrate media
containing enriched, glucose, pyruvate, glutamine, or glutamate, except for one group which
was, compared to the physiological rat medium, deficient in glucose (1.0 mM). A group exposed
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to acrolein in low-serum DME medium was included to compare MTT reduction with respect to
a typical treatment conditions found within the literature using growth medium as the vehicle,
which contains enriched concentrations of glucose (25 mM), pyruvate (1.0 mM), and glutamine
(2.0 mM) that are beyond physiological concentrations encountered. Early trials including the
5.0 mM α-ketoglutarate group were included, but subsequently excluded from further testing,
due to the substrate interference with the MTT reduction assay; otherwise, all other substrate
group-bathed cells retained the capacity to metabolize MTT tetrazolium salt. Three
concentrations of acrolein selected for comparison across substrate media were: 1 µM, 25 µM,
and 250 µM, the highest of which provides a comparison group against all subsequent
mechanistic elucidation trials, e.g., assurance that the stock acrolein (90 %) utilized for testing
repeatedly reduces MTT reduction in the H9c2 cells. Failure to do so would indicate degradation
of acrolein or heterogeneity in acrolein dilution formulation. Expectedly, normalized MTT
reduction measures among all groups at two hours demonstrated pseudo-concentration-response
across acrolein concentrations, and similar patterns at 24 hours post-treatment were observed,
albeit with lowered MTT signaling among treatment groups. Assessment of MTT reduction
following a two-hour post-treatment washout period resulted in a consistent dose-dependent
response in differentiated H9c2 cardiomyoblasts, irrespective of culture oxygen conditions. Two
overarching caveats of were observed: 1) oxygen concentration consistently elevated MTT
metabolism among low-concentration exposure cells (1 µM acrolein) but insignificantly affected
acrolein IC50 among all substrate-medium supplemented groups, except in substrate media with
enriched pyruvate concentrations and 2) glucose supplementation likely modulated MTT
reduction estimates (Table 6 and Figure 9).
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Under standard culturing conditions (20.1 % oxygen), MTT metabolism was
concentration-dependently reduced among all substrate groups, even after exposure to 1 µM
acrolein for the brief 30-minute exposure time, though the magnitude depended upon the
substrate medium (Table 6). No statistical comparisons were to be made except those between
modeled IC50 values. As such, only descriptive statistics are presented. Among substrate groups
exposed to 1 µM compared to their respective controls, except for the RP medium group, MTT
reduction capacity was changed only minimally (≥ 89 % Controls). Cells exposed to acrolein in
RP medium metabolized MTT to 79 ± 5 % of respective controls. Pyruvate-enriched media
groups (1 mM and 2.5 mM pyruvate and the 1 mM pyruvate-containing low-serum DMEM) as
well as the 5.0 mM L-glutamine group consistently retained MTT metabolic reduction capacity
compared to the other substrate media groups at this treatment concentration. The media
containing 2.5 mM pyruvate resulted in a mean MTT reduction higher than its respective control
(102 ± 8 %). A similar pattern was observed H9c2 cells exposed to 25 µM. However, the only
groups for which substantial retention of MTT reduction after acrolein exposure was afforded
were the 1 mM (88 ± 8 %) and 2.5 mM (87 ± 8 %) pyruvate-enriched groups; all other substrate
media demonstrated MTT metabolism reductions to ≤ 78 % compared to their respective
controls. Paradoxically, the 1 mM pyruvate-containing low-serum medium provided
intermediate rescue (80 ± 6 %), and was more similar to the other non-pyruvate containing
substrate media. Increasing the treatment concentration of acrolein to 250 µM significantly
reduced the magnitude of MTT reduction among all substrate-supplemented groups. Since the
treatment group in RP medium would most closely recapitulate rat whole blood, further
comparisons of this group against the remaining substrate-containing treatment media groups
exemplified a lack of comparative rescue among any of the glucose-, glutamine-, and glutamate-

60

supplemented media, especially the glucose-deficient (1.0 mM) medium group. Among such
groups, normalized MTT reduction after acrolein exposure ranged from 32 ± 2 % (5.0 mM
glutamine) to 36 ± 3 % (RP Medium), with all others residing therein. The notable exceptions to
this trend were the pyruvate-containing media groups for which relative rescue by pyruvate
supplementation persisted even after this high-concentration exposure (53-58 % of respective
controls). 2.5 mM pyruvate (58 % of controls) did not provided additional benefit compared to
the 1.0 mM pyruvate-containing medium group. As with H9c2 cells exposed to 25 µM, the lowserum DMEM group analogously lacked attenuation of acrolein treatment-related reductions in
MTT metabolism; with an estimate (35 ± 2 %) similar to groups lacking enriched pyruvate
concentrations. Two trials with 5.0 mM α-KG were performed with negligible MTT formazan
reduction (No different than 0 c/well-containing blanks), possibly suggesting heightened
cytotoxic insult followed by complete cellular degeneration. Upon brightfield microscopy,
however, H9c2 cells did not overtly appear to exhibit a stressed morphology. Thereupon, later
acrolein treatment groups included trypan blue exclusion as the measure of viability.
When H9c2 cardiomyoblasts were acclimated to 5 % oxygen, similar acrolein-dependent
reductions in MTT metabolism was demonstrated (Table 6). However, stark differences in the
relative magnitude of partial rescue by pyruvate were observed compared to standard condition
cultures (20.1 % oxygen) and in normalized MTT metabolism when exposed to 1 µM acrolein.
Unexpectedly, consistent elevations in normalized MTT reduction measures (> 100 % Controls)
among the differentiated H9c2 cells when exposed to 1 µM acrolein were observed, even at 24
hours; analogous groups cultured under 20.1 % oxygen did not exhibit such an analogous re
sponse except for minor elevations among the 2.5 mM pyruvate group (102 ± 8 %) exposed to 1
µM acrolein. Increasing the acrolein concentration to 25 µM resulted in MTT reduction to < 90
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Table 6. MTT Reduction Two Hours Post-Acrolein Exposure

Substrate Group

Control
Low-Serum DMEM
Rat Physiological
1.0 mM d-Glucose
10 mM d-Glucose
1.0 mM Pyruvate
2.5 mM Pyruvate
5.0 mM L-Glutamine
1.0 mM L-Glutamate
5.0 mM α-Ketoglutarate*

Normalized MTT Reduction ± SEM (Percent Respective Control)
1 µM
25 µM
250 µM
5%
20.1 %
5%
20.1 %
5%
20.1 %
Oxygen
Oxygen
Oxygen
Oxygen
Oxygen
Oxygen
100 ± 0 %
100 ± 0 %
100 ± 0 %
100 ± 0 %
100 ± 0 %
100 ± 0 %
111 ± 3 %
99 ± 1 %
83 ± 3 %
80 ± 6 %
48 ± 4 %
35 ± 2 %
125 ± 10 %
79 ± 5 %
99 ± 6 %
75 ± 8 %
46 ± 3 %
36 ± 3 %
121 ± 7 %
91 ± 5 %
112 ± 8 %
78 ± 11 %
37 ± 2 %
35 ± 2 %
113 ± 10 %
89 ± 9 %
84 ± 10 %
77 ± 6 %
39 ± 5 %
37 ± 4 %
107 ± 8 %
96 ± 2 %
103 ± 10 %
88 ± 8 %
51 ± 2 %
53 ± 4 %
116 ± 6 %
102 ± 8 %
97 ± 4 %
87 ± 8 %
51 ± 3 %
58 ± 5 %
126 ± 7 %
96 ± 2 %
103 ± 8 %
78 ± 4 %
47 ± 1 %
32 ± 2 %
105 ± 12 %
89 ± 5 %
97 ± 5 %
76 ± 6 %
48 ± 5 %
34 ± 3 %
93 ± 2 %
95 ± 1 %
95 ± 2 %
94 ± 0 %
92 ± 2 %
89 ± 2 %

*One group was assessed via the trypan blue exclusion method, as cells exposed to α-ketoglutarate did not exhibit MTT
reduction capability. Therefore, α-ketoglutarate at 5 mM was presumed to interfere with the MTT assay.

% respective controls among two groups: 10 mM glucose-supplemented (84 ± 10 %) and the
low-serum DMEM substrate groups (83 ± 3 %); the remaining substrate groups metabolized
MTT ≥ 90 % compared to their respective controls. Interestingly, a strong inverse relationship in
MTT metabolism (Pearson’s correlation coefficient = 0.9997) was observed with respect to
medium glucose concentration. The 1 mM glucose group resulted in a MTT reduction capacity
(112 ± 8 %) substantially higher than the 10 mM glucose group (84 ± 10 %) with the RP medium
intermediary, though significance was not reached (Difference CI95: -2 - 57 %; p = 0.063). The
low-serum DMEM, containing 25 mM glucose, yielded a MTT reduction result (83 ± 3 %) quite
similar to that of the 10 mM glucose-supplemented group. Otherwise, no substantial differences
were observed among substrate groups, as well as compared to respective controls.
Acrolein-induced MTT metabolism reduction curves across substrate groups, and
respective oxygen-concentration- and substrate-specific IC50 values, were derived in order to
compare the effect (Curve displacement) of culturing oxygen conditions on between standard
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Figure 9. MTT Reduction Two Hours After Treatment by Substrate (Continued to Next Page). Differentiated
H9c2 cells were cultured and exposed under 5 (Striped Bars) or 20.1 % (Solid Bars) oxygen with three
concentrations of acrolein for thirty minutes, followed by a 1.5 hour washout period and subsequent MTT assay
initiation or trypan blue exclusion. Reductions in MTT metabolism were acrolein concentration-dependent across all
substrate media, except for the 5 mM α-ketoglutarate group among which viability was assessed by trypan blue
exclusion. All substrate groups were treated analogously, aside from the α-ketoglutarate group, and clustered within
individual charts merely for clarity. A) H9c2 cells were exposed to acrolein in RP medium, glucose deficient (1.0
mM), or glucose enriched (10 mM) DMEM. B) H9c2 cells were exposed to acrolein in RP medium supplemented
with 1.0 and 2.5 mM pyruvate. C) H9c2 cells were exposed to acrolein in RP medium supplemented with 5 mM
glutamine, 1 mM glutamate, and 5 mM α-ketoglutarate. Bars denoting controls were not included as all values were
normalized against the controls, and receive the designation 100 % without a measure of variance. As mentioned
within the text, no statistical analyses were performed with regards to these data directly. Measures are the average
of 3-6 individual experiments with associated SEM denoted by error bars.
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culturing (20.1 % oxygen) and physiologically relevant culturing conditions (5 % oxygen). For
MTT metabolism values above 100 %, such values were presumed “100 %” for the purposes of
IC50 modeling in order to accommodate precise modeling parameters. This assumption was valid
since 24-hour viability on such respective groups with ≥ 100 % MTT reduction values retained
MTT metabolic competence similar to respective control groups, indicating no functional
viability decreases (See 24-hour viability data below). Aside from curve estimations, brief
comparisons of acrolein concentration cross-sectional comparisons were made without statistical
inferences drawn.
Comparisons of modeled acrolein-induced MTT reduction IC50 values resulted in
consistent attenuation of MTT metabolism amongst H9c2 cells cultured under the lower oxygen
tension, three of which substantial shifts were observed. Only one substrate group reached
statistically significant difference between oxygen tensions (Table 7). Neither pyruvate-enriched
substrate group resulted in significant differences between oxygen conditions, likely imparted by
IC50 estimates above the highest tested acrolein concentration (250 µM); estimates were
thereupon denoted simply as “> 250 µM”. Lowered oxygen did substantially shift the toxicity
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curve of the low-serum DMEM group, elevating the IC50 to 1.8-fold higher than the respective
group at 20.1 % oxygen culture (217 ± 37 µM versus 120 ± 26 µM), but did not differ
significantly. Similar curve shifts were observed with the 5.0 mM glutamine group (223 ± 27 µM
versus 119 ± 25 µM; p = 0.011) and 1.0 mM glutamate group (> 250 ± 33 µM versus 147 ± 32
µM). An inverse relationship in MTT metabolism was observed with respect to medium glucose
concentration, with the highest glucose concentration-containing substrate medium (10 mM)
demonstrated the highest sensitivity to acrolein exposure among the 5 % oxygen cultured groups.
This trend was not consistent among 20.1 % oxygen cultures (202 ± 42 µM; fourth highest
estimate) where glucose deficiency was associated with the highest sensitivity of MTT
metabolism reduction. Enriched pyruvate groups cultured across both oxygen tension cultures

Table 7. Modeled Acrolein-induced MTT
Concentrations Two Hours Post-Exposure

Substrate Group
Low-Serum DMEM
Rat Physiological
1.0 mM d-Glucose
10 mM d-Glucose
1.0 mM Pyruvate
2.5 mM Pyruvate
5.0 mM L-Glutamine
1.0 mM L-Glutamate

Metabolism

Reduction

IC50

IC50 ± SEM (µM Acrolein)
5 % Oxygen†
20.1 % Oxygen†
217 ± 37 µM
120 ± 26 µM
218 ± 27 µM
220 ± 42 µM
192 ± 59 µM
145 ± 35 µM
165 ± 26 µM
202 ± 42 µM
> 250 ± 34 µMa
> 250 ± 84 µM
> 250 ± 31 µM
> 250 ± 159 µM
223 ± 27 µM*
119 ± 25 µM
> 250 ± 33 µM
147 ± 32 µM

†Each treatment dose-response curve was derived from 5+ (5 % Oxygen) or 4+ (20.1 % Oxygen)
independent trials per substrate group over three acrolein concentrations and respective substrate control.
a
Modeled IC50 estimates above 250 µM were designated as “> 250 µM”, the respective modeled SEMs
were reported here as conservative estimates of variance from extrapolation. Therefore, statistical
designations for values > 250 µM were presumed 250 µM, and respective confidence intervals were
established therefrom.
*p < 0.05 Compared to matched-substrate 20.1 % oxygen-cultured differentiated H9c2 cells.

conferred retention of MTT metabolism acutely after acrolein exposure. This becomes especially
pronounced among the 5 % oxygen group simply arising from the intrinsically reduced variance
among these modeled estimates compared to analogous estimates derived from 20.1 % oxygen
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cultures; higher concentrations of acrolein would likely enable more confident estimation for
such comparisons. The only substrate group, for which the 20.1 % oxygen modeled IC50 value
was higher than the respective 5 % oxygen group, was derived from H9c2 cells exposed in the 10
mM glucose substrate medium; however, this difference was not significant.
When the washout period was extended to 24 hours post-treatment, a proxy of viability is
presumed when subjecting the differentiated H9c2 cells to the MTT reduction assay. Acrolein
exposure did result in concentration-dependent reductions in cell viability for all substrate
groups, irrespective of oxygen culture conditions (Table 8 and Figure 10). For cells cultured
under 5 % oxygen exposed to low-concentration acrolein (1 µM), viability estimates for all
groups were equal or exceeded unexposed controls (≥ 100 % Respective Control) similarly to
cells assessed for MTT metabolism two-hours post acrolein exposure. Most H9c2 cell substrate
groups cultured under 20.1 % oxygen and exposed to the lowest acrolein concentration equaled
or exceeded non-treatment controls, though notable exceptions were the 2.5 mM pyruvate (88 ±
3 %), 5.0 mM glutamine (80 ± 8 %), and the 1.0 mM glutamate (75 ± 11 %) groups – all of
which were considerably lower than their respective controls. Only after 24-hours, this new
pattern of consistent MTT metabolism elevation compared to respective control was
demonstrated among 20.1 % oxygen cultures was in stark opposition to those assessed two hours
post-exposure. Among the highest treatment concentration (250 µM), all substrate groups
demonstrated substantial viability loss when cultured at 5 % oxygen (≥ 89 % viability loss) and
20.1 % oxygen (≥ 80 % viability loss). However, treatment of H9c2 cells with 25 µM acrolein
under 5 % oxygen reduced cell viability to ≤ 37 % of controls among most substrate groups;
groups with supra-physiological concentrations of pyruvate (≥ 1.0 mM) afforded substantial
retention of MTT reduction potential. For example, supplementation of RP medium with 1.0 mM
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and 2.5 mM pyruvate reduced viability loss to 88 ± 3 % and 87 ± 6 %, respectively, compared to
RP medium viability estimates of 28 ± 8 %. Low-serum medium did produce a rescue phenotype
analogously to simple pyruvate supplementation, though the viability estimate was intermediary
(75 ± 6 %) between pyruvate-supplemented and the RP medium. The same substrate groups did
not produce similar rescue among H9c2 cells cultured at 20.1 % oxygen, implicating the
requirement of lowered oxygen tension for mediation of pyruvate rescue in this model.

Table 8. Viability Twenty-four Hours Post-Acrolein Exposure

Substrate Group

Control
Low-Serum DMEM
Rat Physiological
1.0 mM d-Glucose
10 mM d-Glucose
1.0 mM Pyruvate
2.5 mM Pyruvate
5.0 mM L-Glutamine
1.0 mM L-Glutamate

Normalized Viability ± SEM (Percent Respective Control)*
1 µM
25 µM
250 µM
5%
20.1 %
5%
20.1 %
5%
20.1 %
Oxygen
Oxygen
Oxygen
Oxygen
Oxygen
Oxygen
100 ± 0 %
100 ± 0 %
100 ± 0 %
100 ± 0 %
100 ± 0 %
100 ± 0 %
102 ± 8 % 100 ± 12 %
75 ± 6 %
20 ± 5 %
6±2%
16 ± 3 %
127 ± 13 % 111 ± 13 %
24 ± 8 %
16 ± 5 %
4±2%
18 ± 5 %
112 ± 5 % 102 ± 11 %
28 ± 8 %
17 ± 4 %
11 ± 2 %
20 ± 6 %
129 ± 11 % 107 ± 14 %
28 ± 8 %
15 ± 2 %
5±2%
16 ± 5 %
107 ± 7 %
112 ± 9 %
88 ± 4 %
27 ± 4 %
2±1%
13 ± 3 %
100 ± 6 %
88 ± 3 %
87 ± 6 %
18 ± 3 %
7±2%
18 ± 4 %
110 ± 6 %
80 ± 8 %
37 ± 10 %
19 ± 4 %
8±2%
15 ± 4 %
115 ± 10 % 75 ± 11 %
28 ± 9 %
13 ± 4 %
6±2%
13 ± 4 %

*No statistical comparisons were made, but rather made upon derivation of modeled IC50 values. All samples were
normalized against their respective hydroquinone-only containing substrate medium.

Estimates of IC50 values across substrate groups affirmed a rescue phenotype bestowed
upon pyruvate-supplemented media groups as well as the low-serum DMEM group among cells
cultured under physiologically relevant oxygen tension compared to standard conditions (Table
9). While the modeled RP medium substrate group IC50 was 2 ± 12 µM using a three parameter
log-normal model curve for cells cultured under 20.1 % oxygen, supplementation of any of the
investigated TCA or glycolytic substrates did not protect H9c2 cell from acrolein-induced
cytotoxicity. All parameter estimates resulted in IC50 values between 2 and 7 µM, though the 1.0
mM pyruvate tended to be higher than the remaining groups (7 ± 2 µM). Reduced oxygen
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culturing shifted the estimated IC50 values for 1.0 mM and 2.5 mM pyruvate-supplemented
groups significantly to 60 ± 18 µM (CI95 Difference: 11-95 µM, p = 0.0186) and 74 ± 16 µM
(CI95 Difference: 23-121 µM; p < 0.0095), respectively. Similarly, acrolein exposure in lowserum DMEM resulted in a modeled IC50 of 51 ± 8 µM, which was significantly larger compared
to the analogous culture at 20.1 % oxygen (CI95 Difference: 30-68 µM; p = 0.0035). Comparison
of pyruvate-supplemented groups against the RP medium group confirmed that pyruvate alone
conferred the observed metabolic rescue under 5 % oxygen (p < 0.05 for both 1.0 and 2.5 mM
pyruvate groups compared to 5 % oxygen RP medium H9c2 cells exposed to acrolein); such
conclusions cannot be definitively assigned to the low-serum DMEM, given the heterogeneous
TCA/glycolytic substrate composition. Notwithstanding, low-serum medium and pyruvatesupplemented media provided substantial protection against acrolein treatment, attributable
primarily to substantial viability differences observed between oxygen cultures exposed to 25
µM acrolein.

Table 9. Modeled Acrolein-induced Viability IC50 Estimates Twenty-four Hours
Post-Exposure

Substrate Group
Low-Serum DMEM
Rat Physiological
1.0 mM d-Glucose
10 mM d-Glucose
1.0 mM Pyruvate
2.5 mM Pyruvate
5.0 mM L-Glutamine
1.0 mM L-Glutamate

5 % Oxygen†
51 ± 8 µM**
0.3 ± 1 µM
2 ± 7 µM
3 ± 8 µM
60 ± 18 µM*
74 ± 16 µM**
8 ± 9 µM
1 ± 2 µM

IC50 ± SEM (µM Acrolein)
20.1 % Oxygen†
2 ± 1 µM††
2 ± 12 µM
2 ± 6 µM
2 ± 5 µM
7 ± 2 µM
2 ± 14 µM
3 ± 1 µM
2 ± 2 µM

†Each treatment dose-response curve was derived from 5 (5 % Oxygen) or 6 (20.1 % Oxygen)
independent trials per substrate group over three acrolein concentrations and respective substrate control.
Fixing the upper asymptote of the regression curve for the 20.1 % oxygen provided an optimal reduction
in model residua.
††SEM for low-serum DMEM derived from 4-parameter Weibull Type 2 model, as convergence of the
three-parameter log-normal model reported "N/A" as SEM estimate.
*p < 0.05; **p < 0.01 Compared to 20.1 % Oxygen-cultured Differentiated H9c2 Cells.
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Composition of a six-point dose-response curve for differentiated H9c2 cardiomyoblasts
cultured under 5 % oxygen demonstrated an expected sigmoidal response across exposure
concentrations of 1 to 250 µM (Figure 11). Judging from the dose-response curve produced, the
modeled IC50 value for the RP medium group perceptively overestimates the IC50 value (0.3 ± 1
µM) compared to the apparent value suggested by the dose-response curve (≈16 µM). The
certainty of this notion, however, remains tentative as the 5 and 10 µM values were derived from
trials consisting of a batch of fetal bovine serum, which significantly altered baseline toxicity in
H9c2 cells cultured under the same oxygen conditions (See Discussion). As such, the estimates
for these two points may, indeed, be themselves overestimated, corresponding in a biased
estimate of the IC50 value to a value higher than the three-parameter log-normal modeled value.
Irrespective of the difference for the RP medium group, interpretation of estimated IC50 values
attributed to other substrate-containing media is not expected, as the standard error for the
remaining substrate media tended to be larger in magnitude, thus, controlling for discrepancies
among the remaining estimates.
3.2.1.2 Pyruvate supplementation and medium acrolein. To ascertain whether rescue
via pyruvate supplementation was attributable to an antioxidant effect through interference with
free medium acrolein, acrolein concentration determination in pyruvate-supplemented medium
was performed and compared against similar tests in RP medium over 24 hours. In order to
maximize the likelihood of detecting interference of free acrolein with pyruvate, the highest
pyruvate supplementation concentration, 2.5 mM, was chosen. At this concentration, pyruvate
supplementation was determined to cause no alteration with free acrolein at 24 hours (Table 10).
As the percentage of remaining free acrolein in medium was not altered by the initial acrolein
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Figure 10. Viability Twenty-four Hours After Treatment by Substrate (Continued to Next Page). Differentiated
H9c2 cells were cultured and exposed under 5 (Striped Bars) or 20.1 % (Solid Bars) with three concentrations of
acrolein for thirty minutes, followed by a 23.5-hour washout period and subsequent MTT assay initiation.
Reductions in viability were acrolein concentration-dependent across all substrate media groups. All substrate
groups were treated analogously and clustered within individual charts merely for clarity. A) H9c2 cells were
exposed to acrolein in RP medium, glucose deficient (1.0 mM), or glucose enriched (10 mM) DMEM. B) H9c2 cells
were exposed to acrolein in RP medium supplemented with 1.0 and 2.5 mM pyruvate. C) H9c2 cells were exposed
to acrolein in RP medium supplemented with 5 mM glutamine or 1 mM glutamate. Bars denoting controls were not
included as all values were normalized against the controls, and receive the designation 100 % without a measure of
variance. As mentioned within the text, no statistical analyses were performed with regards to these data directly.
Measures are the average of 3-6 individual experiments with associated SEM denoted by error bars.
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Figure 11. Log-transformed Dose-response Curve. H9c2 cells cultured, differentiated, and exposed under 5 %
oxygen were exposed to a range of acrolein concentrations between 1 and 250 µM, and assessed for viability via
MTT reduction after 24 hours; an accompanying control (Zero acrolein) has been incorporated, and falls on the yaxis. The resultant viability estimates were plotted against the log-transformed acrolein concentration, and a
smoothed line fitted point-to-point. Each estimate is the average of four-five individual trials with associated SEM
denoted by error bars.

concentration among the RP medium and pyruvate-supplemented medium measures over time
when paring media spiked with 25, 50, and 250 µM acrolein, further tests were carried out
utilizing the 250 µM initial concentration to avoid samples below the limit of quantification. In
doing so, no differences were detected in free acrolein 30 minutes after addition to pyruvate71

supplemented medium compared to RP medium (p > 0.05); this time point remains most
pertinent as experimentation for viability estimates were assessed after a 30-minute acrolein
exposure period after which replacement with acrolein-deficient medium ensured the initial
concentration within that 30-minute period attributed to the viability loss assessed after the
washout period. Contrarily, free acrolein was consistently higher in pyruvate-enriched medium
compared to RP medium at both time points, though this difference was not significant and may
be simply attributable to the higher variance among pyruvate-supplemented medium acrolein
measures. Therefore, the shift in IC50 in differentiated H9c2 cells observed by the pyruvatesupplemented substrate groups, 1.0 mM and 2.5 mM, cannot be attributed to simple acrolein
quenching by medium pyruvate.

Table 10. Acrolein Degradation in Two Substrate Media

Initial
Concentration
250 µM
50 µM
25 µM

Substrate Group
Rat Physiological
(+) 2.5 mM Pyruvate
30 Minutes
24 Hours
30 Minutes
24 Hours
234.6 ± 6.5 µM 154.8 ± 9.3 µM
230.5 ± 17.1 µM
160.5 ± 13.9 µM
N.D.*
27.2 ± 0.7 µM
N.D.*
29.9 ± 2.1 µM
N.D.*
13.1 ± 0.1 µM
N.D.*
15.4 ± 1.1 µM

*N.D. = Not Determined. Initial tests included 30-minute and 24-hour measures on the 250 µM concentration only, which
were found to be show no statistical difference between media. Therefore, only 24-hour tests were performed at
concentrations lower than 250 µM.

3.2.1.3 Low-serum DMEM viability assessment. Since treatment in in vitro testing is
regularly conducted where the standard growth culture medium or low-serum medium becomes
the toxicant vehicle, viability assessment of cells exposed to 25 µM acrolein in low-serum
DMEM had been singled out for concentration-based statistical testing. By exposing
differentiated H9c2 cardiomyoblasts in low-serum medium under standard culturing conditions,
a significantly altered cytotoxic profile was clearly evident, whereby culturing under 5 % oxygen
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conferred attenuation of cytotoxicity (75 ± 6 % versus 20 ± 5 %; CI95 Difference: 37-72 %; p <
0.001; Figure 12). While no differences were detected at 24 hours among the lowest (1 µM) or
highest (250 µM) concentration groups between the two oxygen cultures, intermediary
concentrations would likely yield implicit viability data requisite for fully characterizing acrolein
sensitivity differences between the two oxygen conditions.

Viability
(Control-normalized)

100%

†
80%

n=5

60%
40%

***
n =6

20%
0%

5.0% Oxygen

20.1% Oxygen

Figure 12. Viability in Low-serum DMEM After 25 µM Acrolein Exposure. H9c2 cells cultured and exposed
under 5 (Striped Bars) or 20.1 % (Solid Bars) oxygen were exposed to 25 µM acrolein (Blue Bars) in standard lowserum (1 % v/v) DMEM for 30 minutes, followed by a 24 hour post-treatment washout period. H9c2 cells were then
assessed for viability via MTT reduction and normalized against respective controls (Black Bars). After 24-hours,
significant rescue was observed among exposed cells cultured and exposed under 5 % oxygen compared to 20.1 %
oxygen cultures. Bars represent average of noted independent experiments with SEM denoted by error bars. ***p <
0.001 compared to 5 % oxygen cultures exposed to 25 µM acrolein. †p < 0.05 compared to unexposed controls.

3.2.2 Mechanistic Characterization of Acrolein-induced Cytotoxicity
Briefly, elucidation of the mechanistic contribution of calcium transients and
involvement of poly(ADP-ribose) polymerase, the current investigation primarily focused of the
mechanistic underpinnings of a single concentration of acrolein – 25 µM, with only few trials
containing acrolein supplemented at lesser or greater concentrations. Initially, rescue with three
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small molecules was pursued to implicate the contribution of extracellular calcium in
determining cell fate; the impact of PARP activation in determining or exacerbating cell death;
and the contribution of clotrimazole-sensitive calcium transients, i.e., through the TRPM2
channel. PARP activation shortly after acrolein exposure was confirmed by quantitative
measurement of in whole-cell lysates. Subsequently, calcium influx within the cytosol was
confirmed in acrolein-exposed H9c2 cells cultured under standard culture conditions by
quantitative fluorescent measurements using Fluo-4AM; results were not conclusive for cells
cultured at 5 % oxygen, but suggested a lack of cytosolic calcium influx. Lastly, insignificant
ΔΨm reductions were observed at four-hours post-exposure, affirming low-magnitude disruption
of ΔΨm. During the course of experimentation a single batch of FBS was depleted, thus requiring
acquisition of another to continue testing; results of baseline viability estimates at a fixed 25 µM
acrolein concentration exemplified differential sensitivity to acrolein cytotoxicity between the
two FBS batches, though only cells cultured under 5 % oxygen were affected.
3.2.2.1 Modulation of cytotoxicity with small molecules. In order to elucidate the
comparative effect of extracellular calcium reduction in acrolein-induced cytotoxicity among
differentiated H9c2 cardiomyoblasts, concomitant graded supplementation of the calcium
chelator EGTA (1 and 5 mM) in the presence of 25 µM acrolein offered indirect evidence of
extracellular calcium in modulating cytotoxicity. For reasons discussed below, results were
obtained only for H9c2 cells cultured under 5 % oxygen.
For differentiated H9c2 cells exposed to 25 µM acrolein in RP medium for 30 minutes,
cell viability was reduced to 26 ± 3 % of respective controls, which was consistent with the
results from substrate-specific viability assessments above. Upon addition of 1 mM EGTA, nonsignificant elevations in viability were observed (41 ± 3 % of Respective Control, p > 0.05),
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while further rescue was attained with supplementation of 5 mM EGTA (56 ± 6 %; p < 0.01;
Figure 13). Graded concentrations of olaparib (10 and 100 µM) did not confer significant
attenuation to acrolein-related viability loss, as neither concentration group elevated H9c2
viability (28 ± 4 % and 37 ± 4 %, respectively) compared to the vehicle-only containing acrolein
exposure group. Nonetheless, attenuation was dose-dependent with respect to olaparib
concentration despite insignificant differences compared to controls. Efficacy of the 100 µM
olaparib group was still of lesser magnitude compared to 1 mM EGTA; however, further
olaparib concentrations, e.g., 200 or 400 µM, were not assessed, as these values were not within
the initial concentration ceiling determined at the onset (100 µM). Therefore, EGTA proved
more efficacious in attenuating viability loss than did olaparib, despite extreme olaparib
concentrations utilized in this investigation.
To examine whether CTZ-sensitive calcium stores associated with extracellular cation
influx are implicated in determining cell fate, differentiated H9c2 cells were exposed to graded
CTZ concentrations (5 and 10 µM) concomitant with exposure to 25 µM acrolein. After the 30minute exposure to 25 µM acrolein in the presence of graded CTZ followed by a 24-hour
washout, viability estimates for vehicle-containing acrolein-exposed cells demonstrated
substantially differing baseline viability estimates (≈60 ± 4 %) compared to previous trials (≈26
± 3 %); other exposure groups paired with other small molecule groups, 10 mM EGTA and 100
µM olaparib, demonstrated a similar shift in baseline viability (n = 4). Further replication of the
experiment five more times on newly-revitalized H9c2 cardiomyoblasts confirmed the
phenomenon of significantly alterations in baseline toxicity, denoting a consistent, significantlyaltered viability baseline 2.2-fold higher than that of previous trials (p < 0.001). In total, nine
replicates were included in the assessment of acrolein cytotoxicity among cultures under 5 %
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Figure 13. Small Molecule Rescue of Acrolein-induced Viability Reduction. Differentiated H9c2 cardiomyoblasts
cultured under 5 % (Striped Bars) were exposed to 25 µM acrolein (Blue Bars) were supplemented with graded
concentrations of EGTA or olaparib to examine their respective effects on viability reduction. Values derived are the
respective vehicle-normalized average of three or four independent trials with associated SEMs denoted by error
bars. Statistical comparisons were made only between small molecule-supplemented cells and their respective
treatment-only cells. N.S. Not Significant compared to respective vehicle-controlled, treatment groups. **p < 0.01
compared to respective acrolein treatment-only cells.

oxygen. Cultures exposed to acrolein analogously, but cultured under 20.1 % did not exhibit a
significantly altered viability baseline between media consisting of batch 1 (17 ± 4 %) and batch
2 (7 ± 1 %; CI95 Difference: 0-20 %; p = 0.05) FBS, denoting an inconsistency not in exposure
metrics or culturing conditions, but rather a fundamental change likely within the composite
medium. Of note, the two batches were also procured from another vendor (Batch 1: ATCC; Lot
62848232; Batch 2: Sigma-Aldrich; Lot 16A164). Therefore, the results of the latter viability
assessments for mechanistic elucidation could not be aggregated with the previous results
presented in Figure 13, and are, for the purposes of mechanistic elucidation, are considered
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independent. Results are presented in Figure 14. Given the altered cytotoxic baseline, no results
were derived for 20.1 % cultures analogous to those presented in Figure 13.
Exposure of differentiated H9c2 cardiomyoblasts resulted in an approximately 10-fold
higher viability estimate among 5 % oxygen cultured cells (60 ± 4 %) versus 20.1 % oxygen
cultured cells (6 ± 1 %; p < 0.001). Concomitant exposure of cells with CTZ (5 or 10 µM), 10
mM EGTA, or 100 µM olaparib in the presence of 25 µM acrolein did not translate to increases
in viability among hyperoxic (20.1 % Oxygen) cultures, though the 100 µM olaparib group
neared significance (p = 0.072). Conversely, rescue was afforded among some of the small
molecule-supplemented groups cultures and exposed at 5 % oxygen (F3,27 = 5.031; p = 0.007).
Though neither concentration of CTZ resulted in a significant reduction of viability loss, the 5
µM CTZ group tended to reduce cytotoxicity among the differentiated H9c2 cells compared to
acrolein-only exposed cells; doubling the CTZ concentration to 10 µM, paradoxically, not only
did not confer increased rescue, but actually completely negated the insignificant rescue afforded
by the 5 µM CTZ co-exposure, reducing the viability estimates equivalent to those of exposed
vehicle-containing H9c2 cells (60 ± 3 % versus 60 ± 4 % of acrolein-only vehicle-controlled
cells). H9c2 cells supplemented were significantly rescued by either 10 mM EGTA (78 ± 4 %; p
< 0.01) or 100 µM olaparib (86 ± 5 %; p < 0.01) when exposed to acrolein. Paradoxically, 100
µM olaparib rescued cells more efficaciously than EGTA, though the increased EGTA (10 mM
versus previous trials with 5 mM) may have actually impeded rescue in a manner similar to that
of the 10 µM CTZ. Nonetheless, it is prudent to note that EGTA conferred significant cell
rescue, irrespective of baseline cytotoxicity. This was not the case for olaparib, which exhibited
limited attenuation of large-magnitude cytotoxic acrolein-induced injury, but significant
attenuation at lower-magnitude injury within the same system.
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Figure 14. Small Molecule Rescue of Acrolein-induced Viability Reduction – Shifted Baseline. Differentiated
H9c2 cardiomyoblasts cultured under 5 % (Striped Bars) and 20.1 % oxygen (Solid Bars) exposed to 25 µM acrolein
(Blue Bars) were supplemented with 10 mM EGTA, 5 or 10 µM CTZ, or 100 µM olaparib to examine their
respective effects on viability reduction from acrolein exposure. Values derived are the respective vehiclenormalized average of five (20.1 % oxygen) or nine (5 % oxygen) independent trials with associated SEMs denoted
by error bars. Statistical comparisons were made only between small molecule-supplemented cells and their
respective treatment-only cells denoted formally as (+). N.S. Not Significant compared to respective vehiclecontrolled, treatment groups. **p < 0.01 compared to respective acrolein-exposed cells. †p < 0.05; †††p < 0.001
compared to respective vehicle-only unexposed controls.

With respect to interference in viability explicitly due to either small molecule or
respective vehicle, it is expected that neither EGTA nor olaparib deleteriously affected the
viability of differentiated H9c2 cardiomyoblasts under the current culture and exposure
conditions presented here. Neither small molecule produced significant reductions in viability, as
viability estimates neither differed compared to their respective, vehicle-only controls (With
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DMSO at respective dilutions carrying olaparib or CTZ or with water carrying EGTA) nor
exacerbated viability reductions among cells exposed to acrolein concentrations below the
threshold of toxicosis, e.g., 5 µM (Olaparib or EGTA, only – CTZ was not assessed during this
battery of experimentation). Only with differentiated cells cultured under 5 % oxygen did either
vehicle or inhibitor significantly confound the dose-response of acrolein at 10 µM – a
concentration that was not extensively pursued in testing. The baseline viability estimate after
treatment with 10 µM acrolein among EGTA-vehicle exposed cells resulted in viability loss to
78 ± 5 % respective controls, and was consistently different than DMSO-containing treatment
groups exposed to the same concentration of acrolein: Olaparib-vehicle 93 ± 4 %; 5 µM CTZvehicle 95 ± 5 %; and 10 µM CTZ-vehicle 91 ± 3 %. DMSO itself only slightly interfered with
the magnitude of acrolein cytotoxicity, either directly or indirectly – a phenomenon not observed
among other acrolein treatment concentration groups (1, 5, or 25-250 µM), and biased viability
to higher estimates compared to the water-only containing EGTA vehicle controls. With respect
to EGTA supplementation, differentiated H9c2 cardiomyoblasts exposed to acrolein at 10 µM in
the presence of 10 mM EGTA significantly attenuated viability (97 ± 4 %) compared to vehiclecontaining acrolein-exposed H9c2 cells (p < 0.01).
3.2.2.2 Poly(ADP-ribose) polymerase activity. Since several compounds, including
MNNG and hydrogen peroxide, have been shown to significantly activate PARP, little evidence
exists with respect to acrolein-induced cytotoxic injury. Therefore, the current investigation
aimed to confirm PARP activation in the differentiated H9c2 cell model under the current system
to supply indirect evidence the rescue afforded by olaparib co-exposure with acrolein is
associated with PARP activity stimulation by acrolein itself. Indeed, exposure of differentiated
H9c2 cultured under 5 % oxygen to 25 µM acrolein for 5 and 15 minutes resulted in elevated,
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time-dependent increases in PARP activity among acrolein-exposed H9c2 cells compared to
time-matched controls (Figure 15). Even at 5 minutes post-treatment, PARP activity was
increased by 20 ± 15 %, though not significantly different than controls (CI95 Of difference: 92148 % of Respective Controls). At 15 minutes, PARP activity was further elevated in whole-cell
lysate preparations to 45 ± 12 % (CI95: 21-69 %; p < 0.05) higher than time-matched controls.

Normalized PARP Activity
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Figure 15. PARP Activity in Whole-cell Lysate Preparations. H9c2 cells cultured and differentiated under 5 %
oxygen were exposed to 25 µM acrolein (Blue Bars) or hydroquinone (Black Bars; Controls) for the designated time
period, after which the treatment-containing RP medium was cleared, cells washed, and then lysed in a PARP
stabilizing lysis buffer. Whole-cell lysates were analyzed for PARP activity to which the activity (In International
Units/well) was converted to Units/µg lysate based on protein concentration derived from the Bradford assay prior
to normalization against control for comparisons. Bars represent average of 4-5 trials with SEM denoted by error
bars. *p < 0.05 compared to time-matched control.

Therefore, acrolein acutely activates the catalytic activity of PARP in the differentiated
H9c2 cardiomyoblast system under physiologically relevant oxygen tensions. Although PARP
was indeed activated by acrolein, olaparib resulted in differential rescue potential under similar
treatment conditions, but was confounded substantially by the magnitude of cytotoxic injury. At
high-magnitude cytotoxic injury, viability was positively correlated with PARPi concentration
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(R = 99.3 %) beginning with negligible viability increases at 10 µM (28 ± 4 %). Though the
source of this discrepancy was not obliquely apparent, a change in FBS source did coincide with
the alteration in baseline toxicity, revealing a coincidental shift in olaparib rescue potential.
Since PARP activation was observed in this model, the modulatory effect of PARPi comparative
to cytotoxic injury magnitude presents a complex interaction between small molecule inhibitor
concentration and cell rescue potential.
3.2.2.3 Calcium conductance. As calcium is implicated in exacerbating toxicosis,
especially under oxidative stress, the modulatory effect of calcium chelation on cellular viability
was investigated. At high-concentration acrolein exposure, viability of differentiated H9c2 cells
cultured under 5 % oxygen was significantly reduced to 27 % of respective controls. In the
presence of EGTA, viability reduction was attenuated in a concentration-dependent manner at 5
mM EGTA (56 ± 5 %), with minimal rescue at 1 mM (45 ± 5 %). A higher concentration of
EGTA, 10 mM, was investigated but interpretation of viability rescue along the three
concentrations utilized remains convoluted due to the change in baseline toxicity among
differentiated H9c2 cells exposed to acrolein in RP medium. Nonetheless, even 10 mM of EGTA
significantly rescued cells. Therefore, extracellular calcium plausibly alters acrolein-induced
viability response in H9c2 cells. To further characterize such an interaction, direct measure of
intracellular calcium was performed using a cell-permeable Fluo-4 fluorescent indicator.
Differentiated H9c2 cells were exposed to acrolein immediately prior to fluorometric
analysis for intracellular calcium using the cell-permeable version of the fluoroprobe Fluo-4AM.
Among cells cultured under 20.1 % oxygen exposed to 25 µM acrolein, significant fluorescent
signaling was observed beginning at approximately 300 seconds (≈5 minutes) after acrolein
exposure, and returned to control levels at 500 seconds (8.3 minutes) (Figure 16). Consistent
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calcium elevations became significant at 390 and 450 seconds compared to unexposed controls;
significance was not reached at the 420-second peak, primarily due to the high observed point
estimate variability. Following, fluorometric measurements among exposed cells decayed to
control levels for subsequent time points until the final measurement at 540 seconds. These
results coincide with the insignificant elevations in PARP activity at five minutes (300 seconds),
though intracellular calcium transients decay prior to the sustained PARP activity observed at 15
minutes (900 seconds). As previously mentioned, the initial 150 seconds produce unstable
readings; therefore, the perceptively reduced intracellular calcium levels among the acroleinexposed cells cannot be interpreted as such. No discernable pattern of intracellular calcium influx
was observed among 5 % oxygen cultured cells, though the variability was generally larger than
those cells cultured at 20.1 % oxygen may have precluded definitive pattern recognition.
Simultaneous application of small molecule inhibitors (5 µM CTZ or 100 µM olaparib)
or high concentrations (20 mM) of EGTA to differentiated H9c2 cells exposed to 25 µM acrolein
resulted in substantially altered calcium transient patterns (Figure 17) among standard condition
cultures. Ionomycin was normalized in an equivalent manner to treatment and small moleculesupplemented H9c2 cells, and depicted in Figure 17 to demonstrate the method of normalization
(Against vehicle-exposed controls) retains the overall calcium-influx trend reported in validation
testing as reported in baseline adjusted relative fluorescent units (RFU) above, albeit with some
reduction in curve smoothing. Therefore, the normalization of treatment and small moleculesupplemented differentiated H9c2 cells against vehicle-only hydroquinone containing controls
appropriately retains the relative intensity of Fluo-4 reported calcium transients.
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Figure 16. Acrolein-induced Fluo-4-reported Calcium Influx: 5 and 20.1 % Oxygen. H9c2 cells cultured and
differentiated under 5 (Striped) and 20.1 % (Solid) oxygen prior to loading with Fluo-4AM and fluorophore deesterification. After de-esterification, cells were exposed to 25 µM acrolein (Blue Diamonds) or hydroquinone
(Controls; Black Diamonds) and immediately quantitated fluorometrically using the Synergy HT microplate reader
with emission/excitation filters of 485/20 nm and 528/20 nm, respectively. The time between acrolein exposure and
initial was consistently about 60 seconds, thus, the lead-time wherein no data are presented is presented without
accompanying data points. After the fluorometric signal stabilized 210 seconds after acrolein exposure, Fluo-4
associated calcium signaling began elevating between 300 and 330 seconds, which was consistently elevated at 390
seconds, before returning to baseline after 500 seconds for standard condition cultures. Consistent transients were
not observed for 5 % oxygen cultures. Individual points represent average of 3 trials with SEM denoted by error
bars.

As reported previously, the calcium transient induced by acrolein was significant 390 and
450 seconds after exposure, as denoted by the superimposed horizontal solid black line, but not
at the intermediary 420 second (7 minute) measurement. Despite not reaching significance, the
peak of the calcium transient was observed at this measurement, and reached approximately 221
% of time-matched control measures. Application of 20 mM EGTA effectively ablated the
calcium transient induced by acrolein, reducing the fluorometric measurement to 87-106 % of
controls during the same time interval. As EGTA chelates extracellular calcium without altering
intracellular calcium acutely, the method utilized retains specificity for measurement of
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intracellular calcium within the conditions within this cell-based system presented in this
investigation.
In assessing the mechanism leading to acrolein-induced calcium transients from the
extracellular space, CTZ and olaparib were applied similarly to that of EGTA. In the presence of
5 µM CTZ, not only was the observed acrolein-induced calcium transient ablated, but a
significant depression in measured intracellular calcium levels began at 300 seconds, and
continued until the 450 second time-point. After 450 seconds, intracellular calcium levels
remained depressed until the end of measurements. Similarly, olaparib also ablated the observed
transient caused by acrolein. Between 390 and 450 seconds, the relative intracellular
concentration decreased precipitously from 133 to 47 % of controls, after which the Fluo-4
signal remained below controls (< 50 %); no significant differences were observed compared to
controls or EGTA-supplemented differentiated cardiomyoblasts. Since calcium transients were
not detected among acrolein-exposed cells cultured at 5 %, no further comparisons between
acrolein-only exposed cells and small molecule-supplemented cells were made.
3.2.2.4 Mitochondrial membrane potential. Exposure of differentiated H9c2 cells with
100 µM of CCCP resulted in a rapid reduction in ΔΨm to 43-46 % of respective controls as
reported by the ratio of J-aggregates to JC-1 monomers (Figure 18) at four hours; thus, the JC-1
labeling ratiometric analysis is specifically reporting ΔΨm within the H9c2 cells under the test
conditions. Differentiated H9c2 cells cultured under either 5 % or 20.1 % oxygen exposed to 25
µM acrolein resulted in insignificant decreases in ΔΨm to 88 ± 7 % and 89 ± 7 %, respectively,
compared to time-matched controls at four hours; intermediary ΔΨm values were observed at one
and two hours. While a slight time-dependent decrease in ΔΨm among acrolein-exposed H9c2
cells, the magnitude was not altered by oxygen culturing conditions, at least within the initial
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Figure 17. Fluo-4-reported Calcium Influx in H9c2 Cells Cultured Under Standard Conditions. H9c2 cells
cultured under standard conditions were loaded Fluo-4AM, followed by de-esterification. After de-esterification,
cells were exposed to 25 µM acrolein (Blue Diamonds; same as in Figure 16 for comparison purposes) in the
presence of 5 µM CTZ (Teal Diamonds), 100 µM olaparib (Green Diamonds), and 20 mM EGTA (Orange
Diamonds), and immediately quantitated fluorometrically on the Synergy HT microplate reader with
emission/excitation filters of 485/20 nm and 528/20 nm, respectively. Vehicle only-containing controls are
designated by Black Diamonds. The calcium transient caused by ionomycin is presented here in order to establish
maximal calcium influx. The calcium transient induced by acrolein (Denoted by a solid Black Line when
significantly higher than Controls) was effectively disrupted by application of both CTZ and olaparib, both of which
caused reductions in intracellular calcium over time. EGTA equally disrupted the calcium transient induced by
acrolein, but retained the intracellular calcium levels equal to that of controls. The calcium transient becomes
significantly higher than controls at 390 seconds and 450 seconds. Each point is the mean of 3-4 independent trials
with associated SEM denoted by error bars.

four hours post-treatment. It is noteworthy to remark the J-aggregate/monomer ratio was
significantly elevated by 39 % (8.71 ± 0.08 versus 6.28 ± 0.09; p < 0.05) among differentiated
H9c2cells cultured under 5 % oxygen compared to equivalent 20.1 % oxygen cultures; the
contribution of the net ΔΨm reduction, rather than the relative reduction, was not pursued for
further investigation.
Despite only modest reductions in ΔΨm even at four hours, the influence of olaparib and
extracellular calcium were investigated in modulating acrolein-induced ΔΨm in RP medium. As
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Figure 18. Mitochondrial Membrane Potential Measurements. Differentiated H9c2 cells cultured under either 5 or
20.1 % oxygen were exposed to 100 µM CCCP for four hours with repeated fluorometric measures during such
time. The values expressed are normalized against the aggregate/monomer ratio of the control in order to exemplify
the relative ΔΨm. CCCP significantly reduced ΔΨm at four hours, though no difference in ΔΨm reduction was
observed dependent upon culturing oxygen tension. Individual points were the average of three (20.1 % oxygen) or
four (5 % oxygen) independent experiments with SEM indicated by error bars.

previously mentioned, treatment with 25 µM acrolein resulted in insignificant decreases in ΔΨm
to 88 ± 7 % (5 % oxygen cultures) and 89 ± 7 % (20.1 % oxygen cultures) compared to
respective oxygen tension controls. 5 µM CTZ-supplemented cells cultured under 20.1 % oxygen
tended to attenuate the observed reduction in ΔΨm compared to acrolein only-exposed cells;
addition of 100 µM olaparib retained the ΔΨm among acrolein-exposed cells to control levels
(100 ± 2 %), while EGTA caused an unexpected increase in ΔΨm (104 ± 3 %). Conversely,
differentiated H9c2 cardiomyoblasts cultured under 5 % oxygen demonstrated a different
response with respect to CTZ and olaparib supplementation at four hours (Figure 19). Addition
of 10 mM EGTA elevated the basal ΔΨm above respective controls (113 ± 5 %), and provided
significant attenuation of ΔΨm compared to acrolein-exposed cells (CI95 of Difference: 4-45 %, p
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= 0.028). Similarly, addition of 5 µM CTZ elevated the basal ΔΨm above respective CTZ
controls (106 ± 3 %), but ultimately did not significantly attenuate ΔΨm reduction among
acrolein-exposed cells likely due to the wide variability of the acrolein-only treatment group. Coexposure with 100 µM olaparib only modestly attenuated ΔΨm upon exposure to acrolein to 93 ±
4 % control levels versus 88 ± 7 % of treatment only cells, and did not provide retention to
control levels as did the standard culture H9c2 cells.
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Figure 19. Small Molecule Mitochondrial Membrane Potential Reduction Attenuation at Four Hours Postexposure. Differentiated H9c2 cardiomyoblasts cultured under 5 % (Striped Bars) and 20.1 % oxygen (Solid Bars)
exposed to 25 µM Acrolein (Blue Bars) were supplemented with small molecules in order to measure the effect of
extracellular calcium chelation (10 mM EGTA; Orange), inhibition of TRPM2-associated calcium conductance (5
µM CTZ; Teal), or PARP inhibition (100 µM Olaparib; Green) on acrolein-induced ΔΨm reductions. Values derived
are the respective vehicle-normalized average of three (20.1 % oxygen) or four (5 % oxygen) independent trials with
associated error bars denoting SEM. Statistical comparisons were made only between small molecule-supplemented
cells exposed to acrolein and their respective small molecule controls cells denoted formally as (+). *p < 0.05
compared to respective acrolein-exposed cells.
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CHAPTER FOUR:
DISCUSSION

4.1 Evaluation of Hypotheses
The current investigation aimed at examining the influence of oxygen tension in
modulating acrolein-induced cytotoxicity in the differentiated H9c2 cardiomyoblast model. In
order to elucidate the underlying factors causing significant alterations of the toxicogenic
potential from acrolein, varying TCA and glycolytic substrates in vehicle media were utilized to
measure their respective contribution to viability rescue. In doing so, the current investigation
demonstrated significant changes in the cytotoxicity profile of the H9c2 cells after exposure to
acrolein, particularly among media containing enriched pyruvate concentrations. For those
standard condition culture cells, exposure to acrolein in the presence of enriched pyruvate did not
offer cytoprotection. Therefore, the evidence from viability assessment suggests that reduction in
oxygen tension would significantly attenuate cellular viability after exposure to acrolein only
under certain circumstances. Rescue was not afforded for all TCA and glycolytic substrates, as
glucose, glutamine, and glutamate did not significantly attenuate cell death at 24 hours after toxic
insult. Pyruvate enrichment, especially among the standard low-serum DMEM, significantly
attenuated viability loss after acrolein exposure. Therefore, hypothesis one was partially
supported where only pyruvate attenuated cytotoxicity – all other substrate groups were similar
to standard condition cultures with respect to viability.
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Co-exposure of small molecule inhibitors, e.g., olaparib (PARPi), EGTA (Calcium
chelator), and CTZ (Non-specific TRPM2 inhibitor) showed variable potential for viability
attenuation. Under physiologically relevant oxygen culture, differentiated H9c2 cells were
significantly protected by EGTA, while CTZ did not provide similar protection. Olaparib,
however, demonstrated a particularly dubious pattern of rescue, which was associated with
baseline toxicity. At high-magnitude acrolein cytotoxicity (Viability < 50 % controls), olaparib
did not significantly provide protection from toxicosis. Conversely, at lower-magnitude
cytotoxicity using the same concentration of acrolein, the same concentration of olaparib offered
significant protection to H9c2 cells. Therefore, the evidence presented suggests that a complex
interaction between cytotoxic injury and PARP inhibition exists, and PARP plays a partial role in
acrolein toxicosis. As such, the second hypothesis regarding attenuation of viability loss under 5
% oxygen using a PARPi, was neither clearly rejected nor supported, though the potential exists
for the latter scenario.
The effect of olaparib exposure during acrolein exposure on ΔΨm alteration was assessed
on cells maintained and exposed with acrolein cultured under 5 % and 20.1 % oxygen. Olaparib
did not provide significant retention of ΔΨm reductions observed after acrolein treatment, even at
four hours post-acrolein exposure, though the ΔΨm was not significantly different than controls
either. Seemingly, olaparib exposure actually decreased the ΔΨm among 5 % oxygen cultures
compared to the 20.1 % cultures, though the difference was not significant. As previously
mentioned, no obvious calcium transients were observed among cells cultured under 5 % oxygen
and, thus, this parameter was not further explored. Therefore, the evidence of the current
investigation does not clearly support the third hypothesis that PARP inhibition significantly
altered ΔΨm under acrolein toxicosis, though the ΔΨm was significantly different than neither
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controls nor acrolein-exposed cells; a latter tome-point may be prudent for elucidating this
relationship further. Interestingly, both EGTA and CTZ did retain the ΔΨm to control levels,
indicating that extracellular calcium may generally contribute to baseline ΔΨm.
4.2 Methodology - MTT Reduction Assay
The MTT formazan reduction assay performed as a sensitive and stable proxy of
individual well cell count, as denoted by the high coefficient of determination (R2 = 99.7 %)
when modeled as a polynomial-derived regression function. In some instances, however,
estimated cell counts per well of proximal standards, especially those under 500 cells per well,
were subject to reduced predictive power when utilizing a polynomial-derived regression model.
Consequently, substantial underestimation of cell count quantification ensued. In such cases,
exclusion of standard curve estimators, e.g., two of the highest calibration curve standards (7,500
and 5,000 cells per well), provided more accurate predictive power in quantifying low cell count
samples, especially those standard curve wells seeded with 2,000 cells per well or less.
Notwithstanding, when such a regression scheme was required, all samples under the 2,000 were
similarly quantified using the linear regression equation to ensure homogeneity of quantitative
methods; this practice was very reluctantly and infrequently required.
It is known that the MTT formazan reduction assay integrates both cellular number and
metabolic profile of tested cells to derive “viability” estimates based on metabolically competent
cells207. The metabolic profile described by Stepananko et al.207 and Berridge et al.217, to which
MTT formazan reduction varies noticeably among endogenous anti-oxidant systems (e.g., SOD,
HO-1), as well as endogenous respiratory machinery (Glycolysis and pyruvate metabolism), was
likely demonstrated in the present investigation. In the present system, medium glucose proved a
consistent modulator of overall formazan production (Blanked 570 nm optical density) when
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comparing signaling among unexposed controls (Figure 20). In acrolein unexposed
differentiated H9c2 cardiomyoblasts, a linear association consisting of basal MTT reduction
among control cells was consistently observed up to 10 mM glucose; linearity was then lost up to
the 25 mM glucose concentration found in the differentiation medium. A similar trend remained
consistent among trial-matched cardiomyoblasts exposed to 250 µM acrolein for 30 minutes,
albeit with a shallower slope compared to unexposed cells due to reduced MTT metabolism by
H9c2 cells induced by acrolein exposure. The influence of medium glucose concentration on
MTT metabolism was alluded by Vistica et al.218, though that investigation provided
predominantly circumstantial evidence. In the current investigation, we supply quantitative
evidence to reinforce this notion. Therefore, utilization of respective medium controls was
absolutely required. Since substrate medium controls were included, i.e., exposed cells were
normalized against respective controls exposed with dilution-controlled hydroquinone in the
respective substrate medium, the results would not have been construed; thus, the treatment
effects observed would likely be closely representative of that attributable to acrolein.
Furthermore, no substantial viability differences were observed at 24 hours among several
substrate groups, thus the consequences of the apparent altered MTT metabolic kinetics does not
reduce the integrity of toxicant-specific, viability analysis when controlling for medium glucose
or other substrates utilized in this investigation.

4.3 Acrolein Treatment, Substrates, and Small Molecules
All glycolytic and TCA substrates chosen were based on available recognition of cardiacspecific membrane transporters which would allow potential influx of substrates within the H9c2
cells to modulate acrolein-induced alteration of metabolism and cell viability; data corresponding

91

to primary cardiac myocyte transporter identification and localization were considered applicable
to the differentiated H9c2 model (Table 11). Results of MTT reduction among differing
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Figure 20. Dependency of MTT Reduction on Medium Glucose. The MTT reduction results from the two-hour
washout controls (Black Diamonds) and acrolein-exposed (Blue Diamonds) differentiated H9c2 cells were
aggregated and normalized against the RP medium (5 mM glucose-containing DMEM). The 25 mM glucose point
was derived from the low-serum DMEM substrate group as pyruvate was not shown to significantly alter MTT
reduction capacity, at least at the 1.0 mM found in the LS DME medium. Each point corresponds to the mean of 3-5
independent experiments with associated standard deviation denoted by error bars.

oxygen culturing conditions demonstrated two key patterns: 1) likely induction of acute-phase
MTT-reducing xenobiotic machinery and 2) a glucose- and pyruvate-sensitive metabolic and
respiratory rescue phenotype under 5 % oxygen. The former shall be discussed in detail,
followed by substrate-specific effects.
Moghe and colleagues219 published recently a poignant review highlighting not only the
target organs affected by and mechanisms of acrolein as related to human disease, but also
reported potential therapeutic agents specifically shown efficacious in attenuating mechanistic
pathways, e.g., oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, etc.
The myriad of cell-based models and acrolein exposure conditions, i.e. concentration and
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duration of exposure, however, can render interpretation of the current data difficult to decipher
in perspective to other investigation. For example, our laboratory has shown a consistent
concentration-dependent activation of poly(ADP-ribose) polymerase at concentrations between
Table 11. Relevant Cardiac Substrate Transporters

Substrate

Transporter

Source(s)

d-Glucose

GLUT4
GLUT1

Liu et al., 2013a220

L-Pyruvate

MCT2

Lin et al., 1998221; Bonen, 2001222

L-Glutamine

SN1
rATA2

Bode, 2001223; Sugawara et al., 2000224

L-Glutamate

GLT1v
EAAT1

Kugler, 2004225

α-ketoglutarate*

2-OG Transporter
mNaDC-3

Takeda et al., 2012226; Shank and
Bennett, 1993227; Pajor, Gangula, and
Yao, 2001228

*In the current investigation, 5.0 mM of α-ketoglutarate was shown to interfere with the MTT assay.

50 and 100 µM, but reduced activity at and above 250 µM acrolein when cells are exposed to
acrolein for thirty minutes under standard culture conditions (Unpublished data Harand et al.);
however, elevations were observed at 25 µM as early as 5 minutes post-exposure, reaching
significant levels (45 % above controls) at 15 minutes (Current investigation). Though PARP
activity may wane 30 minutes after exposure, it cannot be outright rejected that exposure metrics
substantially alter mechanistic interpretation – the current example merely relates to acrolein
toxicosis within the H9c2 model. Stevens and Maier229, pre-dating the Moghe et al. review,
pointed out some of the key experimental conditions, for example difference in cell lines, culture
conditions, and medium compositions, which explain the multifaceted and, in some cases,
conflicting in vitro-based mechanistic findings characterizing cell death modalities exacted by
acrolein; the authors limited their review only necrosis and apoptosis as viable cell death
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modalities. The current investigation has supplied evidence not to explain the differences in cell
death modalities, but rather a complex interaction whereby specific medium constituents and
physiologically relevant oxygen culture may alter the mechanism of cytotoxicity.
Acrolein exposure under standard culturing conditions did not induce supra-levels of
MTT reduction compared to controls irrespective of initiation time of MTT analysis after
treatment. Presuming MTT reduction as a proxy of viability, MTT analysis of acute exposure
periods (2-hour washout) exemplified the rapid degeneration of H9c2 MTT reduction capacity,
especially after high concentrations of acrolein (250 µM); however, lower concentrations
consistently resulted in near-control MTT signals. In order to assess immediate MTT reduction
capacity changes, similar exposure conditions were conducted across a broad range (0-250 µM)
of concentrations of acrolein followed immediately by initiation of the MTT assay. All exposures
were conducted in the low-serum DMEM. Even in this short period, large reductions in MTT
metabolism capacity were noted at 100 µM (71 ± 6 %; p < 0.01) and 250 µM (64 ± 4 %; p <
0.001) compared to controls (Figure 21). However, no immediate increases in MTT were
observed since transcriptional up-regulation of antioxidant response elements would likely not be
manifested in such a short period after exposure to facilitate enhanced MTT conversion
(Discussed below). Particularly of cells cultured under standard conditions, exposure to acrolein
at even 1 µM consistently reduced MTT reduction capacity within 6 hours, which can reach
levels above controls at 24-hours. These results demonstrate a potential delay in up-regulated or
otherwise and enhanced metabolic pathways due to acrolein. However, transcription-based
methods would undoubtedly confirm these preliminary findings.
Unfortunately, investigations in short-term metabolic competency of acrolein-exposed
H9c2 cells are generally rare. Agarwal and colleagues230 exposed isolated mouse Type II alveo-
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lar ECs (pAT2 cells) with graded acrolein concentrations, and then assessed cytotoxicity via
MTT reduction in deriving an IC50 value. At acrolein concentrations of 10 µM or less, MTT
reduction exceeded respective controls: 5 µM (Approximately 115 %) and 10 µM (Approximat-
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Figure 21. MTT Reduction Immediately After Acrolein Treatment. H9c2 cells were cultured and differentiated
under standard conditions prior to 30-minute acrolein exposure. Immediately after acrolein exposure, H9c2 cells
were assessed for MTT reduction capacity. A decreasing trend was observed beginning at 2.5 µM up to the highest
concentration of 250 µM. Bars are the mean of 4-6 independent trials with associated SEM denoted by error bars.
**p < 0.01 and ***p < 0.001 compared to hydroquinone-only containing controls (Black Bar).

ely 108 %). Similar results were reported for neither primary rat lung epithelial (RLE-6TN) cells
nor human lung adenocarcinoma (H441) cells within the same investigation; no explanation was
given as to this inconsistent finding. It is known that oxidative insult in lung epithelial cells
activates antioxidant response element transcription through nuclear factor erythroid 2–related
factor 2 (Nrf-2) nuclear translocation, after which antioxidant systems, such as HO-1, TRx, GST,
NQO-1, among others, become up-regulated or activated231, and can confer significant
cytoprotection232 by re-establishing cellular redox balance (Succinctly reviewed in Nguyen and
colleagues233). Nrf-2 activation occurs also in the presence of electrophiles, particularly the
NAPQI-induced antioxidant response in rodent hepatocytes when treated with acetaminophen234
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or acrolein235. What remains little known, contrarily, is the contribution of up-regulated
antioxidant systems and microsomal xenobiotic metabolism in MTT reduction within 12 hours of
oxidative injury. Ishii and colleagues236 demonstrated that macrophages show significant Nrf-2dependent up-regulation in HO-1 for select compounds, e.g., hydrogen peroxide, at 9 hours of
treatment. Tirumalai and colleagues235 showed increased NQO1 mRNA transcripts in as little as
30 minutes and heavy chain γ-glutamylcysteine synthetase at one hour, though functional
metabolic competence was not characterized. In the CD-1 mouse, high-dose acetaminophen
causes hepatic Nrf-2 nuclear translocation dose-dependently within 60 minutes237, while total
HO-1 protein was found insignificantly elevated to 150 % of controls at five hours, despite the
significant elevations in mRNA transcripts238. Should a short-term Nrf-2-mediated response hold
true in the current model, the potential for enhanced antioxidant up-regulation even within such a
short exposure period may explain enhance MTT reduction at low treatment levels.
In the current investigation, low concentration acrolein-exposed differentiated H9c2 cells
cultured under 5 % oxygen demonstrated consistent elevations in MTT reduction when assessed
after a two hour exposure (In addition to a 3 hour MTT incubation period). Interestingly, the
magnitude of MTT reduction did not depend upon substrate supplementation, for which all 1
µM-exposed groups were above controls. If pyruvate does act as an acrolein scavenger, it would
be expected that such MTT reduction capacity increases would be minimally, if at all, observed
among pyruvate groups, especially among the higher, 2.5 mM pyruvate concentration at the 1
µM acrolein exposure groups. In opposition, near-control MTT reduction values were,
nonetheless, not observed for the pyruvate groups, and were actually inversely related to
pyruvate concentration – statistical differences are not expected. At 25 µM of acrolein, MTT
reduction was inversely related to medium glucose concentration, but not statistically significant.
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Physiological concentrations and supra-physiological glucose levels (10 mM in glucose-enriched
physiological medium as well as 25 mM in low-serum DME medium) seemingly sensitized
H9c2 cells to acrolein toxicity, though this was not entirely unforeseen. Glucose has been shown
to be cytotoxic (See below for extended discussion) in the H9c2 cells line239, leading to
reductions in viability. The results of the current investigation seemingly support this notion
though the mechanism was not further explored.
After 24 hours, H9c2 cells exposed in pyruvate-supplemented medium (Including lowserum DMEM) did, indeed, provided significant rescue in cellular viability after 25 µM
treatment. Pyruvate rescue has been reported extensively within the literature, particularly in
conjunction with PARP activation58. Numerous mechanisms have been proposed including, but
not limited to: increasing respiratory support240, acting as an antioxidant241, and promoting
increases and retention in intracellular glutathione (Via GPx activity induction)241. Wang et
al.240, for example, showed rescue by pyruvate supplementation in the human neuroblastoma cell
line, SK-N-SH, after treatment with modest concentrations of hydrogen peroxide. The authors
attributed the rescue to pyruvate-dependent reduction in mitochondrial oxidative species
secondary to H2O2 treatment, which was in concordance to significant retention of ΔΨm among
pyruvate-supplemented cells. Since pyruvate has also been implicated as an antioxidant in
culture systems241, indirect measurement of acrolein to characterize the interaction of acrolein
with medium-supplemented pyruvate was undertaken. Consequently, pyruvate does not confer
protection by mere scavenging since medium acrolein concentrations were not altered by 2.5
mM pyruvate supplementation compared to basal RP medium, 230.5 ± 17.1 µM versus 234.6 ±
6.5 µM, respectively, at 30 minutes post-addition to medium at room temperature. Some
compounds, as do the arterial vasodilators hydralazine and dihydralazine and MAO inhibitor
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phenelzine (Reviewed in Hamann and Shi242), have been shown to scavenge acrolein; the current
investigation essentially ruled out this potential avenue of cytoprotection. Therefore, the
mechanism of pyruvate rescue could not be attributed simply due to acrolein depletion from high
pyruvate-supplemented medium, and likely suggests a compensatory mechanism in energy
production or substrate utilization. This interpretation seems befitting as H9c2 cells cultured
under standard culture conditions exposed to 25 and 250 µM resulted in significantly increased
MTT reduction at 250 µM compared to RP medium exposed cells, but insignificant elevations at
the intermediary 25 µM treatment group. Conclusively, a unified mechanism of pyruvate-based
rescue most appropriately characterizes the results observed, but only for H9c2 cells under
physiologically relevant oxygen tension. The pyruvate-dependent capacity for offering
cytoprotection was limited under standard culturing conditions, i.e., the rescue by pyruvate after
25 µM acrolein treatment was no different than any other substrate group. As such, a metabolic
reprogramming is most likely observed.
Notwithstanding, the actual medium composition has a contributory, but not absolute,
effect on the magnitude of cytotoxicity. For example, freshly isolated mouse lung slices treated
with acrolein displayed a profoundly heterogeneous ATP depletion pattern in L2 cells (Cultured
cell line) compared to fresh lung slices243. Reduction of ATP to 80 % of control levels in lung
slices required approximately one order of magnitude higher acrolein (50 µM versus 5 µM)
compared to the more acrolein-sensitive L2 culture cells, though the heterogeneous cell matrix of
precision lung slices undermine direct comparisons to L2 cells solely on a mechanistic basis.
Some of the rescue found within precision lung slices may be attributed to the underlying
microenvironment. Co-culture of cardiomyocytes with endothelial cells demonstrate a dynamic
interaction between the two cells types to offer energy support via respiratory substrates,
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including pyruvate244. Thereupon the microenvironment enshrouding any given cardiomyocyte
in situ may provide more pyruvate equivalents than offered simply by the diffusive capacity from
intra-cardiac blood supplies. Coupling the data with cell isolates230 definitively demonstrates
respiratory and metabolic differences between cell line- and tissue isolate-derived cytotoxicity
investigations. With respect to the current investigation, the source of cytotoxic sensitivity likely
relies in part upon oxygen-dependent increases in both energy production and xenobiotic
detoxification induction reserve capacity under physiologically relevant oxygen culturing
conditions (5 %) compared to the limited, to plausibly absent, potential within the 20.1 %
cultures. If true, such a finding would have a substantial impact on in vitro-based cytotoxicity
data interpretation when extrapolated to in vivo correlations.
Enrichment of medium with glucose did not offer cytoprotection under either oxygen
culturing condition. As such, the results of the current investigation corroborates evidence
demonstrating not only negligible rescue via glucose enrichment in either astrocytes or
neurons54, but short term metabolic MTT analysis suggest that high glucose, both in the 10 mM
glucose and the low-serum DME medium (25 mM glucose), may actually be deleterious. An
inverse relationship between acute MTT reduction and glucose supplementation after 25 µM
acrolein exposure was observed, but was less pronounced among cells treated with 1 µM
acrolein. These results are in corroboration with Li et al.239 who reported increased TUNEL
positivity and associated 72-hour viability reductions in H9c2 cells incubated with 35 mM
glucose. The authors did not report values for an analogous 25 mM glucose concentration
utilized in the current investigation. Conversely, 24-hour viability measurements among the 10
mM glucose group (129 ± 11 %) were similar to that of the 1 mM glucose group (127 ± 13 %),
with the low-serum DME medium resulting in the lowest viability (102 ± 8 %). Since the MTT
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assay is sensitive to incubation medium glucose207(And this investigation), relative viability
comparisons among unexposed H9c2 cells incubated in differing glucose-containing media in
the current investigation are not permissible, but would provide additional evidence that enriched
glucose does indeed result in viability/metabolic reductions in the present system.
Since pyruvate utilization for the TCA was likely enhanced in media containing 1.0 or
2.5 mM pyruvate, enrichment of glucose was hypothesized to contribute more pyruvate
equivalent via the end-product of glycolysis. While glucose conversion can neither be ruled in
nor out in the current investigation mechanistically, functional glycolytic production of energy
equivalents for the TCA cycle resulting in metabolic rescue was not observed irrespective of
culture oxygen conditions. There results are paradoxical as a shift in metabolic reprogramming
was denoted by pyruvate rescue. It is to be presumed that a reduced oxygen tension would
subsequently activate HIF-1α in the current culture system under 5 % oxygen, as previously
demonstrated in other systems245, though duration of oxygen tension reduction – chronically in
the current investigation compared to typical acute hypoxic insults – may undermine such a
simplistic extrapolation. Nonetheless, since virtually every enzyme involved in glucose
metabolism has been shown to be up-regulated by HIF-1α induction (Reviewed in Semenza246),
glucose supplementation would have the potential to provide metabolic rescue. A glucose-based
rescue was not observed. Three plausible explanations exist: Firstly, while neither specific to
cardiac tissue nor being the major cardiac glucose transporter for H9c2 cells220, acrolein has been
associated with inhibition of the GLUT3 isoform found primarily in primary cortical neurons in
vitro247. Whether acrolein inhibits cardiac GLUT4 in H9c2 cells is unknown. Should GUT4
inhibition hold under acrolein exposure within the differentiated H9c2 model, enrichment or
glucose deficiency would be expected to influence functional metabolism minimally – the
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observed results corroborate this as a plausible notion. Secondly, glycolysis requires two
oxidized NAD+ equivalents as well as two ATP equivalents in the early phase of glycolysis –
two adenine nucleotide substrates which become rapidly reduced or depleted under acroleinassociated oxidative stress248. Under this assumption, enriched glucose may provide rescue under
metabolic stress, but whose efficacy may be restricted kinetically with respect to adenine
nucleotide equivalents. Andrabi and colleagues249 present stark evidence contesting NAD+ as a
major contributor to inhibition of glycolysis under DNA alkylation with MNNG, as NAD+ and
ATP levels were paradoxically retained after 15 minutes of exposure to MNNG. Furthermore,
inhibition of glycolysis was shown significant within same investigation, and was reversed by
pyruvate supplementation, suggesting specific sensitivity of the glycolytic pathway to acrolein
exposure. Thirdly, enzyme-specific inhibition of glycolytic machinery may account for the
observed negligent rescue. Martyniuk and colleagues250 showed potent inhibition of purified
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by acrolein via direct enzyme adduction
with an acrolein-specific Ki of 38.1 ± 0.83 µM (Mean ± SD) – approximately 1.5-fold higher
than the concentration utilized in the current investigation; other α,β-unsaturated carbonyl
aldehydes also inhibited GAPDH in the same investigation, and likely demonstrates a class
effect. Agarwal and colleagues230 showed such inhibition effectively translates to consequential
glycolytic inhibition within an in vitro system. All together, the negligible rescue afforded by
glucose supplementation in the current investigation likely reflects a mechanism whereby
glycolytic metabolism remains sensitive to acrolein adduction of GAPDH. Evidence suggesting a
metabolic shift by low oxygen tension may alter glycolytic capacity, but direct acrolein
inhibition may not permit rescue by acrolein due simply to GAPDH inhibition. The exact
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mechanism in the H9c2 model after exposure to acrolein requires further attention in order to
confirm these presumptions.
Finally, medium supplementation with glutamine (5.0 mM) and glutamate (1.0 mM)
provided short-term MTT reduction capacity among 5 % oxygen cultures compared to those
cultured at 20.1 % oxygen exposed to 25 µM, but did not offer significant long-term protection
at 24 hours. Non-significant elevations in viability were observed among similarly-exposed H9c2
cells supplemented with 5.0 mM glutamine (37 ± 10 %) compared to the glucose- and glutamatesupplemented cells (24-28 % viability). Li and colleagues239 rescued H9c2 cells from reperfusion
in the presence of high concentrations of glucose concentration-dependently with glutamine
supplementation. Isolated embryonic ventricular cardiomyocyte reduction in viability was
attenuated significantly by glutamine after in vitro simulations of reperfusion injury251. On an
organ level, isolated rat hearts tend to have increased intracellular ATP concentrations compared
to tissue extracts252, denoting, at least partially, rescue may be afforded by glutamine through
respiratory support. Given the tendency of glutamine to rescue differentiated H9c2 cells in the
current investigation, a lower acrolein (< 25 µM) may exemplify such a plausible end-point,
though further testing is required to confirm. Since catalytic production of α-ketoglutarate
requires glutamate and oxaloacetate via aspartate transaminase, restriction of pyruvate
equivalents by GAPDH inhibition may shunt the efficacy of glutamine, which is converted via
glutaminases to glutamate, or glutamate rescue observed in the ischemic models described. In
summary, the results of the current investigation affirm the metabolic reprogramming when
adapting cells to 5 % oxygen, as described by Pereira and colleagues65 though the inhibitory
effect of acrolein itself may restrict metabolic rescue via metabolic pathway shunting.
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In the current investigation, acrolein exposure to 25 µM was shown to acutely activate
poly(ADP-ribose) polymerase significantly at 15 minutes post-exposure, while insignificant
activation was demonstrated in as little as 5 minutes. Earlier or latter time-points were not
investigated. Hyper-activation of PARP is known to induce parthanatos, a relatively novel
cellular death subroutine253, consequently leading to cell death. Early activators of PARP
included gamma radiation254-257, hydrogen peroxide160,255,258, and the DNA alkylator
MNNG58,160,172,259, among others. While the aforementioned three activators exemplify three
canonical mechanisms of exacting DNA structure-altering lesions (Radiation, oxidative injury,
and direct alkylation) leading to PARP activation260, such a broad promotion of activation, e.g.,
non-B conformation DNA261, suggests that a plethora of cytotoxicants could plausibly activate,
and possibly over-activate, PARP. Indeed, interest in characterizing the activity of PARP with
respect to acrolein toxicosis has been investigated. Abraham and Rabi248 attributed, at least in
part, PARP overactivation as a collateral mechanism of cyclophosphamide-associated
hemorrhagic cystitis, as significant elevations in histochemical staining of poly(ADP-ribose)
polymers with associated NAD+ reductions was found in rat bladder tissue. Another
investigation, however, suggested that PARP was cleaved early in CP-associated bladder tissue
injury262, but may demonstrate a dose-dependent phenomenon where low-dose CP (80 mg CP/kg
BW262) induces early caspase activation, whilst higher doses (150 mg CP/kg BW248) causes
PARP overactivation, thereby shunting reduction equivalent, e.g., NAD+, input into apoptotic
machinery with such a severity as to abrogate caspase induction and subsequent PARP cleavage.
Tanel and Averill-Bates263 demonstrated executioner caspase activity intensification at a
remarkably low acrolein exposure window of 1-30 fmol acrolein per CHO cell, particularly that
of caspase-7. Interestingly, at 50 fmol per cell, pan-caspase activation, with the exception of
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caspase-9, was not significantly different than that observed at 30 fmol acrolein per cell in their
CHO model. This result is in accordance with the current investigation as 80,000 seeded H9c2
cells exposed with 800 µL of medium supplemented to a concentration of 25 µM acrolein
corresponds to approximately 250 pmol (250,000 fmol) per H9c2 cell - PARP inactivation, at
least to the level whereby PARP activity was lower than controls, was not observed. It cannot be
ruled out that some cells do exhibit caspase activation, while others do not – such a modality
would undoubtedly be the product of microenvironment heterogeneities even within microplate
wells. Should an acrolein concentration-dependent threshold of differential, or at least shifting
contribution of, mechanistic initiation exist, the data point to a predominance of lowconcentration caspase activation with high-concentration mediated PARP activation; the
discussed in vivo data seemingly corroborate this ill-defined in vitro phenomenon.
A hyper-acute, modest exposure of acrolein significantly activated PARP in the H9c2 cell
line under physiologically relevant oxygen tension. Since PARP activity was enhanced 20 % and
45 % at 5 minutes and 15 minutes, respectively, and the latter time-point was significantly higher
than time-matched controls, PARP inhibition would be presumed efficacious in attenuating
viability reductions if PARP contributes to the toxicogenic mechanism of acrolein-induced
toxicosis at the investigated exposure concentration. Initial tests of high concentration olaparib
(100 µM) provided limited rescue at 24-hours as viability loss was reduced by 14 % with
concomitant olaparib exposure in RP medium derived from FBS batch 1; the analogous
reduction of viability loss among cells exposed in RP medium supplemented with batch 2 FBS
was approximately 5-fold higher at 65 % (Figure 22).
The results may overtly suggest an issue with toxic insult irreproducibility; however,
modulation of viability to acrolein exposure was not observed among H9c2 cells cultured under
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standard oxygen culturing condition, restricting the heterologous response to a single group.
Since the current investigation had shown demonstrative increases in cellular viability during
pyruvate supplementation, the observed effect may represent a change in exogenous pyruvate
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Figure 22. Rescue Enhancement by Olaparib in the Presence of Two Differing FBS Batches. H9c2 cells were
cultured in either 20.1 % oxygen (Solid Diamonds) or 5 % oxygen (Striped Diamonds) prior to differentiation and
treatment with 25 µM acrolein (Blue Diamonds) or respective controls (Black Diamonds; both 5 and 20.1 % oxygen
cultures included in single point estimate). Concomitant exposure with 100 µM olaparib (Orange Diamonds) in the
presence of acrolein resulted in differential rescue, and depended on FBS batch. Furthermore, increases in baseline
viability were also observed. PARPi efficacy was only observed among cells cultured at 5 % oxygen with medium
containing batch 2 FBS. Each point represents the mean of 4-9 individual treatments with associated SEM denoted
by error bars.

concentration contributed by FBS; the effects of other FBS-containing constituents cannot be
dissected for contribution under the limited scope of this investigation, but warrants further
characterization. Heterogeneous composition of FBS, especially between production sources, has
been long identified and implicated in undermining the certainty of cell-based research
reproducibility264,265. The current investigation likely reports another manifestation of this
insidious notion with a major caveat: the division of impact across cell cultures maintained and
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exposed in differing oxygen tensions undermines an overly simplistic batch-to-batch effect, since
cells under 20.1 % oxygen were unaffected. Furthermore, a substantially different proportional
rescue of acrolein-exposed differentiated H9c2 cells was observed, and deserves considerable
discussion. The implication of these seemingly unfortunate results may have inadvertently
unveiled differential weights of mechanistic cellular fate, which could act independently of
toxicant concentration. Thereupon, the rescue potential of PARP inhibition went from
insignificant under demonstrative toxicant insult, i.e., batch one baseline toxicity versus olaparib
administration, to largely efficacious when baseline toxicity was reduced (FBS batch 2
containing medium). Of note, olaparib did not ablate viability reductions, as olaparibsupplemented acrolein-exposed cells still demonstrated significantly lower viability than
respective controls (86 ± 5 % versus 100 %; p < 0.05). Conclusively, two separate key findings
are to be observed from this phenomenon: 1) batch-to-batch variation may affect viability
estimates within the same cell system differentially, especially when physiologically relevant
oxygen tensions are introduced; and 2) the influence of PARP activation in determining cell fate
may impinge upon the magnitude of cytotoxicity, rather than simply upon toxicant concentration.
Acrolein exposure did not significantly reduce ΔΨm at either oxygen culture four hours
post-treatment, though a decreasing trend was noted. Furthermore, no difference in normalized
ΔΨm after treatment between the two oxygen concentrations was found. Given a decreasing trend
up to four hours, it is expected that further ΔΨm reductions would occur when the post-treatment
period is extended, especially since viability estimates denote substantial cytotoxic injury after a
24-hour exposure. Jia and colleagues266 did not observe significant reductions in human retinal
epithelial ARPE-19 cells exposed to 25 µM one day post-exposure. Cells analyzed 8 days postexposure to as little 5 µM acrolein showed significant ΔΨm reductions via JC-1 labeling

106

compared to controls, denoting a latent disruption of mitochondrial integrity in the ARPE-19
model. Nonetheless, even small reductions in ΔΨm were substantially reversed among exposed
cells cultured under 20.1 % oxygen in the presence of the extracellular calcium chelator, EGTA,
but only minimally attenuated in the presence of CTZ (94 % Controls); the PARPi olaparib
retained the ΔΨm to 100 % of controls. Territo and colleagues94 demonstrated relative changes in
oxygen consumption with respect to free calcium using an isolated mitochondrial system.
Though they did not isolate the ΔΨm as a dependent factor, they showed that: 1) oxidative
uncoupling does not occur at extra-mitochondrial free calcium concentrations even up to 500
nM; and 2) increases in extra-mitochondrial calcium did result in reductions in ΔΨm, despite
increases in oxygen consumption. These results denote an inverse relationship between calcium
and ΔΨm. With H9c2 cells cultured at 20.1 % in the current investigation, consistent, low-grade
calcium transients were observed when cells were exposed to 25 µM. Ablation of this transient
by extracellular EGTA provided complete ΔΨm retention after acrolein exposure, affirming the
likely role of extracellular stores in determining mitochondrial integrity. This observation was
mimicked in cultures under 5 % oxygen, though calcium transients were not consistently found
among cells cultured at the lower oxygen tension. It is known that ΔΨm can undergo a transient
voltage potential reduction and recover, especially when calcium influx from extracellular stores
is prevented267. The current investigation likely affirmed this notion among EGTA-exposed
H9c2 cultured under both oxygen conditions; however, the insignificant reductions in ΔΨm may
indeed signify a persistent, progressive reduction in ΔΨm, from which cells may not be able to
recover in the long-term, i.e., 24 hours. Since viability assessment definitively shows drastic
viability losses at the same acrolein concentration, particularly among standard cultures, it would
be expected that ΔΨm measurements beyond four hours would definitively provide evidence of
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eventual mitochondrial dysfunction and collapse. Extension of the ΔΨm assessment period would
also provide additional evidence regarding the mechanistic underpinnings of PARP activation
and possibly related clotrimazole-sensitive calcium transient, i.e., TRPM2 channels in
determining cell sensitivity or fate under acrolein toxicosis. Otherwise, increases in ΔΨm among
samples exposed to 20 mM EGTA suggest a definitive role of calcium in determining
mitochondrial membrane potential, irrespective of oxygen tension.
While the current investigation was not able to demonstrate a calcium conductance
among cells cultured in 5 % oxygen after acrolein exposure, a Fluo-4 reported peak 221 % of
controls was observed among standard condition cultures and decayed after a lapse in time.
Therefore, at least among standard condition cultures, rapid calcium transients were confirmed
which was explicably due to an intracellular flux through extracellular conductance channels,
suggestive by ablation by high concentrations of extracellular EGTA. To characterize if
conductance via PAR-gated TRPM2 channels was involved in this transient, H9c2 were exposed
in the presence of 5 µM CTZ, which, similarly to EGTA, retained intracellular calcium to control
levels up to 270 second post-exposure. Thereafter, intracellular calcium reduced significantly at
300 seconds until the end of measurements. The current results are consistent with patch-clamp
studies investigating the effect of clotrimazole-sensitive calcium conductance in the presence of
high intracellular PAR levels268. Since time-dependent activation of PARP in this model was
confirmed in as little as five minutes, whereby significant PARP activation occurred at 15
minutes, the potential for excluding extracellular calcium from CTZ-sensitive transients initiated
by free PAR with CTZ would implicate TRPM2 channels in contributing in calcium transients.
Indeed, ablation of the calcium transient observed affirmed this potential mechanism. Since CTZ
has been associated with PARP activation-associated calcium transients through the TRPM2
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channel in the presence of oxidative species, i.e., H2O2 and other oxidants, it may be presumed
that CTZ was successful in inhibiting TRPM2 channels and subsequent calcium influx.
However, since this only provides circumstantial activation of PARP involvement, co-exposure
with high-concentrations of PARPi olaparib (100 µM) similarly blunted the calcium transient. At
360 seconds insignificant calcium transients were observed and corresponded to an increase of
55 ± 100 % above controls in the presence of olaparib. Nonetheless, these results demonstrate
that an acute exposure to 25 µM acrolein induces an extracellularly-derived calcium transient
through a PARP activation-initiated conductance mechanism which was sensitive to CTZ. This
describes the consistent pattern of TRPM2-associated calcium transients. Since the current
investigation did not confirm that acrolein induces a rise in intracellular calcium in 5 % oxygen
cultures, likely credited to inexplicably high variation among those cells cultured under low
oxygen, concordance between extracellular calcium depletion and the rescue phenotype observed
remain tentative for this culture condition. It is important to note that cells cultured under 20.1 %
were not protected by the same concentration of EGTA, despite confirmation of a calcium
transient, and remains an important caveat to the proposed mechanism. The demonstrative
viability loss observed among these cultures (> 90 % loss) suggests that standard cultured cells
are intrinsically primed for cellular death by acrolein, and that calcium influx may play a
minimal role in the summation of toxicogenic insult. However, concordance to calcium transient
data and PARP activation may still be applicable to 20.1 % oxygen cultures at lower acrolein
exposure concentrations.
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4.4 Why the Transient, and What is With the Delay in Transient?
It is prudent at this time to state that acrolein, at the concentration investigated under the
tested conditions, likely did not cause a disintegration and permeation of the plasma membrane.
This was concluded since acrolein-only exposed cells exhibited a self-limiting calcium transient
of approximately 240 seconds in duration. Should membrane permeability be enhanced, a
persistent spike in intracellular calcium would have been noted. Additionally, small moleculesupplemented cells also did not exhibit consistent rises in intracellular calcium, denoting the
membrane remained effectively intact during calcium transient measurements.
As for the rapid transient observed, the time to peak may offer support in a PARPactivation-mediated induction of intracellular calcium rise. In patch clamp experiments, various
toxicants are delivered through the patch pipette, allowing direct access to the site of action, e.g.,
hydrogen peroxide143. ADP-ribose polymers are delivered in this manner, as they cannot traverse
the hydrophobic plasma membrane readily115. In doing so, however, a significant reduction in the
time between the rise intracellular PAR levels and calcium conductance reporting would be
observed. Where PAR is injected intracellularly, the direct ligation of the cell membrane in
whole-cell patch clamping can, however, reduce the time to adequately facilitate PAR-induced
gating of TRPM2 channels, thus reducing the requisite time to activate TRPM2 channels. Under
physiological conditions, the cytosolic PAR concentration would depend on diffusive capacity
from the point of origination within the nucleus. For example, in whole-cell models, cytosolic
PARP increases requires not only PARP activation, but preceding DNA damage causes PARG
liberation of auto-ribosylated PARP-associated PAR to activate PARP in the repair signaling
cascade; subsequent PARG-, and possibly ARH3-, dependent hydrolysis of histone-associated
PAR upon completion of DNA repair is the most prominent contributor to free PAR269,270. In the
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current investigation, the duration of time from acrolein exposure to initiation of fluorometric
measurements was monitored, and resultant reported time post-exposure adjusted accordingly.
Such an adjustment was made in order to coordinate cytosolic calcium data with PARP
activation characterization and to offer insight in the absolute time-to-calcium rise characteristics
in differentiated whole-cell H9c2 cardiomyoblasts. In doing so, the initial activation of PARP
coincides with initial influx of calcium recordings. Which event, e.g., PARP associated autoribosylated PAR or histone-associated PAR hydrolysis, contributed to the observed calcium
transient activation remains unknown. Data implicating the initial liberation source of PAR in
TRPM2 activation simply does not exist. The rapid phase of DNA damage and PARP activation
does not lend itself readily to discerning the exact time between DNA damage and following
PARP overactivation, from which post-repair PAR may be distinguished from pre-liberated PAR
associated with initial PARP activation.
Fluorometric measurements of calcium transients were performed until 960 seconds postexposure, and even acrolein-only exposed cells even under standard culture conditions returned
to the baseline levels (≈100-130 %) of unexposed controls (Data not shown) without further
transients. Considering significant PARP activation at 15 minutes (900 seconds), the lack of
latent or recurring calcium transients up to 16 minutes remains unknown. One source could have
arisen from depletion of intracellular Fluo-4 fluoroprobe via extracellular extrusion.
Investigations measuring intracellular calcium concentrations with Fluo-4 typically include
probenecid or sulfinpyrazone, inhibitors of the organic anion transport system, to prevent Fluo-4
extrusion271. Therefore, it is expected that the fluorophore would be extruded from H9c2 cells,
biasing calcium transients towards lower magnitudes, and resulting in a decreasing signal. The
current investigation did not include the use of inhibitors for the following reason: Transport
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inhibitors, such as probenecid for example, were excluded, as this drug actually inhibits
TRPV1272 and activates TRPV2273 calcium channels simultaneously. Though these TRPV
isoforms do not have confirmed expression profiles in differentiated H9c2 cells, TRPV2
channels have been found in rodent (Both mouse and rat) cardiac tissue274,275, while TRPV1
channels

have

been

confirmed

undifferentiated

H9c2

cell

line276

and

in

murine

cardiomyocytes277. Inclusion of OAT inhibitors could have confounded the source and
specificity of calcium transients observed, thus requiring caution towards mechanistic
interpretation. As for the interpretation of the current investigation, a calcium transient among
standard cultures exposed to acrolein was indeed observed, and the magnitude of calcium influx
may have been underestimated within the present system. An investigation using hydrogen
peroxide as the treatment did result in an intracellular calcium rise equivalent143 to that observed
here, though the authors attributed calcium transients independent of ADP-ribose concentrations.
Since the delay roughly coincides with a period of increasing PARP activity, the results suggest
that a cytosolic ADP-ribose concentration builds rapidly after acrolein treatment and
subsequently activates clotrimazole-sensitive calcium conductance channels, i.e., TRPM2. The
instantaneous activity level of PARP likely does not determine cytosolic PAR levels, but rather
an integration of cumulative PARP activity integrated with time. As for the calcium reduction
shortly after transient induction, a rise in cytosolic calcium to an indeterminate threshold likely
triggered sequestration of calcium into store-operated calcium channels, e.g., extracellularly,
mitochondria, and the ER (most important calcium uptake store in conjunction with
mitochondria)278. Specifically, the H9c2 cell line has been shown to preferentially load excess
cytosolic calcium into reticular stores279. Measurement of this compartment as well as the
mitochondria would be beneficial in confirming this phenomenon under the model utilized here.
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The calcium transient observed in the current investigation likely reflects such a mechanism,
whereby intracellular calcium elevations were rapidly reversed after reaching a specific
threshold, but a transient was observed nonetheless.

4.5 Limitations
No investigation is complete without discussion of the study limitations. Firstly, the
presentation of possible inter-batch variation in acrolein cytotoxicity modulation undermined the
comparative mechanistic comparisons between viability data and the later mechanistic
elucidation studies, e.g., ΔΨm and calcium conductance. Since the baseline viability estimates
were unchanged among standard culture H9c2 cells, this was viewed as both an advantage,
especially regarding baseline-specific modulation of olaparib efficacy, but also as a disadvantage
as the viability IC50 for the 5 % oxygen culture estimates will quite likely be severely altered,
depending on the underlying FBS composite of the medium. With respect to serum
supplementation in medium, the use of a serum-free composition for comparative purposes could
have contributed a more stable baseline viability estimate of IC50 derivation, but the applicability
of such exposure metrics to the physiologically relevant in situ circumstance would be limited,
especially given the complex composition of FBS. For example, the current investigation has
shown significant changes in cytotoxicity depending on the medium TCA/glycolytic substrate
composition, but the influence of hormones and growth factors in serum could have also
contributed to the modulatory effects observed. It is imperative to note this, as serum-free
physiological buffers generally lack the specificity of presence and/or concentration of
hormones, free amino acids, and growth factors present in serum-containing medium280. While
facilitation of stabilizing viability estimates when minor concentration changes of pyruvate, for
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example, could increase observed variance, the lack of TCA and glycolytic substrates in such
buffers would likely overestimate cytotoxicity when physiologically relevant oxygen tension
studies are conducted. Since even modest additions of pyruvate (1.0 mM) to the basal pyruvate
supplied in the RP medium (160 µM) demonstratively increased viability estimates, actual
biochemical derivations of batch pyruvate would have supplied evidence in explaining the
observed inter-batch variation in viability due to serum contents.
Utilization of the statistical program R, and the associated “drc” Package synthesized the
viability and short-term metabolic IC50 curves well. However, the standard error estimates were
comparatively large, and may have reduced the likelihood of uncovering significant rescue
potential for particular TCA substrates, e.g., glutamine and glutamate. On the one hand, the
limited number of points, the totality of which composed the individual substrate-specific curves,
may have inadvertently inflated the uncertainty in curve parameter estimation. Further acrolein
concentrations could have been included, but the amount of data generation required would have
limited the resources required to enable the characterization of cytotoxic mechanisms pursued in
this investigation. Additionally, the influence of medium FBS on viability may have rendered
interpretation difficult or inconclusive; at least viability and metabolic estimates were derived
from the same batch and are, therefore, comparable. On the other hand, this method substantially
reduced the probability of a Type I error by reducing the number of statistical comparisons
required for complete data summarization.
For short-term (2 hour) MTT analyses, an accompaniment of Nrf-2 activation, and
associated downstream target genes responsible for antioxidant response, would have greatly
contributed to the affirmation that MTT reduction values above respective controls were
certainly caused by an increase in metabolic potential. Since cultures at 20.1 % demonstrated a
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limited capacity to evoke such a response, at least within two hours, it is assumed that Nrf-2
response time or capacity were enhanced under 5 % oxygen culture conditions; the latter was
presumed as the likely explanation. Further characterization would shed light on this matter. As
previously stated, other mechanistic phenomena were pursued in the current investigation, and a
possible Nrf-2-mediated metabolic activation was not expected at the onset. As such, this
plausible mechanism was not pursued in the initial research plan.
With respect to mechanistic elucidation, continued measurements of ΔΨm up to 24 hours
would have supplied evidence that, indeed, reductions of ΔΨm or complete potential ablation
occur under the experimental conditions. The method proposed for measuring ΔΨm included preloading cells with JC-1 prior to acrolein exposure; reversal of acrolein exposure and later JC-1
loading, followed by measurements, would have allowed for further characterization of
mitochondrial fate at later time-points. Evidence in other cells lines, particularly ARPE-19 cells,
have demonstrated dose-dependent reductions in ΔΨm with acrolein, especially at 25 µM. Since
AIF is typically characterized as both a marker of parthanatos and key player in ΔΨm dissipation,
characterization of AIF nuclear mobilization would have enhanced the mechanistic
characterization of the phenomenon observed. Furthermore, the specificity of PARP-1
involvement in calcium transients and cell death could have been investigated using siRNA
knock-down or transfection knock-out studies to attain conclusive evidence of parthanatos
induction. Currently, the technology and infrastructure do not accommodate such technical
capabilities, and may be later pursued for confirmatory purposes. Nonetheless, the primary focus
of the investigation remained characterization of oxygen tension on acrolein cytotoxicity using
TCA and glycolytic substrates.
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Finally, the current investigation only attempted to characterize a single modulatory
oxygen tension, 5 % mol/mol. While many would denote this as “hypoxic”, 5 % was interpreted
as physiologically normal based on in vivo measurements (See Introduction), especially in
balancing the venous and arterial oxygen tension of cardiac tissue. The literature base has
proposed a range of “normal” oxygen tensions, ranging from 3 % up to greater than blood
oxygen tension (100-120 mm Hg), depending on the investigation team and method of oxygen
concentration determination utilized, e.g., Clark electrode. Based on the evidence, 5 % was
chosen as a compromise of the variability present in the literature as well as for venous and
arterial tension differences; others have also included 10 % oxygen. Nonetheless,
undifferentiated H9c2 cells were acclimatized for a minimum of one week in 5 % oxygen prior
to subdivision and plating in preparation for the week-long differentiation regimen (2 days
attachment and five days differentiation). With respect to acclimatization to low oxygen, Hif-1α
activation was not affirmed via biochemical assessment after shifting the H9c2 cells to 5 %
oxygen. Therefore, it is not expected that the results could be due to hypoxic precondition,
though this phenomenon cannot be ruled out definitively. Such long acclimatization was
presumed to minimize such confounding, especially given the duration of culture prior to
experimentation and adherence to medium changes, cell plating, acrolein treatment, and MTT
reduction assay execution within an oxygen-controlled acrylic exposure chamber.
The translation of this investigation to an in vivo setting would provide a logical
progression towards the potential of PARP inhibition in cyclophosphamide-induced cardiac
failure. While this investigation cannot implicitly provide sufficient evidence to support the
notion that acrolein alone imparts the progression to heart failure among chemotherapy patients
treated with cyclophosphamide, the results offer promising evidence that PARP activation
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contributes to the cytotoxic events of the potent α,β-unsaturated aldehyde, acrolein. Further still,
evidence in vivo with ischemia/reperfusion, for which PARPi have proven partially efficacious,
consistently show TRPM2 involvement in the significant reduction of necrotic tissue damage
after an ischemic event; this effect has been coincidently observed in murine cerebral ischemia
models281 which were genetically deficient in Trpm2 expression. The authors noted significant
reductions in neutrophilic invasion – an event associated with exacerbation of infarct volume and
intensity, though the exact role of TRPM2 in cardiac ischemia remains the subject of debate282.
As for the model presented in the current investigation, the utilization of a whole-organism
model may provide further evidence of potential efficacy as the indirect effect of inflammatorymediated tissue damage cannot be captured in monoculture in vitro models, such as the one
presented here.
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CHAPTER FIVE:
CONCLUSION

Conclusively, the results of the current investigation demonstrate that H9c2 cells
maintained, differentiated, and exposed to acrolein under physiologically relevant oxygen
tension likely results in metabolic reprogramming which likely involves the TCA cycle; an
observation exemplified by pyruvate rescue only among cells cultured under 5 % oxygen.
Pyruvate did not spare differentiated H9c2 cells cultured under standard conditions; thus,
concluding that reduction of oxygen tension promotes metabolic reprogramming among 5 %
cultures. Further, extracellular calcium was demonstrated as a partial contributor in determining
cell fate during acrolein exposure, as 5-10 mM of EGTA significantly attenuated cell death from
exposure to acrolein. However, the contribution of TRPM2 channels may only be partial, since
extracellular influx was shown to be completely blocked via CTZ, but did not reduced cell
viability loss significantly as did EGTA. Olaparib demonstrated a complex interaction with
respect to cell rescue. Similar to CTZ, olaparib reduced calcium conductance to EGTA levels
among cells cultured under standard conditions, though a similar reduction in calcium transients
under 5 % oxygen was not conclusive. Therefore, the evidence suggests that modest-high
acrolein exposure activates PARP and induces extracellular influx partially through clotrimazolesensitive stores, all of which operate in concert and ultimately contribute to reductions in ΔΨm
and resultant cell death. The influence of PARP-associated reductions in viability remains
closely influenced by the magnitude of cytotoxic insult. Consideration of physiologically
118

relevant culture conditions may enhance in vitro representation of in vivo responses with respect
to toxicogenic insult in preclinical phases of drug discovery or in toxicological analyses.

119

REFERENCES
1.

Chabner BA, Bertino J, Cleary J, et al. Cytotoxic Agents. In: Brunton LL, Chabner B,
Knollmann BC, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics.
12th ed. New York, N.Y.: McGraw-Hill Medical; 2011.

2.

Storb R, Thomas ED, Weiden PL, et al. Aplastic anemia treated by allogeneic bone
marrow transplantation: a report on 49 new cases from Seattle. Blood. 1976;48(6):817841.

3.

Cox PJ. Cyclophosphamide cystitis--identification of acrolein as the causative agent.
Biochemical Pharmacology. 1979;28(13):2045-2049.

4.

Luce JK, Simons JA. Efficacy of mesna in preventing further cyclophosphamide-induced
hemorrhagic cystitis. Medical and Pediatric Oncology. 1988;16(6):372-374.

5.

Hows JM, Mehta A, Ward L, et al. Comparison of mesna with forced diuresis to prevent
cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a
prospective randomised study. British Journal of Cancer. 1984;50(6):753-756.

6.

Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity:
an analysis of dosing as a risk factor. Blood. 1986;68(5):1114-1118.

7.

Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity
associated with high-dose cyclophosphamide therapy. Archives of Internal Medicine.
1981;141(6):758-763.

120

8.

Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide
cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing
regimens. Journal of Clinical Oncology. 1991;9(7):1215-1223.

9.

Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with
cyclophosphamide. Medical and Pediatric Oncology. 1981;9(5):417-422.

10.

Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and
prospects of prophylaxis. European Journal of Heart Failure. 2002;4(3):235-242.

11.

Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute
myocardial infarction. Bone Marrow Transplantation. 1993;12(2):169-172.

12.

Gardner SF, Lazarus HM, Bednarczyk EM, et al. High-dose cyclophosphamide-induced
myocardial damage during BMT: assessment by positron emission tomography. Bone
Marrow Transplantation. 1993;12(2):139-144.

13.

Meserve EE, Lehmann LE, Perez-Atayde AR, Labelle JL. Cyclophosphamide-associated
cardiotoxicity in a child after stem cell transplantation for beta-thalassemia major: case
report and review of the literature. Pediatric and Developmental Pathology.
2014;17(1):50-54.

14.

Katayama M, Imai Y, Hashimoto H, et al. Fulminant fatal cardiotoxicity following
cyclophosphamide therapy. Journal of Cardiology. 2009;54(2):330-334.

15.

Dadfarmay S, Berkowitz R, Kim B. Irreversible end-stage cardiomyopathy following a
single dose of cyclophosphamide. Congestive Heart Failure. 2012;18(4):234-237.

121

16.

Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ. Comparative study on human
pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified
fluorometric test. Journal of Cancer Research and Clinical Oncology. 1981;100(1):95104.

17.

Draminski W, Eder E, Henschler D. A new pathway of acrolein metabolism in rats.
Archives of Toxicology. 1983;52(3):243-247.

18.

Kehrer JP, Biswal SS. The molecular effects of acrolein. Toxicological Sciences.
2000;57(1):6-15.

19.

Ren S, Kalhorn TF, Slattery JT. Inhibition of human aldehyde dehydrogenase 1 by the 4hydroxycyclophosphamide degradation product acrolein. Drug Metabolism and
Disposition: The Biological Fate of Chemicals. 1999;27(1):133-137.

20.

Alarcon RA. Fluorometric determination of acrolein and related compounds with maminophenol. Analytical Chemistry. 1968;40(11):1704-1708.

21.

Baumann F, Schmidt R, Teichert J, Preiss R. Influence of protein binding on acrolein
turnover in vitro by oxazaphosphorines and liver microsomes. Journal of Clinical
Laboratory Analysis. 2005;19(3):103-109.

22.

Günther M, Wagner E, Ogris M. Acrolein: unwanted side product or contribution to
antiangiogenic properties of metronomic cyclophosphamide therapy? Journal of Cellular
and Molecular Medicine. 2008;12(6b):2704-2716.

23.

Chaudhary KR, Batchu SN, Seubert JM. Cytochrome P450 enzymes and the heart.
International Union of Biochemistry and Molecular Biology: Life. 2009;61(10):954-960.

24.

Michaud V, Frappier M, Dumas MC, Turgeon J. Metabolic activity and mRNA levels of
human cardiac CYP450s involved in drug metabolism. PloS One. 2010;5(12):e15666.

122

25.

Dorr RT, Lagel K. Effect of sulfhydryl compounds and glutathione depletion on rat heart
myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro.
Chemico-Biological Interactions. 1994;93(2):117-128.

26.

Bjelogrlic SK, Lukic ST, Djuricic SM. Activity of dexrazoxane and amifostine against
late cardiotoxicity induced by the combination of doxorubicin and cyclophosphamide in
vivo. Basic & Clinical Pharmacology & Toxicology. 2013;113(4):228-238.

27.

Conklin DJ, Haberzettl P, Jagatheesan G, et al. Glutathione S-transferase P protects
against cyclophosphamide-induced cardiotoxicity in mice. Toxicology and Applied
Pharmacology. 2015;285(2):136-148.

28.

Adams JD, Jr., Klaidman LK. Acrolein-induced oxygen radical formation. Free Radical
Biology and Medicine. 1993;15(2):187-193.

29.

Yoshida M, Tomitori H, Machi Y, et al. Acrolein toxicity: Comparison with reactive
oxygen

species.

Biochemical

and

Biophysical

Research

Communications.

2009;378(2):313-318.
30.

Fischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys,
hamsters and rabbits. Journal of Reproduction and Fertility. 1993;99(2):673-679.

31.

Dole WP, Nuno DW. Myocardial oxygen tension determines the degree and pressure
range of coronary autoregulation. Circulation Research. 1986;59(2):202-215.

32.

Grunewald WA, Sowa W. Distribution of the myocardial tissue PO2 in the rat and the
inhomogeneity of the coronary bed. Pflügers Archiv. European Journal of Physiology.
1978;374(1):57-66.

123

33.

Kondrikov D, Elms S, Fulton D, Su Y. eNOS-beta-actin interaction contributes to
increased peroxynitrite formation during hyperoxia in pulmonary artery endothelial cells
and mouse lungs. Journal of Biological Chemistry. 2010;285(46):35479-35487.

34.

Meuter A, Rogmann LM, Winterhoff BJ, Tchkonia T, Kirkland JL, Morbeck DE.
Markers of cellular senescence are elevated in murine blastocysts cultured in vitro:
molecular consequences of culture in atmospheric oxygen. Journal of Assisted
Reproduction and Genetics. 2014;31(10):1259-1267.

35.

Csete M. Oxygen in the cultivation of stem cells. Annals of the New York Academy of
Sciences. 2005;1049:1-8.

36.

Peura TT, Bosman A, Stojanov T. Derivation of human embryonic stem cell lines.
Theriogenology. 2007;67(1):32-42.

37.

Li TS, Marban E. Physiological levels of reactive oxygen species are required to maintain
genomic stability in stem cells. Stem Cells. 2010;28(7):1178-1185.

38.

Hoffman DL, Salter JD, Brookes PS. Response of mitochondrial reactive oxygen species
generation to steady-state oxygen tension: implications for hypoxic cell signaling.
American Journal of Physiology: Heart and Circulatory Physiology. 2007;292(1):H101108.

39.

Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and
senescence of human diploid fibroblast cells. Proceedings of the National Academy of
Sciences. 1995;92(10):4337-4341.

40.

Fehrer C, Brunauer R, Laschober G, et al. Reduced oxygen tension attenuates
differentiation capacity of human mesenchymal stem cells and prolongs their lifespan.
Aging Cell. 2007;6(6):745-757.

124

41.

Kilburn DG, Lilly MD, Self DA, Webb FC. The effect of dissolved oxygen partial
pressure on the growth and carbohydrate metabolism of mouse LS cells. Journal of Cell
Science. 1969;4(1):25-37.

42.

Sher PK. The effects of acidosis on chronically hypoxic neurons in culture. Experimental
Neurology. 1990;107(3):256-262.

43.

Estrada JC, Albo C, Benguria A, et al. Culture of human mesenchymal stem cells at low
oxygen tension improves growth and genetic stability by activating glycolysis. Cell
Death and Differentiation. 2012;19(5):743-755.

44.

Bambrick LL, Kostov Y, Rao G. In vitro cell culture pO2 is significantly different from
incubator pO2. Biotechnology Progress. 2011;27(4):1185-1189.

45.

Kim J-w, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of
pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to
hypoxia. Cell Metabolism. 2006;3(3):177-185.

46.

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to
hypoxia by actively downregulating mitochondrial oxygen consumption. Cell
Metabolism. 2006;3(3):187-197.

47.

Konigsberg M, Perez VI, Rios C, et al. Effect of oxygen tension on bioenergetics and
proteostasis in young and old myoblast precursor cells. Redox Biology. 2013;1:475-482.

48.

Wilson DF, Erecinska M, Drown C, Silver IA. Effect of oxygen tension on cellular
energetics. American Journal of Physiology. 1977;233(5):C135-140.

49.

Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines:
recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death and
Differentiation. 2012;19(1):107-120.

125

50.

Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspaseindependent cell death. Oncogene. 2004;23(16):2785-2796.

51.

Wielckens K, Schmidt A, George E, Bredehorst R, Hilz H. DNA fragmentation and NAD
depletion. Their relation to the turnover of endogenous mono(ADP-ribosyl) and
poly(ADP-ribosyl) proteins. Journal of Biological Chemistry. 1982;257(21):1287212877.

52.

Kovacs K, Hanto K, Bognar Z, et al. Prevalent role of Akt and ERK activation in
cardioprotective effect of Ca(2+) channel- and beta-adrenergic receptor blockers.
Molecular and Cellular Biochemistry. 2009;321(1-2):155-164.

53.

Ying W, Alano CC, Garnier P, Swanson RA. NAD+ as a metabolic link between DNA
damage and cell death. Journal of Neuroscience Research. 2005;79(1-2):216-223.

54.

Ying W, Chen Y, Alano CC, Swanson RA. Tricarboxylic acid cycle substrates prevent
PARP-mediated death of neurons and astrocytes. Journal of Cerebral Blood Flow and
Metabolism. 2002;22(7):774-779.

55.

Zeng J, Yang GY, Ying W, et al. Pyruvate improves recovery after PARP-1-associated
energy failure induced by oxidative stress in neonatal rat cerebrocortical slices. Journal
of Cerebral Blood Flow and Metabolism. 2007;27(2):304-315.

56.

Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage
stimulates a regulated form of necrotic cell death. Genes and Development.
2004;18(11):1272-1282.

57.

Cheung EC, Joza N, Steenaart NA, et al. Dissociating the dual roles of apoptosisinducing factor in maintaining mitochondrial structure and apoptosis. EMBO Journal.
2006;25(17):4061-4073.

126

58.

Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA. NAD+
depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated
neuronal death. Journal of Neuroscience. 2010;30(8):2967-2978.

59.

Alano CC, Tran A, Tao R, Ying W, Karliner JS, Swanson RA. Differences among cell
types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac
myocytes. Journal of Neuroscience Research. 2007;85(15):3378-3385.

60.

Liu J, Segal M, Yoo S, et al. Antioxidant effect of ethyl pyruvate in respiring neonatal
cerebrocortical

slices

after

H(2)O(2)

stress.

Neurochemistry

International.

2009;54(2):106-110.
61.

Chiu SC, Huang SY, Tsai YC, et al. Poly (ADP-ribose) polymerase plays an important
role in intermittent hypoxia-induced cell death in rat cerebellar granule cells. Journal of
Biomedical Science. 2012;19:29.

62.

Cregan SP, Fortin A, MacLaurin JG, et al. Apoptosis-inducing factor is involved in the
regulation of caspase-independent neuronal cell death. Journal of Cell Biology.
2002;158(3):507-517.

63.

Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADP-ribose) polymerase-1dependent cell death by apoptosis-inducing factor. Science. 2002;297(5579):259-263.

64.

Yarana C, Sripetchwandee J, Sanit J, Chattipakorn S, Chattipakorn N. Calcium-induced
cardiac mitochondrial dysfunction is predominantly mediated by cyclosporine Adependent mitochondrial permeability transition pore. Archives of Medical Research.
2012;43(5):333-338.

127

65.

Pereira SL, Ramalho-Santos J, Branco AF, Sardao VA, Oliveira PJ, Carvalho RA.
Metabolic remodeling during H9c2 myoblast differentiation: relevance for in vitro
toxicity studies. Cardiovascular Toxicology. 2011;11(2):180-190.

66.

Ménard C, Pupier S, Mornet D, Kitzmann M, Nargëot J, Lory P. Modulation of L-type
calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac
cells. Journal of Biological Chemistry. 1999;274(41):29063-29070.

67.

Pagano M, Naviglio S, Spina A, et al. Differentiation of H9c2 cardiomyoblasts: The role
of adenylate cyclase system. Journal of Cellular Physiology. 2004;198(3):408-416.

68.

Brostrom MA, Reilly BA, Wilson FJ, Brostrom CO. Vasopressin-induced hypertrophy in
H9c2 heart-derived myocytes. International Journal of Biochemistry and Cell Biology.
2000;32(9):993-1006.

69.

Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein
synthesis in isolated perfused adult rat heart via the V1 receptor. Molecular and Cellular
Biochemistry. 1999;195(1-2):93-98.

70.

Mejia-Alvarez R, Tomaselli GF, Marban E. Simultaneous expression of cardiac and
skeletal muscle isoforms of the L-type Ca2+ channel in a rat heart muscle cell line.
Journal of Physiology. 1994;478 ( Pt 2):315-329.

71.

Bregant E, Renzone G, Lonigro R, et al. Down-regulation of SM22/transgelin gene
expression during H9c2 cells differentiation. Molecular and Cellular Biochemistry.
2009;327(1-2):145-152.

72.

Branco AF, Pereira SP, Gonzalez S, Gusev O, Rizvanov AA, Oliveira PJ. Gene
Expression Profiling of H9c2 Myoblast Differentiation towards a Cardiac-Like
Phenotype. PloS One. 2015;10(6):e0129303.

128

73.

Branco AF, Sampaio SF, Moreira AC, et al. Differentiation-dependent doxorubicin
toxicity on H9c2 cardiomyoblasts. Cardiovascular Toxicology. 2012;12(4):326-340.

74.

Yi M, Weaver D, Eisner V, et al. Switch from ER-mitochondrial to SR-mitochondrial
calcium coupling during muscle differentiation. Cell Calcium. 2012;52(5):355-365.

75.

Comelli M, Domenis R, Bisetto E, et al. Cardiac differentiation promotes mitochondria
development

and

ameliorates

oxidative

capacity

in

H9c2

cardiomyoblasts.

Mitochondrion. 2011;11(2):315-326.
76.

Olah G, Szczesny B, Brunyanszki A, et al. Differentiation-Associated Downregulation of
Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their
Resistance to Oxidative Stress. PloS One. 2015;10(7):e0134227.

77.

Crawford RM, Jovanovic S, Budas GR, et al. Chronic mild hypoxia protects heartderived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the
SUR2A subunit of the ATP-sensitive K+ channel. Journal of Biological Chemistry.
2003;278(33):31444-31455.

78.

Garnier P, Ying W, Swanson RA. Ischemic preconditioning by caspase cleavage of
poly(ADP-ribose) polymerase-1. Journal of Neuroscience. 2003;23(22):7967-7973.

79.

Sarkar K, Cai Z, Gupta R, et al. Hypoxia-inducible factor 1 transcriptional activity in
endothelial cells is required for acute phase cardioprotection induced by ischemic
preconditioning. Proceedings of the National Academy of Sciences. 2012;109(26):1050410509.

80.

Cai Z, Luo W, Zhan H, Semenza GL. Hypoxia-inducible factor 1 is required for remote
ischemic preconditioning of the heart. Proceedings of the National Academy of Sciences.
2013;110(43):17462-17467.

129

81.

Martin-Puig S, Tello D, Aragones J. Novel perspectives on the PHD-HIF oxygen sensing
pathway in cardioprotection mediated by IPC and RIPC. Frontiers in Physiology.
2015;6:137.

82.

Huang C, Andres AM, Ratliff EP, Hernandez G, Lee P, Gottlieb RA. Preconditioning
involves selective mitophagy mediated by Parkin and p62/SQSTM1. PloS One.
2011;6(6):e20975.

83.

Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired
mitochondria to activate Parkin. PLoS Biology. 2010;8(1):e1000298.

84.

Diers AR, Broniowska KA, Chang CF, Hogg N. Pyruvate fuels mitochondrial respiration
and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition.
Biochemical Journal. 2012;444(3):561-571.

85.

Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates
convergence of protection signaling to inhibit the mitochondrial permeability transition
pore. Journal of Clinical Investigation. 2004;113(11):1535-1549.

86.

Branco AF, Pereira SL, Moreira AC, Holy J, Sardao VA, Oliveira PJ. Isoproterenol
cytotoxicity is dependent on the differentiation state of the cardiomyoblast H9c2 cell line.
Cardiovascular Toxicology. 2011;11(3):191-203.

87.

di Giacomo V, Rapino M, Sancilio S, et al. PKC-delta signalling pathway is involved in
H9c2 cells differentiation. Differentiation. 2010;80(4-5):204-212.

88.

de Jesus García-Rivas G, Carvajal K, Correa F, Zazueta C. Ru(360), a specific
mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional
recovery in rats in vivo. British Journal of Pharmacology. 2006;149(7):829-837.

130

89.

Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and
ROS-induced ROS release. Physiological Reviews. 2014;94(3):909-950.

90.

Schonekess BO, Brindley PG, Lopaschuk GD. Calcium regulation of glycolysis, glucose
oxidation, and fatty acid oxidation in the aerobic and ischemic heart. Canadian Journal
of Physiology and Pharmacology. 1995;73(11):1632-1640.

91.

Glancy B, Balaban RS. Role of mitochondrial Ca2+ in the regulation of cellular
energetics. Biochemistry. 2012;51(14):2959-2973.

92.

Balaban RS, Bose S, French SA, Territo PR. Role of calcium in metabolic signaling
between cardiac sarcoplasmic reticulum and mitochondria in vitro. American Journal of
Physiology: Cell Physiology. 2003;284(2):C285-293.

93.

Das AM, Harris DA. Control of mitochondrial ATP synthase in heart cells: inactive to
active transitions caused by beating or positive inotropic agents. Cardiovascular
Research. 1990;24(5):411-417.

94.

Territo PR, Mootha VK, French SA, Balaban RS. Ca(2+) activation of heart
mitochondrial oxidative phosphorylation: role of the F(0)/F(1)-ATPase. American
Journal of Physiology: Cell Physiology. 2000;278(2):C423-435.

95.

Territo PR, French SA, Dunleavy MC, Evans FJ, Balaban RS. Calcium activation of
heart mitochondrial oxidative phosphorylation: rapid kinetics of mVO2, NADH, AND
light scattering. Journal of Biological Chemistry. 2001;276(4):2586-2599.

96.

de Jesus García-Rivas G, Guerrero-Hernandez A, Guerrero-Serna G, Rodriguez-Zavala
JS, Zazueta C. Inhibition of the mitochondrial calcium uniporter by the oxo-bridged
dinuclear ruthenium amine complex (Ru360) prevents from irreversible injury in
postischemic rat heart. FEBS Journal. 2005;272(13):3477-3488.

131

97.

Kirichok Y, Krapivinsky G, Clapham DE. The mitochondrial calcium uniporter is a
highly selective ion channel. Nature. 2004;427(6972):360-364.

98.

Kwong JQ, Lu X, Correll RN, et al. The Mitochondrial Calcium Uniporter Selectively
Matches Metabolic Output to Acute Contractile Stress in the Heart. Cell Reports.
2015;12(1):15-22.

99.

Holmuhamedov EL, Ozcan C, Jahangir A, Terzic A. Restoration of Ca2+-inhibited
oxidative phosphorylation in cardiac mitochondria by mitochondrial Ca2+ unloading.
Molecular and Cellular Biochemistry. 2001;220(1-2):135-140.

100.

Duan Y, Gross RA, Sheu SS. Ca2+-dependent generation of mitochondrial reactive
oxygen species serves as a signal for poly(ADP-ribose) polymerase-1 activation during
glutamate excitotoxicity. Journal of Physiology. 2007;585(Pt 3):741-758.

101.

Kushnareva YE, Wiley SE, Ward MW, Andreyev AY, Murphy AN. Excitotoxic injury to
mitochondria isolated from cultured neurons. Journal of Biological Chemistry.
2005;280(32):28894-28902.

102.

Luongo TS, Lambert JP, Yuan A, et al. The Mitochondrial Calcium Uniporter Matches
Energetic Supply with Cardiac Workload during Stress and Modulates Permeability
Transition. Cell Reports. 2015;12(1):23-34.

103.

Litsky ML, Pfeiffer DR. Regulation of the mitochondrial Ca2+ uniporter by external
adenine nucleotides: the uniporter behaves like a gated channel which is regulated by
nucleotides and divalent cations. Biochemistry. 1997;36(23):7071-7080.

104.

Holmström KM, Pan X, Liu JC, et al. Assessment of cardiac function in mice lacking the
mitochondrial calcium uniporter. Journal of Molecular and Cellular Cardiology.
2015;85:178-182.

132

105.

Liu T, O'Rourke B. Enhancing mitochondrial Ca2+ uptake in myocytes from failing
hearts

restores

energy

supply

and

demand

matching.

Circulation Research.

2008;103(3):279-288.
106.

Matlib MA, Zhou Z, Knight S, et al. Oxygen-bridged dinuclear ruthenium amine
complex specifically inhibits Ca2+ uptake into mitochondria in vitro and in situ in single
cardiac myocytes. Journal of Biological Chemistry. 1998;273(17):10223-10231.

107.

Kimchi-Sarfaty C, Kasir J, Ambudkar SV, Rahamimoff H. Transport activity and surface
expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive
agent cyclosporin A and by the nonimmunosuppressive agent PSC833. Journal of
Biological Chemistry. 2002;277(4):2505-2510.

108.

Griffiths EJ. Reversal of mitochondrial Na/Ca exchange during metabolic inhibition in rat
cardiomyocytes. FEBS Letters. 1999;453(3):400-404.

109.

Elbaz B, Valitsky M, Davidov G, Rahamimoff H. Cyclophilin A is involved in functional
expression of the Na(+)-Ca(2+) exchanger NCX1. Biochemistry. 2010;49(35):7634-7642.

110.

Rahamimoff H, Elbaz B, Alperovich A, et al. Cyclosporin A-dependent downregulation
of the Na+/Ca2+ exchanger expression. Annals of the New York Academy of Sciences.
2007;1099:204-214.

111.

Braun FJ, Broad LM, Armstrong DL, Putney JW, Jr. Stable activation of single Ca2+
release-activated Ca2+ channels in divalent cation-free solutions. Journal of Biological
Chemistry. 2001;276(2):1063-1070.

112.

Togashi K, Inada H, Tominaga M. Inhibition of the transient receptor potential cation
channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). British Journal of
Pharmacology. 2008;153(6):1324-1330.

133

113.

Dobrydneva Y, Blackmore P. 2-Aminoethoxydiphenyl borate directly inhibits storeoperated calcium entry channels in human platelets. Molecular Pharmacology.
2001;60(3):541-552.

114.

Sano Y, Inamura K, Miyake A, et al. Immunocyte Ca2+ influx system mediated by
LTRPC2. Science. 2001;293(5533):1327-1330.

115.

Yu P, Wang Q, Zhang LH, Lee HC, Zhang L, Yue J. A cell permeable NPE caged ADPribose for studying TRPM2. PloS One. 2012;7(12):e51028.

116.

Montell C. The TRP superfamily of cation channels. Science: Signal Transduction
Knowledge Environment. 2005;2005(272):re3.

117.

Bari MR, Akbar S, Eweida M, et al. H2O2-induced Ca2+ influx and its inhibition by N(p-amylcinnamoyl) anthranilic acid in the beta-cells: involvement of TRPM2 channels.
Journal of Cellular and Molecular Medicine. 2009;13(9b):3260-3267.

118.

Chokshi R, Fruasaha P, Kozak JA. 2-aminoethyl diphenyl borinate (2-APB) inhibits
TRPM7 channels through an intracellular acidification mechanism. Channels.
2012;6(5):362-369.

119.

Liu X, Cotrim A, Teos L, et al. Loss of TRPM2 function protects against irradiationinduced salivary gland dysfunction. Nature Communications. 2013b;4:1515.

120.

Jia J, Verma S, Nakayama S, et al. Sex differences in neuroprotection provided by
inhibition of TRPM2 channels following experimental stroke. Journal of Cerebral Blood
Flow and Metabolism. 2011;31(11):2160-2168.

121.

Verma S, Quillinan N, Yang YF, et al. TRPM2 channel activation following in vitro
ischemia contributes to male hippocampal cell death. Neuroscience Letters.
2012;530(1):41-46.

134

122.

Harteneck C, Frenzel H, Kraft R. N-(p-amylcinnamoyl)anthranilic acid (ACA): a
phospholipase A(2) inhibitor and TRP channel blocker. Cardiovascular Drug Reviews.
2007;25(1):61-75.

123.

Kraft R, Grimm C, Frenzel H, Harteneck C. Inhibition of TRPM2 cation channels by N(p-amylcinnamoyl)anthranilic acid. British Journal of Pharmacology. 2006;148(3):264273.

124.

Hill K, Benham CD, McNulty S, Randall AD. Flufenamic acid is a pH-dependent
antagonist of TRPM2 channels. Neuropharmacology. 2004a;47(3):450-460.

125.

Hill K, McNulty S, Randall AD. Inhibition of TRPM2 channels by the antifungal agents
clotrimazole and econazole. Naunyn-Schmiedebergs Archives of Pharmacology.
2004b;370(4):227-237.

126.

Chen SJ, Zhang W, Tong Q, et al. Role of TRPM2 in cell proliferation and susceptibility
to oxidative stress. American Journal of Physiology: Cell Physiology. 2013;304(6):C548560.

127.

Takahashi K, Sakamoto K, Kimura J. Hypoxic stress induces transient receptor potential
melastatin 2 (TRPM2) channel expression in adult rat cardiac fibroblasts. Journal of
Pharmacological Sciences. 2012;118(2):186-197.

128.

Gasser A, Glassmeier G, Fliegert R, et al. Activation of T cell calcium influx by the
second messenger ADP-ribose. Journal of Biological Chemistry. 2006;281(5):2489-2496.

129.

Starkus J, Beck A, Fleig A, Penner R. Regulation of TRPM2 by extra- and intracellular
calcium. Journal of General Physiology. 2007;130(4):427-440.

135

130.

Shimizu S, Yonezawa R, Hagiwara T, et al. Inhibitory effects of AG490 on H2O2induced TRPM2-mediated Ca(2+) entry. European Journal of Pharmacology.
2014;742:22-30.

131.

Hu HZ, Gu Q, Wang C, et al. 2-aminoethoxydiphenyl borate is a common activator of
TRPV1, TRPV2, and TRPV3. Journal of Biological Chemistry. 2004;279(34):3574135748.

132.

Xu SZ, Zeng F, Boulay G, Grimm C, Harteneck C, Beech DJ. Block of TRPC5 channels
by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent
effect. British Journal of Pharmacology. 2005;145(4):405-414.

133.

Peppiatt CM, Collins TJ, Mackenzie L, et al. 2-Aminoethoxydiphenyl borate (2-APB)
antagonises inositol 1,4,5-trisphosphate-induced calcium release, inhibits calcium pumps
and has a use-dependent and slowly reversible action on store-operated calcium entry
channels. Cell Calcium. 2003;34(1):97-108.

134.

Bilmen JG, Michelangeli F. Inhibition of the type 1 inositol 1,4,5-trisphosphate receptor
by 2-aminoethoxydiphenylborate. Cellular Signalling. 2002;14(11):955-960.

135.

Iwasaki H, Mori Y, Hara Y, Uchida K, Zhou H, Mikoshiba K. 2-Aminoethoxydiphenyl
borate (2-APB) inhibits capacitative calcium entry independently of the function of
inositol 1,4,5-trisphosphate receptors. Receptors and Channels. 2001;7(6):429-439.

136.

Takahashi K, Yokota M, Ohta T. Molecular mechanism of 2-APB-induced Ca(2)(+)
influx in external acidification in PC12. Experimental Cell Research. 2014;323(2):337345.

136

137.

Kukkonen JP, Lund PE, Akerman KE. 2-aminoethoxydiphenyl borate reveals
heterogeneity in receptor-activated Ca(2+) discharge and store-operated Ca(2+) influx.
Cell Calcium. 2001;30(2):117-129.

138.

Hwang SM, Koo NY, Jin M, et al. Intracellular acidification is associated with changes in
free cytosolic calcium and inhibition of action potentials in rat trigeminal ganglion.
Journal of Biological Chemistry. 2011;286(3):1719-1729.

139.

Li S, Hao B, Lu Y, Yu P, Lee HC, Yue J. Intracellular alkalinization induces cytosolic
Ca2+ increases by inhibiting sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). PloS
One. 2012;7(2):e31905.

140.

Kwak YG, Park SK, Kim UH, et al. Intracellular ADP-ribose inhibits ATP-sensitive K+
channels in rat ventricular myocytes. American Journal of Physiology. 1996;271(2 Pt
1):C464-468.

141.

Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983;305(5930):147148.

142.

Hecquet CM, Ahmmed GU, Vogel SM, Malik AB. Role of TRPM2 channel in mediating
H2O2-induced Ca2+ entry and endothelial hyperpermeability. Circulation Research.
2008;102(3):347-355.

143.

Wehage E, Eisfeld J, Heiner I, Jungling E, Zitt C, Luckhoff A. Activation of the cation
channel long transient receptor potential channel 2 (LTRPC2) by hydrogen peroxide. A
splice variant reveals a mode of activation independent of ADP-ribose. Journal of
Biological Chemistry. 2002;277(26):23150-23156.

137

144.

Heiner I, Eisfeld J, Halaszovich CR, et al. Expression profile of the transient receptor
potential (TRP) family in neutrophil granulocytes: evidence for currents through long
TRP channel 2 induced by ADP-ribose and NAD. Biochemical Journal. 2003;371(Pt
3):1045-1053.

145.

Zhang Z, Zhang W, Jung DY, et al. TRPM2 Ca2+ channel regulates energy balance and
glucose metabolism. American Journal of Physiology: Endocrinology and Metabolism.
2012;302(7):E807-816.

146.

Akaishi T, Nakazawa K, Sato K, Saito H, Ohno Y, Ito Y. Hydrogen peroxide modulates
whole cell Ca2+ currents through L-type channels in cultured rat dentate granule cells.
Neuroscience Letters. 2004;356(1):25-28.

147.

Hudasek K, Brown ST, Fearon IM. H2O2 regulates recombinant Ca2+ channel alpha1C
subunits but does not mediate their sensitivity to acute hypoxia. Biochemical and
Biophysical Research Communications. 2004;318(1):135-141.

148.

Csanády L, Törocsik B. Four Ca2+ ions activate TRPM2 channels by binding in deep
crevices near the pore but intracellularly of the gate. Journal of General Physiology.
2009;133(2):189-203.

149.

Ishii M, Hagiwara T, Mori Y, Shimizu S. Involvement of TRPM2 and L-type Ca(2)(+)
channels in Ca(2)(+) entry and cell death induced by hydrogen peroxide in rat beta-cell
line RIN-5F. Journal of Toxicological Sciences. 2014;39(2):199-209.

150.

Kühn FJ, Lückhoff A. Sites of the NUDT9-H domain critical for ADP-ribose activation
of the cation channel TRPM2. Journal of Biological Chemistry. 2004;279(45):4643146437.

138

151.

Perraud AL, Fleig A, Dunn CA, et al. ADP-ribose gating of the calcium-permeable
LTRPC2 channel revealed by Nudix motif homology. Nature. 2001;411(6837):595-599.

152.

Heiner I, Eisfeld J, Warnstedt M, Radukina N, Jungling E, Luckhoff A. Endogenous
ADP-ribose enables calcium-regulated cation currents through TRPM2 channels in
neutrophil granulocytes. Biochemical Journal. 2006;398(2):225-232.

153.

Toth B, Iordanov I, Csanady L. Ruling out pyridine dinucleotides as true TRPM2 channel
activators reveals novel direct agonist ADP-ribose-2'-phosphate. Journal of General
Physiology. 2015;145(5):419-430.

154.

Lange I, Penner R, Fleig A, Beck A. Synergistic regulation of endogenous TRPM2
channels by adenine dinucleotides in primary human neutrophils. Cell Calcium.
2008;44(6):604-615.

155.

Beck A, Kolisek M, Bagley LA, Fleig A, Penner R. Nicotinic acid adenine dinucleotide
phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB
Journal. 2006;20(7):962-964.

156.

Hara Y, Wakamori M, Ishii M, et al. LTRPC2 Ca2+-permeable channel activated by
changes in redox status confers susceptibility to cell death. Molecular Cell.
2002;9(1):163-173.

157.

Magnone M, Bauer I, Poggi A, et al. NAD+ levels control Ca2+ store replenishment and
mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2
channel gating in human T lymphocytes. Journal of Biological Chemistry.
2012;287(25):21067-21081.

139

158.

Kolisek M, Beck A, Fleig A, Penner R. Cyclic ADP-ribose and hydrogen peroxide
synergize with ADP-ribose in the activation of TRPM2 channels. Molecular Cell.
2005;18(1):61-69.

159.

Perraud AL, Takanishi CL, Shen B, et al. Accumulation of free ADP-ribose from
mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels.
Journal of Biological Chemistry. 2005;280(7):6138-6148.

160.

Buelow B, Song Y, Scharenberg AM. The Poly(ADP-ribose) polymerase PARP-1 is
required for oxidative stress-induced TRPM2 activation in lymphocytes. Journal of
Biological Chemistry. 2008;283(36):24571-24583.

161.

Gerace E, Masi A, Resta F, et al. PARP-1 activation causes neuronal death in the
hippocampal CA1 region by increasing the expression of Ca(2+)-permeable AMPA
receptors. Neurobiology of Disease. 2014;70:43-52.

162.

Herson PS, Ashford ML. Activation of a novel non-selective cation channel by alloxan
and H2O2 in the rat insulin-secreting cell line CRI-G1. Journal of Physiology. 1997;501 (
Pt 1):59-66.

163.

Tong Q, Zhang W, Conrad K, et al. Regulation of the transient receptor potential channel
TRPM2 by the Ca2+ sensor calmodulin. Journal of Biological Chemistry.
2006;281(14):9076-9085.

164.

McHugh D, Flemming R, Xu SZ, Perraud AL, Beech DJ. Critical intracellular Ca2+
dependence of transient receptor potential melastatin 2 (TRPM2) cation channel
activation. Journal of Biological Chemistry. 2003;278(13):11002-11006.

140

165.

Roberge S, Roussel J, Andersson DC, et al. TNF-alpha-mediated caspase-8 activation
induces ROS production and TRPM2 activation in adult ventricular myocytes.
Cardiovascular Research. 2014;103(1):90-99.

166.

Ishii M, Oyama A, Hagiwara T, et al. Facilitation of H2O2-induced A172 human
glioblastoma cell death by insertion of oxidative stress-sensitive TRPM2 channels.
Anticancer Research. 2007;27(6b):3987-3992.

167.

Fonfria E, Marshall IC, Benham CD, et al. TRPM2 channel opening in response to
oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. British
Journal of Pharmacology. 2004;143(1):186-192.

168.

Yang KT, Chang WL, Yang PC, et al. Activation of the transient receptor potential M2
channel and poly(ADP-ribose) polymerase is involved in oxidative stress-induced
cardiomyocyte death. Cell Death and Differentiation. 2006;13(10):1815-1826.

169.

Blenn

C,

Wyrsch

P,

Bader

J,

Bollhalder

M,

Althaus

FR.

Poly(ADP-

ribose)glycohydrolase is an upstream regulator of Ca2+ fluxes in oxidative cell death.
Cellular and Molecular Life Sciences. 2011;68(8):1455-1466.
170.

Buelow B, Uzunparmak B, Paddock M, Scharenberg AM. Structure/function analysis of
PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation. PloS
One. 2009;4(7):e6339.

171.

Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent
modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA
repair. Journal of Biological Chemistry. 2006;281(44):33684-33696.

172.

Malanga M, Althaus FR. Poly(ADP-ribose) molecules formed during DNA repair in
vivo. Journal of Biological Chemistry. 1994;269(26):17691-17696.

141

173.

Yu SW, Andrabi SA, Wang H, et al. Apoptosis-inducing factor mediates poly(ADPribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of
Sciences. 2006;103(48):18314-18319.

174.

Fujihara H, Ogino H, Maeda D, et al. Poly(ADP-ribose) Glycohydrolase deficiency
sensitizes mouse ES cells to DNA damaging agents. Current Cancer Drug Targets.
2009;9(8):953-962.

175.

Illuzzi G, Fouquerel E, Ame JC, et al. PARG is dispensable for recovery from transient
replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose)
upon prolonged replicative stress. Nucleic Acids Research. 2014;42(12):7776-7792.

176.

Hatakeyama K, Nemoto Y, Ueda K, Hayaishi O. Purification and characterization of
poly(ADP-ribose) glycohydrolase. Different modes of action on large and small
poly(ADP-ribose). Journal of Biological Chemistry. 1986;261(32):14902-14911.

177.

Geistrikh I, Visochek L, Klein R, et al. Ca2+-induced PARP-1 activation and ANF
expression are coupled events in cardiomyocytes. Biochemical Journal. 2011;438(2):337347.

178.

Niere M, Kernstock S, Koch-Nolte F, Ziegler M. Functional localization of two
poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix. Molecular and
Cellular Biology. 2008;28(2):814-824.

179.

Abramov AY, Duchen MR. Mechanisms underlying the loss of mitochondrial membrane
potential in glutamate excitotoxicity. Biochimica et Biophysica Acta. 2008;1777(78):953-964.

180.

Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for
mitochondrial permeability transition in cell death. Nature. 2005;434(7033):658-662.

142

181.

Yang JC, Cortopassi GA. Induction of the mitochondrial permeability transition causes
release of the apoptogenic factor cytochrome c. Free Radical Biology and Medicine.
1998;24(4):624-631.

182.

Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial
apoptosis-inducing factor. Nature. 1999;397(6718):441-446.

183.

Cao G, Clark RS, Pei W, et al. Translocation of apoptosis-inducing factor in vulnerable
neurons after transient cerebral ischemia and in neuronal cultures after oxygen-glucose
deprivation. Journal of Cerebral Blood Flow and Metabolism. 2003;23(10):1137-1150.

184.

Zhang X, Chen J, Graham SH, et al. Intranuclear localization of apoptosis-inducing factor
(AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in
neuronal cultures exposed to peroxynitrite. Journal of Neurochemistry. 2002;82(1):181191.

185.

Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation
downregulates apoptosis-inducing factor. Nature. 2002;419(6905):367-374.

186.

Gagne JP, Isabelle M, Lo KS, et al. Proteome-wide identification of poly(ADP-ribose)
binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids
Research. 2008;36(22):6959-6976.

187.

Andrabi SA, Kim NS, Yu SW, et al. Poly(ADP-ribose) (PAR) polymer is a death signal.
Proceedings of the National Academy of Sciences. 2006;103(48):18308-18313.

188.

Cipriani G, Rapizzi E, Vannacci A, Rizzuto R, Moroni F, Chiarugi A. Nuclear
poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. Journal of
Biological Chemistry. 2005;280(17):17227-17234.

143

189.

Artus C, Boujrad H, Bouharrour A, et al. AIF promotes chromatinolysis and caspaseindependent programmed necrosis by interacting with histone H2AX. EMBO Journal.
2010;29(9):1585-1599.

190.

Elrod JW, Wong R, Mishra S, et al. Cyclophilin D controls mitochondrial pore-dependent
Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. Journal
of Clinical Investigation. 2010;120(10):3680-3687.

191.

Zhu C, Wang X, Deinum J, et al. Cyclophilin A participates in the nuclear translocation
of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. Journal of
Experimental Medicine. 2007;204(8):1741-1748.

192.

Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during
cardiac ischaemia, but open upon reperfusion. Biochemical Journal. 1995;307 ( Pt 1):9398.

193.

Yu SW, Wang Y, Frydenlund DS, Ottersen OP, Dawson VL, Dawson TM. Outer
mitochondrial membrane localization of apoptosis-inducing factor: mechanistic
implications for release. American Society for Neurochemistry: Neuro. 2009;1(5).

194.

Bollman JL, Flock EV. Pyruvate in working muscles of normal and vitamin B1-deficient
rats. Journal of Biological Chemistry. 1939;130(2):565-571.

195.

Frohman CE, Day HG. Effect of oxythiamine on blood pyruvate-lactate relationships and
the excretion of thiamine in rats. Journal of Biological Chemistry. 1949;180(1):93-98.

196.

Lu G. Studies on the metabolism of pyruvic acid in normal and vitamin B1-deficient
states: Blood pyruvate levels in the rat, pigeon, rabbit and man. III. The relation of blood
pyruvate to cardiac changes. Biochemical Journal. 1939;33(5):774.

144

197.

Babich H, Liebling EJ, Burger RF, Zuckerbraun HL, Schuck AG. Choice of DMEM,
formulated with or without pyruvate, plays an important role in assessing the in vitro
cytotoxicity of oxidants and prooxidant nutraceuticals. In Vitro Cellular and
Developmental Biology: Animal. 2009;45(5-6):226-233.

198.

Vahsen N, Cande C, Briere JJ, et al. AIF deficiency compromises oxidative
phosphorylation. EMBO Journal. 2004;23(23):4679-4689.

199.

Villeneuve L, Tiede LM, Morsey B, Fox HS. Quantitative proteomics reveals oxygendependent changes in neuronal mitochondria affecting function and sensitivity to
rotenone. Journal of Proteome Research. 2013;12(10):4599-4606.

200.

Ali SS, Hsiao M, Zhao HW, Dugan LL, Haddad GG, Zhou D. Hypoxia-adaptation
involves mitochondrial metabolic depression and decreased ROS leakage. PloS One.
2012;7(5):e36801.

201.

Moubarak RS, Yuste VJ, Artus C, et al. Sequential activation of poly(ADP-ribose)
polymerase 1, calpains, and Bax is essential in apoptosis-inducing factor-mediated
programmed necrosis. Molecular and Cellular Biology. 2007;27(13):4844-4862.

202.

Daugas E, Susin SA, Zamzami N, et al. Mitochondrio-nuclear translocation of AIF in
apoptosis and necrosis. FASEB Journal. 2000;14(5):729-739.

203.

Kimes BW, Brandt BL. Properties of a clonal muscle cell line from rat heart.
Experimental Cell Research. 1976;98(2):367-381.

204.

Cselenyak A, Pankotai E, Horvath EM, Kiss L, Lacza Z. Mesenchymal stem cells rescue
cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell
connections. BMC Cell Biology. 2010;11:29.

145

205.

Chen PA, Xu ZH, Huang YL, et al. Increased serum 2-oxoglutarate associated with high
myocardial energy expenditure and poor prognosis in chronic heart failure patients.
Biochimica et Biophysica Acta. 2014;1842(11):2120-2125.

206.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to
proliferation and cytotoxicity assays. Journal of Immunological Methods. 1983;65(12):55-63.

207.

Stepanenko AA, Dmitrenko VV. Pitfalls of the MTT assay: Direct and off-target effects
of inhibitors can result in over/underestimation of cell viability. Gene. 2015;574(2):193203.

208.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities
of protein utilizing the principle of protein-dye binding. Analytical Biochemistry.
1976;72:248-254.

209.

Smiley ST, Reers M, Mottola-Hartshorn C, et al. Intracellular heterogeneity in
mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation
JC-1. Proceedings of the National Academy of Sciences. 1991;88(9):3671-3675.

210.

Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or
rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells:
implications for studies on mitochondrial functionality during apoptosis. FEBS Letters.
1997;411(1):77-82.

211.

Owen CS. Phorbol ester (12-O-tetradecanoylphorbol 13-acetate) partially inhibits rapid
intracellular free calcium transients triggered by anti-immunoglobulin in murine
lymphocytes. Journal of Biological Chemistry. 1988;263(6):2732-2737.

146

212.

Roychowdhury S, Noack J, Engelmann M, Wolf G, Horn TF. AMPA receptor-induced
intracellular calcium response in the paraventricular nucleus is modulated by nitric oxide:
calcium imaging in a hypothalamic organotypic cell culture model. Nitric Oxide.
2006;14(4):290-299.

213.

Justel A, Peña D, Zamar R. A multivariate Kolmogorov-Smirnov test of goodness of fit.
Statistics & Probability Letters. 1997;35(3):251-259.

214.

Peat JKa, Barton Ba. Medical statistics : A guide to SPSS, data analysis, and critical
appraisal. Second edition. ed. Chichester, West Sussex ; Hoboken, NJ: John Wiley &
Sons Inc; 2014.

215.

Ritz C, Baty F, Streibig JC, Gerhard D. Dose-Response Analysis Using R. PloS One.
2015;10(12):e0146021.

216.

International Conference on Harmonisation Expert Working Group. Guidance for
Industry: Q2B Validation of Analytical Procedures: Methodology. In: Harmonisation
ICo, ed. Brussels, Belgium: International Conference on Harmonisation; 1996.

217.

Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights
into their cellular reduction. Biotechnology Annual Review. 2005;11:127-152.

218.

Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based
assays for cellular viability: a critical examination of selected parameters affecting
formazan production. Cancer Research. 1991;51(10):2515-2520.

219.

Moghe A, Ghare S, Lamoreau B, et al. Molecular mechanisms of acrolein toxicity:
relevance to human disease. Toxicological Sciences. 2015;143(2):242-255.

147

220.

Liu Q, Huang QX, Lou FC, et al. Effects of glucose and insulin on the H9c2 (2-1) cell
proliferation may be mediated through regulating glucose transporter 4 expression.
Chinese Medical Journal. 2013a;126(21):4037-4042.

221.

Lin RY, Vera JC, Chaganti RS, Golde DW. Human monocarboxylate transporter 2
(MCT2) is a high affinity pyruvate transporter. Journal of Biological Chemistry.
1998;273(44):28959-28965.

222.

Bonen A. The expression of lactate transporters (MCT1 and MCT4) in heart and muscle.
European Journal of Applied Physiology. 2001;86(1):6-11.

223.

Bode BP. Recent molecular advances in mammalian glutamine transport. Journal of
Nutrition. 2001;131(9 Suppl):2475S-2485S; discussion 2486S-2477S.

224.

Sugawara M, Nakanishi T, Fei YJ, et al. Cloning of an amino acid transporter with
functional characteristics and tissue expression pattern identical to that of system A.
Journal of Biological Chemistry. 2000;275(22):16473-16477.

225.

Kugler P. Expression of glutamate transporters in rat cardiomyocytes and their
localization in the T-tubular system. Journal of Histochemistry and Cytochemistry.
2004;52(10):1385-1392.

226.

Takeda K, Ishida A, Takahashi K, Ueda T. Synaptic vesicles are capable of synthesizing
the VGLUT substrate glutamate from α-ketoglutarate for vesicular loading. Journal of
Neurochemistry. 2012;121(2):184-196.

227.

Shank RP, Bennett DJ. 2-Oxoglutarate transport: a potential mechanism for regulating
glutamate and tricarboxylic acid cycle intermediates in neurons. Neurochemical
Research. 1993;18(4):401-410.

148

228.

Pajor AM, Gangula R, Yao X. Cloning and functional characterization of a high-affinity
Na(+)/dicarboxylate cotransporter from mouse brain. American Journal of Physiology:
Cell Physiology. 2001;280(5):C1215-1223.

229.

Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions
relevant to human health and disease. Molecular Nutrition & Food Research.
2008;52(1):7-25.

230.

Agarwal AR, Yin F, Cadenas E. Metabolic shift in lung alveolar cell mitochondria
following acrolein exposure. American Journal of Physiology: Lung Cellular and
Molecular Physiology. 2013;305(10):L764-773.

231.

Reddy NM, Kleeberger SR, Yamamoto M, et al. Genetic dissection of the Nrf2dependent redox signaling-regulated transcriptional programs of cell proliferation and
cytoprotection. Physiological Genomics. 2007;32(1):74-81.

232.

Osburn WO, Wakabayashi N, Misra V, et al. Nrf2 regulates an adaptive response
protecting against oxidative damage following diquat-mediated formation of superoxide
anion. Archives of Biochemistry and Biophysics. 2006;454(1):7-15.

233.

Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway
and

its

activation

by

oxidative

stress.

Journal

of

Biological

Chemistry.

2009;284(20):13291-13295.
234.

Enomoto A, Itoh K, Nagayoshi E, et al. High sensitivity of Nrf2 knockout mice to
acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated
drug

metabolizing

enzymes

and

antioxidant

2001;59(1):169-177.

149

genes.

Toxicological

Sciences.

235.

Tirumalai R, Rajesh Kumar T, Mai KH, Biswal S. Acrolein causes transcriptional
induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549)
cells. Toxicology Letters. 2002;132(1):27-36.

236.

Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a
group of oxidative stress-inducible genes in macrophages. Journal of Biological
Chemistry. 2000;275(21):16023-16029.

237.

Goldring CE, Kitteringham NR, Elsby R, et al. Activation of hepatic Nrf2 in vivo by
acetaminophen in CD-1 mice. Hepatology. 2004;39(5):1267-1276.

238.

Randle LE, Goldring CE, Benson CA, et al. Investigation of the effect of a panel of
model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice.
Toxicology. 2008;243(3):249-260.

239.

Li K, Cui YC, Zhang H, et al. Glutamine Reduces the Apoptosis of H9C2 Cells Treated
with High-Glucose and Reperfusion through an Oxidation-Related Mechanism. PloS
One. 2015;10(7):e0132402.

240.

Wang X, Perez E, Liu R, Yan LJ, Mallet RT, Yang SH. Pyruvate protects mitochondria
from oxidative stress in human neuroblastoma SK-N-SH cells. Brain Research.
2007;1132(1):1-9.

241.

Fernandez-Gomez FJ, Pastor MD, Garcia-Martinez EM, et al. Pyruvate protects
cerebellar granular cells from 6-hydroxydopamine-induced cytotoxicity by activating the
Akt signaling pathway and increasing glutathione peroxidase expression. Neurobiology of
Disease. 2006;24(2):296-307.

150

242.

Hamann K, Shi R. Acrolein scavenging: a potential novel mechanism of attenuating
oxidative

stress

following

spinal

cord

injury.

Journal

of

Neurochemistry.

2009;111(6):1348-1356.
243.

Monteil C, Le Prieur E, Buisson S, Morin JP, Guerbet M, Jouany JM. Acrolein toxicity:
comparative in vitro study with lung slices and pneumocytes type II cell line from rats.
Toxicology. 1999;133(2-3):129-138.

244.

Garcia NA, Moncayo-Arlandi J, Sepulveda P, Diez-Juan A. Cardiomyocyte exosomes
regulate glycolytic flux in endothelium by direct transfer of GLUT transporters and
glycolytic enzymes. Cardiovascular Research. 2016;109(3):397-408.

245.

Malhotra R, Tyson DW, Rosevear HM, Brosius FC, 3rd. Hypoxia-inducible factor1alpha is a critical mediator of hypoxia induced apoptosis in cardiac H9c2 and kidney
epithelial HK-2 cells. BMC Cardiovascular Disorders. 2008;8:9.

246.

Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annual Review of
Physiology. 2014;76:39-56.

247.

Lovell MA, Xie C, Markesbery WR. Acrolein, a product of lipid peroxidation, inhibits
glucose and glutamate uptake in primary neuronal cultures. Free Radical Biology &
Medicine. 2000;29(8):714-720.

248.

Abraham P, Rabi S. Protein nitration, PARP activation and NAD+ depletion may play a
critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the
rat. Cancer Chemotherapy and Pharmacology. 2009;64(2):279-285.

249.

Andrabi SA, Umanah GK, Chang C, et al. Poly(ADP-ribose) polymerase-dependent
energy depletion occurs through inhibition of glycolysis. Proceedings of the National
Academy of Sciences. 2014;111(28):10209-10214.

151

250.

Martyniuk CJ, Fang B, Koomen JM, et al. Molecular mechanism of glyceraldehyde-3phosphate dehydrogenase inactivation by alpha,beta-unsaturated carbonyl derivatives.
Chemical Research in Toxicology. 2011;24(12):2302-2311.

251.

Wischmeyer PE, Vanden Hoek TL, Li C, et al. Glutamine preserves cardiomyocyte
viability and enhances recovery of contractile function after ischemia-reperfusion injury.
Journal of Parenteral & Enteral Nutrition. 2003;27(2):116-122.

252.

Liu J, Marchase RB, Chatham JC. Glutamine-induced protection of isolated rat heart
from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway
and increased protein O-GlcNAc levels. Journal of Molecular and Cellular Cardiology.
2007;42(1):177-185.

253.

David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death.
Front Biosci (Landmark Ed). 2009;14:1116-1128.

254.

Fernet M, Ponette V, Deniaud-Alexandre E, et al. Poly(ADP-ribose) polymerase, a major
determinant of early cell response to ionizing radiation. International Journal of
Radiation Biology. 2000;76(12):1621-1629.

255.

Cristovao L, Rueff J. Effect of a poly(ADP-ribose) polymerase inhibitor on DNA
breakage and cytotoxicity induced by hydrogen peroxide and gamma-radiation.
Teratogenesis, Carcinogenesis, and Mutagenesis. 1996;16(4):219-227.

256.

Wang X, Ohnishi K, Takahashi A, Ohnishi T. Poly(ADP-ribosyl)ation is required for
p53-dependent signal transduction induced by radiation. Oncogene. 1998;17(22):28192825.

152

257.

Weinfeld M, Chaudhry MA, D'Amours D, et al. Interaction of DNA-dependent protein
kinase and poly(ADP-ribose) polymerase with radiation-induced DNA strand breaks.
Radiation Research. 1997;148(1):22-28.

258.

Zhang S, Lin Y, Kim YS, Hande MP, Liu ZG, Shen HM. c-Jun N-terminal kinase
mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose)
polymerase-1 activation. Cell Death and Differentiation. 2007;14(5):1001-1010.

259.

Chiu LY, Ho FM, Shiah SG, Chang Y, Lin WW. Oxidative stress initiates DNA damager
MNNG-induced poly(ADP-ribose)polymerase-1-dependent parthanatos cell death.
Biochemical Pharmacology. 2011;81(3):459-470.

260.

Lonskaya I, Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL,
Soldatenkov VA. Regulation of poly(ADP-ribose) polymerase-1 by DNA structurespecific binding. Journal of Biological Chemistry. 2005;280(17):17076-17083.

261.

Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent
poly(ADP-ribosyl)ation by human PARP-1. Science. 2012;336(6082):728-732.

262.

Hughes

FM,

Jr.,

Corn

AG,

Nimmich

AR,

Pratt-Thomas

JD,

Purves

JT.

Cyclophosphamide Induces an Early Wave of Acrolein-Independent Apoptosis in the
Urothelium. Advances in Bioscience and Biotechnology. 2013;4(88).
263.

Tanel A, Averill-Bates DA. Activation of the death receptor pathway of apoptosis by the
aldehyde acrolein. Free Radical Biology and Medicine. 2007;42(6):798-810.

264.

Boone CW, Mantel N, Caruso TD, Jr., Kazam E, Stevenson RE. Quality control studies
on fetal bovine serum used in tissue culture. In Vitro. 1971;7(3):174-189.

265.

Price PJ, Gregory EA. Relationship between in vitro growth promotion and biophysical
and biochemical properties of the serum supplement. In Vitro. 1982;18(6):576-584.

153

266.

Jia L, Liu Z, Sun L, et al. Acrolein, a toxicant in cigarette smoke, causes oxidative
damage and mitochondrial dysfunction in RPE cells: protection by (R)-alpha-lipoic acid.
Investigative Ophthalmology and Visual Science. 2007;48(1):339-348.

267.

Petit PX, Goubern M, Diolez P, Susin SA, Zamzami N, Kroemer G. Disruption of the
outer mitochondrial membrane as a result of large amplitude swelling: the impact of
irreversible permeability transition. FEBS Letters. 1998;426(1):111-116.

268.

Olah ME, Jackson MF, Li H, et al. Ca2+-dependent induction of TRPM2 currents in
hippocampal neurons. Journal of Physiology. 2009;587(Pt 5):965-979.

269.

Cozzi A, Cipriani G, Fossati S, et al. Poly(ADP-ribose) accumulation and enhancement
of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice.
Journal of Cerebral Blood Flow and Metabolism. 2006;26(5):684-695.

270.

Bonicalzi ME, Vodenicharov M, Coulombe M, Gagne JP, Poirier GG. Alteration of
poly(ADP-ribose) glycohydrolase nucleocytoplasmic shuttling characteristics upon
cleavage by apoptotic proteases. Biologie Cellulaire. 2003;95(9):635-644.

271.

Di Virgilio F, Steinberg TH, Silverstein SC. Inhibition of Fura-2 sequestration and
secretion with organic anion transport blockers. Cell Calcium. 1990;11(2-3):57-62.

272.

McClenaghan C, Zeng F, Verkuyl JM. TRPA1 agonist activity of probenecid desensitizes
channel responses: consequences for screening. Assay Drug Development Technologies.
2012;10(6):533-541.

273.

Bang S, Kim KY, Yoo S, Lee SH, Hwang SW. Transient receptor potential V2 expressed
in sensory neurons is activated by probenecid. Neuroscience Letters. 2007;425(2):120125.

154

274.

Koch SE, Gao X, Haar L, et al. Probenecid: novel use as a non-injurious positive inotrope
acting via cardiac TRPV2 stimulation. Journal of Molecular and Cellular Cardiology.
2012;53(1):134-144.

275.

Entin-Meer M, Levy R, Goryainov P, et al. The transient receptor potential vanilloid 2
cation channel is abundant in macrophages accumulating at the peri-infarct zone and may
enhance their migration capacity towards injured cardiomyocytes following myocardial
infarction. PloS One. 2014;9(8):e105055.

276.

Sun Z, Han J, Zhao W, et al. TRPV1 activation exacerbates hypoxia/reoxygenationinduced apoptosis in H9C2 cells via calcium overload and mitochondrial dysfunction.
International Journal of Molecular Sciences. 2014;15(10):18362-18380.

277.

Wu Z, He EY, Scott GI, Ren J. alpha,beta-Unsaturated aldehyde pollutant acrolein
suppresses cardiomyocyte contractile function: Role of TRPV1 and oxidative stress.
Environmental Toxicology. 2015;30(6):638-647.

278.

Wieckowski MR, Szabadkai G, Wasilewski M, Pinton P, Duszynski J, Rizzuto R.
Overexpression of adenine nucleotide translocase reduces Ca2+ signal transmission
between

the

ER

and

mitochondria.

Biochemical and Biophysical Research

Communications. 2006;348(2):393-399.
279.

Lax A, Soler F, Fernandez-Belda F. Intracellular ca(2+) pools and fluxes in cardiac
muscle-derived h9c2 cells. Journal of Bioenergetics and Biomembranes. 2005;37(4):249259.

280.

Freshney IR. Serum-Free Medium. Culture of Animal Cells: A Manual of Basic
Technique and Specialized Applications. 6th ed. Hoboken, NJ: John Wiley & Sons, Inc.;
2010.

155

281.

Gelderblom M, Melzer N, Schattling B, et al. Transient receptor potential melastatin
subfamily member 2 cation channel regulates detrimental immune cell invasion in
ischemic stroke. Stroke. 2014;45(11):3395-3402.

282.

Zhan KY, Yu PL, Liu CH, Luo JH, Yang W. Detrimental or beneficial: the role of
TRPM2 in ischemia/reperfusion injury. Acta Pharmacologica Sinica. 2016;37(1):4-12.

283.

Purnell MR, Whish WJ. Novel inhibitors of poly(ADP-ribose) synthetase. Biochemical
Journal. 1980;185(3):775-777.

284.

Motulsky HJ, Christopoulos A. Fitting models to biological data using linear and
nonlinear regression. A practical guide to curve fitting. San Diego, CA: GraphPad
Software Inc.; 2003.

156

APPENDICES

157

Appendix 1: Theory

Figure A1. Diagram of Problem Statement and Theoretical Framework. Removal of cardiac cells from an in vivo
system into an in vitro system with altered oxygen tension likely alters gene expression and underlying metabolic
and respiratory machinery. When in vitro cytotoxicity studies are conducted, the distance of gene expression
alteration remains unknown, and has an ill-defined modulation on in vitro toxicogenic response. Plausibly, returning
cells back to physiologically relevant oxygen tension culture system may reprogram the cells to a phenotype similar
to niche protein expression within the in vivo system, and, therefore, recapitulate nearer a toxicogenic response
observed in in vivo cardiac cells.
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Figure A2. Overview of Parthanatos with Integrated Calcium Conductance Channels. Poly(ADP-ribose)
polymerase overactivation from toxic insult results in adenine nucleotide depletion and excess ADP-ribose polymers
(Red arbors). As DNA is repaired, PARG, and to a lesser extent ARH3, cleave ADPr polymers, which diffuse to the
cytoplasm and, if in excess, can bind outer leaf-associated AIF and TRPM2 channels. AIF then mobilizes to the
nucleus and initiates large-scale nuclear fragmentation and cell death (Parthanatos). Simultaneously, ADPr
polymers, in conjunction with stress-mediated ROS, activate the TRPM2 channels, allowing conductance of
extracellular cations sodium, potassium, and calcium. Calcium, if in high concentration intracellularly, can be
shuttled within the intramembranous space of the mitochondria via VDAC channels, and finally within the matrix
via MCU channels. Calcium overload within the matrix directly inhibits the ETC, reducing the proton drive
necessary for ATP synthesis and mitochondrial membrane potential retention. Reduction in the ΔΨm causes
generation of ROS, which can, in turn, initiate or exacerbate TRPM2 calcium conductance. Similarly, reduction in
ΔΨm is associated with extrusion of intramembranous AIF in association with the mitochondrial membrane pore
transition, leading to mitochondrial dysfunction and parthanatos. Abbreviations: adenine diphosphate (ADP);
adenine nucleotide translocator (ANT); adenine triphosphate (ATP); ADP-ribosylhydrolase 3 (ARH3); apoptosisinducing factor (AIF); cyclophilin A (CypA); cyclophilin D (CypD); electron transport chain (ETC); mitochondrial
calcium uniporter (MCU); nicotinamide adenine dinucleotide, oxidized (NAD+); poly(ADP-ribose) glycohydrolase
(PARG); poly(ADP-ribose) polymerase (PARP); reactive oxygen species (ROS); sarco/endoplasmic reticulum Ca2+ATPase (SERCA); sodium/calcium exchanger (Na+/Ca2+ Exchanger); transient receptor potential cation channel,
subfamily M, member 2 (TRPM2); voltage-dependent anion channel (VDAC).
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Appendix 2: Dulbecco’s Modified Eagle’s Medium
Table A1: Sigma-Aldrich Product Formulation for SKU: D5030
DMEM Composition (Stock Powder; Sigma-Aldrich Catalog Number: D5030)
Constituent

Grams/Litre

Constituent

Inorganic Salts

Grams/Litre
Amino Acids

CaCl2
Fe(NO3)39H2O
MgSO4
KCl
NaCl
NaH2PO4

0.2
0.0001
0.09767
0.4
6.4
0.109

Vitamins
Choline Chloride
Folic Acid
myo-Inositol
Niacinamide
D-Pantothenic Acid0.5Ca
PyridoxalHCl
Riboflavin
ThiamineHCl

0.004
0.004
0.0072
0.004
0.004
0.004
0.0004
0.004

L-ArginineHCl
L-Cystine2HCl
Glycine
L-HistidineHClH2O
L-Isoleucine
L-Leucine
LysineHCl
Methionine
L-Phenylalanine
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine2Na2H2O
L-Valine

0.084
0.0626
0.03
0.042
0.105
0.105
0.146
0.03
0.066
0.042
0.095
0.016
0.10379
0.094

Note: Composition of commercially available DMEM from powder utilized for experimentation. The powder
composite presented formed the basis for which the pre-basal medium was later derived (See Methods). Note: The
information in this table is available free of charge and without disclaimer of credit on the manufacturer’s website.
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Appendix 3: Acrylic Exposure Chamber

Figure A3. Initial Acrylic Exposure Chamber Construction Plans. The initial proposed dimensions of the acrylic
exposure chamber are presented for comparison of final controlled volume calculation. The plans were modified
during construction, especially with respect to the ante-chamber to accommodate ergonomic utilization with gloves
installed in situ after completion.
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Figure A4. Completed Exposure Chamber – Oxygen Retention Testing. (Top) Upon completion of the acrylic
exposure chamber (Top), measurements of internal oxygen concentration were made with respect to time, as
presented in Figure 4 after reducing internal oxygen concentration to 5.4 % mol/mol with pure nitrogen. During
testing, a handheld oximeter was utilized to monitor in real-time the oxygen concentration. (Bottom) The image
shows the placement of the oximeter within the main chamber during measurements taken up to 99.5 hours after
initial oxygen concentration reduction. At this time point, the internal oxygen concentration was 8.4 % at
approximately 58 hour.
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Appendix 4: Validation of the Poly(ADP-ribose) Polymerase Activity Assay
Preliminary validation included an inhibitor study with a compound of known PARP-1
kinetic data – 3-aminobenzamide (3-AB); the published 3-AB Ki value was reported to be 1.8 ±
0.2 µM283. Using the optimized detection system developed producing a strong, consistent PARP
colorimetric signal, an experiment was conducted in order to experimentally derive the 3-AB Ki
parameter for comparison against the aforementioned reported value. Purified PARP enzyme and
a commercial source of 3-AB were purchased from Trevigen in order to conduct the experiment.
Seven sets of triplicate wells were seeded with 5 IU of purified PARP enzyme per well, wherein
each set was co-incubated with graded concentrations of 3-AB spanning seven orders of
magnitude (20 nM to 20 mM) during the NADB incorporation step. Thereafter, the assay was
conducted as per the method described above (See Methods). The results were normalized
against the activity observed for the 20 nM 3-AB concentration triplicate set, which was denoted
as 100 %. In order to derive the Ki value for the inhibitor experiment results, a three parameter
log-logistic model with a fixed lower limit asymptote of 0 % was derived using the R statistical
software program facilitated through the “drc” package. In order to include the fitted threeparameter log-logistic function to the observed data, the three parameter estimates produced by
the statistical software were re-inserted into the general three-parameter log-logistic equation284:
𝑓 𝑥 =𝑐+

𝑑−𝑐
1+𝑒

! !"# ! !!"# !

Where:
b

=

Hill’s slope coefficient

c

=

Lower limit asymptote; fixed at 0

d

=

Upper limit asymptote

e

=

Curve inflection point
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The resultant model parameter derivations are presented in Table A2. Using the curve parameters
derived, an inhibition curve was produced, wherein the observed PARP activity values were
plotted against the base-10 logarithmic 3-AB concentration with the units of molar (M) and
presented in Figure A5. Based on the model residua, the three-parameter log-logistic model aptly
regressed against the observed data.

Table A2. Three-Parameter Log-Logistic Inhibition Curve Estimation
Model Parameters
Symbol

Estimate

Estimate
Standard Error

Note(s)

Hill’s slope coefficient
Lower limit asymptote
Upper Limit Asymptote
Point of Curve Inflection

b
c
d
e

0.086582
0
100.18
0.0021995

0.063154
N/A
2.0234
0.00021693

None
Fixed at Zero
None
None

Derived Parameter Estimate
Ki Estimate ± SEM
(CI95%)

Theoretical Value

Note

1.8 µM (1.6-2.0 µM)

95% Confidence Interval includes
1.8 µM

Parameter

2.2 ± 0.2 µM
(1.7-2.7 µM)

The concentration required to inhibit 50 % of PARP activity in the optimized detection
system was approximated to be 2.2 ± 0.2 µM of 3-AB. Comparison to the theoretical Ki value of
1.8 ± 0.2 µM denoted that the observed estimate was not statistically significant than the
theoretical, as the 95 % confidence interval of the point estimate around the derived Ki value
includes 1.8 µM (1.7-2.7 µM). Therefore, the evidence suggests that the detection system
developed for quantitating PARP activity does not alter the activation kinetics of PARP, and
provides a method of measuring the specific activity of PARP, at least in simple sample
matrices, i.e., a simple buffer.
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Figure A5. 3-AB Ki Derivation for PARP. Seven sets of triplicate wells containing 5 IU purified PARP were coincubated with 3-AB at graded concentrations ranging from 20 nM to 20 mM. Over the 3-AB concentration range, a
characteristic sigmoidal inhibition curve resulted. Derivation of the Ki estimate and associated 95 % confidence
interval resulted in a value of 2.2 µM (CI95%: 1.7-2.7 µM), an interval which includes the value published by
Purnell283. The regressed log-logistic model was overlain with the observed normalized PARP activity values
obtained from experimentation. Each point estimate is the average of three technical replicates. Error bars denote
SEM.

In optimizing the assay for use on biological samples, measuring activity of PARP in
sample mouse liver was performed (Unpublished data, Coyle et al.). Differential fractionation of
liver tissue homogenates via centrifugation into the nuclear and cytosolic fractions [Extraction
buffer: 50 mM Tris-HCl, pH 8.0, 1.0 % Triton X-100, 400 mM NaCl, 2 mM MgCl2, 100 ng/µL
BSA, 1 mM D-l-1,4-dithiothreitol] were assayed for PARP activity in lysates containing 10 µg
protein per 25 µL (One well volume). Baseline PARP activity in the nuclear and cytosolic
fraction were 230 mU/10 µg protein and below the detection limit, respectively; concomitant
incubation with 3 mM 3-AB resulted in both nuclear and cytosolic fraction PARP below the
detection limit [Figure A6]. Therefore, the activity observed in the 3-AB deficient nuclear
fraction, which disappeared with incubation with 3-AB, demonstrates successful isolation of
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functional PARP enzyme. Moreover, demonstration of nuclear fraction PARP activity with
negligible crossover to the cytosolic fraction, denotes attainment of assay specificity in assessing
nucleic PARP activity, presuming the nuclear fraction did indeed isolate intact nuclei prior to
envelope lysis and PARP stabilization. This is further evident since there were negligible
cytosol-associated non-specific signals reported upon assessment via spectrophotometric
measurement (Below detection limit).

PARP Activity (IU/10 µg Protein)

0,25

(-) 3-AB

0,20

0,15

0,10

0,05

Below Detection Limit
(+) 3-AB

(-) 3-AB

(+) 3-AB

0,00

Nuclear Fraction

Cytosolic Fraction

Figure A6. PARP Assay Specificity Verification. PARP activity in mouse liver tissue was determined using the
developed assay to assess specificity. Assessment for PARP activity in the nuclear and cytosolic fractions after
differential fractionation via centrifugation resulted in detectable PARP activity in the nuclear (Solid Black Bars),
but not in the cytosolic (Clear White Bars), fraction in the absence of the PARPi, 3-AB. In the presence of 3 mM 3AB, PARP activity in the nuclear fraction was reduced to below the detection limit, thus confirming specificity of
PARP activity measurement. The bar labeled Below Detection Limit denotes underlying samples were
indistinguishable from blank wells, thus unquantifiable.
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